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ABSTRACT 
                Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality 
worldwide. Current treatments are subpar, with late stage diagnosis and poor prognosis 
contributing to limited treatment options.  The evolutionarily conserved, ubiquitously 
expressed transcription factor LSF is overexpressed in HCC, and its expression is 
positively correlated with disease severity.  Certain small molecules, known as Factor 
Quinolinone Inhibitors (FQIs), specifically inhibit LSF DNA-binding activity, inhibit 
HCC cell proliferation in vitro and prevent tumor growth in an endogenous mouse liver 
cancer model without apparent toxicity. The targeting of transcription factors by small 
molecule inhibitors has been historically difficult, warranting further molecular 
investigation into the requirement for LSF in HCC to confirm that the anti-tumor effects 
of FQIs are the consequence of LSF inhibition. 
This body of work investigates a dual approach for inhibiting LSF function in 
order to determine the molecular consequences for HCC cells. To identify the specific 
point of the cell cycle where LSF is required for HCC proliferation, synchronous HCC 
cells were treated with FQI or with short interfering RNA to reduce levels of LSF. The 
results indicate that LSF is required for proper mitotic progression in HCC cells. 
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Specifically, these data show a reduction of key mitotic regulators Aurora Kinase B and 
Cdc20, at the level of mRNA and protein expression. Time-lapse microscopy also 
demonstrated an increase in the time for progression through mitosis, with a 
prometaphase/metaphase delay. Immunofluorescence analysis revealed a prometaphase 
delay plus aberrant cell division and generation of multi-nucleated cells. These findings 
were consistent with both FQI1 treatment and RNA interference. Additionally, shorter 
incubation with FQI1 surprisingly revealed a distinct, non-transcriptional regulation of 
mitosis in HCC cells, suggesting that mitotic regulation by LSF is multi-faceted.   
As a targeted therapy for use in the clinic, the in vivo toxicity of FQIs is critical to 
investigate. Whole blood provides populations of rapidly dividing normal cells that can 
test susceptibility to anti-mitotic compounds. When mice were treated with FQI1, the 
blood analysis showed no toxicity. Taken together, these findings indicate that LSF is a 
mitotic regulator in HCC, further supporting the therapeutic promise of molecular 
therapies targeting LSF. 
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CHAPTER ONE 
INTRODUCTION 
The following is a collection of work probing the requirement for Late SV40 
Transcription Factor (LSF) function in Hepatocellular Carcinoma (HCC) cells.  
Reports have shown that small molecules targeting LSF, Factor Quinolinone 
Inhibitors (FQIs),  have successfully reduced and/or prevented tumor growth in 
both a mouse HCC xenograft model and an endogenous liver model (Grant et al., 
2012; Rajasekaran et al., 2015).  Using a dual approach to interrogate the 
functionality of LSF in HCC cells, a role in mitotic regulation has been identified and 
will be described in detail.  This chapter will provide the necessary background to 
define both the relevance of this work and to allow proper interpretation of the data 
to follow. 
Hepatocellular Carcinoma  
According to the National Cancer Institute, cancer is a collection of related 
diseases where some cells of the body begin to divide without stopping and spread into or 
invade surrounding tissues   Cancerous cells may form solid tumors which are masses of 
tissue or manifest as cancers of the blood which are not solid and may be referred to as 
liquid tumors.  Tumors that break off, travel through the blood or lymph and establish 
themselves at distal sites are called metastatic.   Hepatocellular Cancer is a form of solid 
tumor which arises de novo from hepatocyte cells in the liver; it is the predominant type 
of primary liver cancer. Unfortunately, the incidence of primary liver cancer is on the 
rise.    
 
 
2 
Liver cancer in adult men is the fifth most frequently diagnosed cancer 
worldwide, and is the second leading cause of cancer-related death in the world. In adult 
women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of 
cancer death. Globally, liver cancer rates are 2 to 4 times that for men than women.   As 
of 2008, there were an estimated 748,000 new liver cancer cases and 695,900 cancer 
deaths worldwide, with half of these cases and deaths occurring in China (Jemal et al., 
2011). The histological subtype known as Hepatocellular carcinoma (HCC) dominates 
those primary liver cancer cases observed with incidence rates reaching 70-80% that of 
total liver cancer burden worldwide (El-Serag and Kanwal, 2014; Jemal et al., 2011).  In 
the United States (US), the annual incidence of hepatocellular carcinoma was at least 6 
per 100,000 in 2010 with men three times more susceptible than women.  The majority of 
cases, ~80%, are thought to be the result of chronic infection with HBV and HCV 
(Venook et al., 2010). 
While new treatments have emerged as curative agents for HCV and others in the 
works for HBV, the sheer number of infected people worldwide with both viruses 
indicates that HCC will remain an area of high unmet need for years to come.  While 
viral infections remain the top causative agents for the development of HCC, other 
factors such as chronic fatty liver and alcoholism also contribute.  In western countries, 
risk factors that dominate besides HCV include both alcohol related cirrhosis and non-
alcoholic fatty liver disease (NAFLD), a disease associated with obesity.  Other risk 
factors include aflatoxin B1, a toxin common to parts of Africa and Asia which has been 
shown to increase HCC incidence in HBV positive patients (Venook et al., 2010). 
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NAFLD, the hepatic manifestation of metabolic syndrome, affects approximately 
1/3 of the US adult population, a population that is on the rise (El-Serag and Kanwal, 
2014).  Typically, these patients can develop nonalcoholic steatohepatitis (NASH) where 
inflammation combined with fatty liver can trigger fibrotic development.  Epidemiology 
studies support an association between NAFLD or NASH and HCC.  An increasing 
disease prevalence of (NASH), impacting over 1 million adults and children to date, 
indicate that a significant increased HCC patient population is on the horizon as NASH 
fibrosis converts to HCC over time (Marengo et al., 2016).   
With HCC incidence rates expected to continue to be on the rise in the West, the 
introduction of universal HBV vaccinations are expected to continue to reduce incidence 
in the East.  However, the HBV vaccination will not impact those already afflicted with 
the virus.  With the rising epidemic of obesity in the western world the incidence of 
NASH related HCC is growing and may become the predominant driver for HCC in the 
developed world in the future (Venook et al., 2010).   A recent mathematical model 
generated using the prevalence and natural history of HCV in the U.S. population 
indicated that the number of HCC cases increased from 1990 to 1999 from 37,697 to 86, 
765 between 2000 and 2009, an increase of 130%, with a projected increase to 130,366 
(+50%) by 2019. However, this model simply examines HCV as a risk factor.  Even 
though HCC cases induced by HCV viral infections are projected to be reduced, the 
overall incidence likely will not decline as NASH related cirrhosis is increasing HCC 
incidence with metabolic syndrome incidence on the rise.   
 
 
4 
 The risk factors discussed above (mainly liver infections and NASH) operate by 
promoting development of cirrhosis which exerts a promotional effect via the induction 
of hepatocyte regeneration (Marquardt et al., 2012; Perz et al., 2006; Zhou et al., 2014).  
Exceptions are rare in HCV related HCC as most cases documented occur with the 
concurrence of some type of fibrosis.  Whereas most HBV related HCC cases also 
include cirrhosis, ~85%, there have been cases where HBV can cause HCC in the 
absence of advanced documented fibrosis or cirrhosis (Perz et al., 2006).  Several 
mechanisms have been proposed for progression of NAFLD to HCC in instances of mild 
or undetected fibrosis; however, there has not been a systematic analysis to quantify this 
contention.  The risk of developing HCC in patients with cirrhosis varies with the 
underlying condition (El-Serag and Kanwal, 2014; Perz et al., 2006). Combinations of 
various risk factors have increased risk of HCC development, for example heavy alcohol 
intake in HCV afflicted individuals has been documented to increase risk of progression 
to HCC.   
Current therapeutic options for the HCC population are subpar (Bruix and 
Sherman, 2011).   HCC is often diagnosed late in disease as it produces non-specific 
symptoms, lacks early diagnostic biomarkers, and the option to diagnose by biopsy is not 
ideal.  One third of those diagnosed qualify for invasive treatments including surgical 
resection or liver transplantation (Kim et al., 2016).  However, two thirds of patients do 
not qualify for such treatments as their disease is too far advanced, leaving only palliative 
treatment options.  Few molecular therapies have shown promise, with Sorafenib 
currently the only approved treatment.  Sorafenib, a molecular inhibitor of vascular 
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endothelial growth factor receptor (VEGFR) as well as C and B-raf kinase was originally 
approved for use in kidney cancer patients, but has demonstrated an improvement in 
overall survival rates of 3 months in clinical trials of HCC (Llovet et al., 2008; 
Santhekadur et al., 2012b).  Bevacizumab, a vascular endothelial growth factor (VEGF) 
pathway inhibitor, examined alone or in a combinatorial approach with chemotherapy, 
has also demonstrated limited positive responses (Torrecilla and Llovet, 2015).   The 
recent SHARP clinical trial which re-evaluated Sorafenib efficacy in HCC observed 
median survival rates of 7 to 11 months, an impact attributed to the improved clinical trial 
design for the HCC patient population (Llovet et al., 2015; Worns and Galle, 2014).  The 
re-examination of clinical trial design for this patient population paved the way for 
numerous other molecular targeted therapies to be evaluated as the trial established 
critical criteria required to determine drug efficacy.  Many types of therapies have been 
examined including anti-angiogenics, epigenetic modulators, pro-apoptotic or DNA 
damaging agents, immune modulators, and, lastly, cell cycle inhibitors.  Unfortunately, of 
the numerous therapies evaluated to date, not a single agent improved survival or 
progression free survival rates to a greater degree than Sorafenib (Bruix and Sherman, 
2011; Llovet et al., 2015).   
Clearly, given the lack of current effective therapies, the unmet need for novel 
approaches to treat HCC is very high.  The lack of clinical translation of therapies 
showing promise in pre-clinical models has been problematic. It has, however, led to 
multiple hypotheses as to what types of new or combined therapies might make an impact 
on this patient population.   
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A hallmark of cancer is loss of cell cycle and cell division control; whereas 
normal cell division is tightly regulated with multiple checkpoints to ensure genomic 
integrity.  Targeting oncogenic cell cycle regulators has been a favored hypothesis to 
preferentially target tumor cell populations in the body.  To navigate through the 
proposed molecular breakthrough therapies for HCC, many that target cell cycle 
regulators, we must first understand the complexities of cell cycle regulation.   
Mammalian Cell Division 
Mitosis, the portion of the mammalian cell cycle that results in cell division, 
comprises a spatiotemporal regulated system reliant on sequential expression/and 
degradation of key proteins as well as post translational modifications; processes that are 
tightly regulated to ensure proper cell division following DNA replication (Carmena et 
al., 2012; Foley and Kapoor, 2013; Guttinger et al., 2009; Hardwick and Shah, 2010).  
The cell cycle is comprised of Interphase and Mitosis (M), where the former 
encompasses the following phases: Gap 0 (G0), Gap 1 (G1), DNA synthesis (S), and Gap 
2 (G2).  External growth factors introduced to G0 cells, which are by definition quiescent 
or resting, can trigger cell cycle entry.   The overall cell cycle is depicted in Illustration 
1.1, a depiction which also includes the estimated time spent in each phase. 
Illustration 1.1 The Mammalian Cell Cycle  
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 Upon entry into the first Gap phase, G1, the cell stimulates production of both key 
proteins and cytoplasmic organelles in preparation for cellular division, so that the 
process, once complete, will result in the production of two identical daughter cells.  
Genome duplication is executed under intense scrutiny in Synthesis, or “S” phase.  
Completion of DNA synthesis is followed by the second Gap phase, G2, where the cell 
completes the growth phase and prepares for mitotic entry, a point at which all 
transcriptional activities will cease until re-entry into G1/G0 (Bertoli and de Bruin, 2014; 
Bertoli et al., 2013) (Illustration 1.1).  Completion of the G2 phase allows a rapid entry 
into Mitosis where telophase/cytokinesis completes successful cellular division.   
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Although normal mitotic progression requires the least time of all cell cycle 
stages, it is the most complicated with multiple sub phases regulated by post translation 
modifications, both prior expression and degradation of key proteins, cytoskeletal events, 
and chromatid separation and re-location.  Mitosis therefore comprises five sub stages, 
including prophase, prometaphase, metaphase, anaphase and telophase.  
Illustration 1.2 Microtubule Attachment is a Mitotic Requirement 
 
 
 Illustration 1.2 summarizes the events in each of the mitotic stages as the 
duplicated chromatids are separated into opposite sides of the cell by microtubules.  The 
microtubules, attached to the centrosomes located at each pole, first attach to the 
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kinetochore on each sister chromatid.  Once all kinetochores have successfully attached, 
only then can the microtubules facilitate successful separation with a bipolar orientation, 
pulling each sister chromatid to opposite sides of the cell.  The cleavage furrow forms 
immediately following telophase where cytokinesis permits the separation into two 
identical daughter cells.   
Each cell cycle phase has a surveillance system, or checkpoint, responsible 
for ensuring successful completion of each stage.  Following a successful growth 
period, the cell arrives at the G1 checkpoint, where a successful growth period and 
proper DNA integrity is confirmed prior to genome duplication in S phase.  The G1 
checkpoint, which has been studied extensively, ensures DNA integrity in order to 
allow proper entry in S phase.  If any risk factors identified at this check point 
cannot be remedied, then pathways may be activated to trigger cellular demise 
through apoptotic signaling or senescence (a state in which the cell will never 
divide).   A cell that satisfies the G1 checkpoint will duplicate its genome.  In mitosis, 
a distinct type of checkpoint occurs.  The proper attachment of microtubules to the 
kinetochores is closely monitored by the Spindle Assembly Checkpoint (SAC), involving 
a complex that includes Mad2 and Bub1.  The SAC delays or prevents the metaphase to 
anaphase transition through sequestering of Cdc20, the key member of the Anaphase 
Promoting Complex (APC/C).  Once the SAC has been satisfied through proper 
attachment of the microtubules to the kinetochores, Cdc20 will be released to 
associate with APC/C; this allows anaphase onset through degradation of key 
mitotic proteins.  The APC/C coordinates destruction of mitotic proteins including 
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Cyclin B1, the major mitotic cyclin upregulated prior to mitotic entry (Casimiro et 
al., 2012; Lim and Kaldis, 2013).   Successful anaphase is followed by telophase and 
cytokinesis.  Cancer cells have dysregulated division which can be a direct result of 
abnormal activity or expression of various factors controlling cellular division, a 
crucial observation that led to both the identification of dysregulated mitotic 
proteins and pathways in HCC. 
 
Clinical Targets for Cancer 
Given that cancers have dysregulated mitoses, is not a stretch that investigators 
have been proposing therapies targeting known mitotic regulators required for cell 
division as a means of exploiting this cancer cell vulnerability.  This vulnerability was 
hypothesized to allow for selective targeting of cancer cells as the majority of normal 
cells are typically in quiescence, a state in which the cells are not dividing.  To date, there 
have been a large number of small molecules targeting various aspects of mitotic 
regulation evaluated for anti-tumor activity. Two of different targets that have been 
extensively evaluated to date are microtubule (MT) binding agents (MBAs) and Aurora 
Kinase B inhibitors, both of which will be discussed below.   A third strategy for 
targeting mitotic regulation will also be reviewed, which involves inhibiting the 
Anaphase Promoting Complex (APC/C). This has merely been proposed as 
advantageous, although not yet clinically evaluated.   
 
Microtubule Dynamics  
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Microtubules have a critical regulatory function not only for proper mitotic 
progression, but also for maintenance of cytoskeletal shape, cell motility, and 
intracellular protein and organelle transport.  Composed of α and β tubulin heterodimer 
subunits, these subunits interact in a dynamic equilibrium allowing tubulin to both 
polymerize and depolymerize (Foley and Kapoor, 2013).  Two fundamental aspects of 
tubulin dynamics that occur in vivo are treadmilling and dynamic instability (Foley and 
Kapoor, 2013).  The first process, dynamic instability, is accelerated during mitosis, as 
required for spindle formation and attachment of the mitotic spindles to chromosomes.  
The second process, treadmilling, is defined as the net growth at one end of the 
microtubule and the net shortening at the opposite end, a process required in the polar 
movement of the chromosomes during anaphase.  These dynamics are regulated by 
various microtubule associated proteins and other regulatory proteins, variable expression 
of tubulin isotypes, post translational tubulin modifications and tubulin mutations.   
Microtubule binding agents, MBAs, are compounds that disrupt microtubule 
dynamics involving the mitotic spindle.  Suppression of these two key dynamic 
microtubule functions are the principal means by which MBAs disrupt cellular function 
and induce cellular death. A large collection of MBAs have been or are currently being 
evaluated in clinical trials, however few have are being tested in HCC (Loong and Yeo, 
2014).  Gene expression profiling studies have recently shown that microtubule–related 
cellular assembly and organization is crucial in HCC development indicating that 
molecular therapies targeting microtubules could be successful (Loong and Yeo, 2014).  
Evaluations of MBAs in clinical trials have had mixed results with clinical activity not 
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translating as well as expected based on preclinical models. Only moderate responses at 
best were observed in select patients.  The lack of efficacy was puzzling in light of the 
success of early MBA in other cancer settings.  For instance, two decades ago paclitaxel 
treatment achieved clinical response rates for 17-62% in breast cancer, 20-48% in ovarian 
cancer and 21-41% in lung cancer.  Although some individuals had a minimal response, 
there were positive results.  While these agents displayed clinical activity, they were not 
without side effects as they were unable to distinguish between tumor and normal cells, 
killing off both. Significant toxicities included neurotoxicity, impacts on movement, 
sensation, and even organ function failure.   
The challenge to identify safe and effective MTAs capable of specifically inhibiting 
mitosis of cancer cells but not normal cells remains.   
Illustration 1.3 The Expression Profile of Mitotic Cyclin 
 
Aurora Kinases 
Aurora Kinases include three major mitotic kinases required for mitotic entry, 
progression, and cellular division.  These three distinct isoforms were named A, B, and 
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C.   Aurora Kinase A has documented roles in early mitosis through regulation of 
centrosome maturation and disjunction allowing establishment of the bipolar mitotic 
spindle.  Aurora Kinase B is the key member of the chromosomal passenger complex 
(CPC) where it associates with survivin, INCENP, and borealin (Ditchfield et al., 2003; 
Kim et al., 2011; Le et al., 2013; Poon, 2013).  The CPC contributes to SAC function at 
kinetochores by correcting faulty spindle attachments.  One key role of Aurora Kinase B 
is for proper microtubule-kinetochore attachment, through phosphorylation of key mitotic 
proteins at the kinetochores where Aurora kinase B destabilizes incorrect attachments and 
stabilizes proper microtubule-kinetochore attachments.  Aurora Kinase B regulates 
modification of other phosphorylated proteins required for mitotic processes, such as 
Histone 3 on both Serine 10 and 28 as well CENPA;  more than 50 targets of Aurora 
Kinase B have been identified (Carmena et al., 2012; Ditchfield et al., 2003).  Another 
role for such protein modification occurs after anaphase, when Aurora kinase B regulates 
cytokinesis and localizes to the cleavage furrow (Vader and Lens, 2008).  
Abnormal activities of Aurora Kinases are associated with defects in cell division 
and aneuploidy.  Aurora Kinase A is amplified in multiple cancer types including breast, 
ovary, lung, bladder stomach, and colon whereas Aurora Kinase B is increased in breast 
cancer, glioblastoma, and prostate cancer (Andrews, 2005).  A role for Aurora Kinase C 
in cancer has not yet been described.  Aurora Kinase B is not only upregulated in HCC, 
but its expression positively correlates with disease severity. It has, therefore, been 
proposed as a promising therapeutic target for the HCC patient population (Sistayanarain 
et al., 2006).  In fact, Aurora Kinases in general generated great excitement in recent 
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decades for cancer therapeutics, as promising preclinical anti-tumor activity observed 
with various small molecules led to 30 entering into clinical trials (Andrews, 2005).  
However, the clinical translation of these targets has been disheartening.  
Danusertib, a pan Aurora Kinase inhibitor, resulted in meager efficacy when 
tested in chronic lymphocytic leukemia with a 13-22% response.  Investigation of 
Barasertib, an inhibitor specific to Aurora Kinase B (AurkB), resulted in complete 
response in 25% of the acute myeloid leukemia patients (Bavetsias and Linardopoulos, 
2015).  However, both therapies resulted in toxicities including myelosuppression and 
gastrointestinal effects.  The observed toxicities are most likely due to the requirement of 
these mitotic kinases in normal cell division. The surprising lack of efficacy observed has 
been attributed to dose limitations due to toxic side effects, the low proliferation index in 
human tumors, as well as pathway redundancy in human cells where the tumor cells are 
not reliant on Aurora Kinases.  The implication of pathway redundancy in ineffective 
tumor therapies is discussed in greater detail below.   
APC/C Proteasome: Cdc20/Cdh1 
 The Anaphase Promoting Complex (APC), has a key role in mitotic timing 
through formation of two functionally distinct E3 ubiquitin ligase sub complexes with 
cofactors, Cdc20 or Cdh1, responsible for targeting key mitotic proteins for 
ubiquitination resulting in subsequent degradation by the proteasome.  Most notably, the 
APC in complex with Cdc20 targets securin, the inhibitory protein for separase, allowing 
cleavage of cohesin thereby permitting the sister chromatids to separate and migrate to 
opposite poles.  Other key targets include cyclins, where Cyclin A is degraded in early 
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mitosis and Cyclin B is degraded prior to mitotic exit. This process is a requirement for 
mitotic exit in normal cells.   
Cdc20, a key cofactor of the APC/C complex, has not yet been targeted for 
inhibition in clinical trials.  However, Cdc20 is overexpressed in some cancers, and in 
complex with APC degrades p21, a tumor suppressor (Wang et al., 2015; Wu et al., 
2013).  Further, increased expression of Cdc20 was associated with clinical progression 
in human tumors.  Recently, Cdc20 was proposed as a potential target for tumor therapies 
(Wang et al., 2013).  Additionally, RNAi mediated knockdown of Cdc20 increased 
mitotic arrest in cancer cells treated with an anti-mitotic, a combinatorial treatment 
approach that resulted in mitotic death rather than mitotic slippage (Huang et al., 2009).   
 
Clinical Translation 
Thus far, large amounts of preclinical data have demonstrated robust anti-tumor 
responses, however, where explored these agents have not translated into positive tumor 
response or survival in clinical trials (Wang et al., 2015; Wu et al., 2013).  In certain 
cases it is possible that the lack of efficacy is due to functional redundancy in mammalian 
cell cycle control with multiple family members possibly covering for or being 
upregulated under selective pressure (Fernando et al., 2008; Sasai et al., 2004; Slattery et 
al., 2009). A second hypothesis takes into account the proliferation rate paradox put forth 
by Tim Mitchison (Mitchison, 2012).  He describes an obstacle that anti-mitotic drugs 
face in general, that they have been chosen based on their cytotoxic properties for rapidly 
proliferating cells, while HCC and many other tumor types are slow growing.  Other  key 
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characteristics include drug retention and the ability to kill quiescent cells (Mitchison, 
2012).   
Consistent with the family or pathway redundancy hypothesis, tumor escape 
has been observed in treatments with molecular therapies targeting a single 
oncogenic factor (Llovet et al., 2015; Torrecilla and Llovet, 2015; Villanueva and 
Llovet, 2011).  This phenomenon led to the hypothesis that targeting oncogenic 
transcription factors could provide a significant therapeutic benefit, in which inhibition of 
a broader oncogenic pathway could prevent tumor escape.  Additionally, cases of 
oncogene addiction have been highlighted, where certain tumor types are dependent on 
single genes that, when removed, result in immediate cancer cell death whereas normal 
cells with functional redundancy are spared.  Ideally if one were to attempt to target a 
transcription factor for cancer, it would be an oncogenic transcription factor to which 
cancer cells are addicted.   
A therapy targeting an oncogenic transcription factor (TF), a TF that was a proven 
case of oncogene addiction, would have multiple advantages: (1) In contradiction to the 
normal human cell that has built in functional redundancy for a complex operating 
system, the tumor cells are literally addicted to a single factor, incapable of surviving or 
proliferating without it.  (2)  Targeting an entire pathway could potentially eliminate 
tumor cell escape.  Exploiting a case of oncogene addiction would theoretically protect 
normal cells, however, identification of an oncogenic transcription factor that regulates 
mitotic cells would select for the proliferating tumor cells.  LSF has recently been shown 
to be on oncogenic transcription factor to which HCC tumors are addicted.   
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The Transcription Factor LSF 
LSF, a ubiquitously expressed, evolutionarily conserved transcription factor was 
first discovered while investigating Simian Virus 40 in HeLa cells, where it was 
identified as a transcriptional activator of the late promoter (Veljkovic and Hansen, 
2004).  LSF binds DNA as a homotetramer, targeting a bipartite site with two repeated 
consensus sequences spaced 10 bp apart (Huang et al., 1990; Veljkovic and Hansen, 
2004).  An LSF family member, LBP1a, can oligomerize with LSF suggesting that the 
regulation of key targets and pathways could potentially involve both TFs.  LSF is 
involved in many biological processes including cell growth, cell cycle regulation and 
development (Hansen et al., 2009; Saxena et al., 2009; Veljkovic and Hansen, 2004).  
Specifically, LSF binds the thymidylate synthase (Tyms) promoter and activates Tyms 
expression following cell cycle re-entry of quiescent cells. LSF is essential at the G1/S 
transition in a mouse fibroblast line as well as a human prostate cancer cell line, as 
expression of a dominant negative LSF caused apoptosis in S phase (Powell et al., 2000).  
Apoptosis was a consequence of reduction of Tyms, the rate limiting enzyme required for 
dTTP production for DNA synthesis, as apoptosis was circumvented with the addition of 
a low concentration of exogenous thymidine.   
Enhanced LSF expression was found in 90% of Hepatocellular Carcinoma patient 
samples analyzed, and its expression positively correlated with disease severity (Fan et 
al., 2011b; Yoo et al., 2010).  In vivo analysis in a mouse xenograft model demonstrated 
that increased expression resulted in increased tumorigenicity as shown with reduced 
tumor proliferation in a LSF dominant negative line and overexpression resulted in tumor 
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formation in a previously non-tumorigenic HCC cell line (Yoo et al., 2010).  In addition, 
expressing a dominant negative LSF in a highly tumorigenic HCC cell line reduced 
colony formation and tumorigenicity in vivo.   LSF is also linked to key oncogenic 
processes including angiogenesis, through regulation of matrix malloproteinase 9 
(MMP9)(Santhekadur et al., 2012a) and to the epithelial to mesenchymal transition 
(EMT) through mediating Snail 1 induced upregulation of fibronectin, an EMT marker 
(Porta-de-la-Riva et al., 2011).  EMT is a key process required for tumor metastasis. 
Finally, LSF is downstream of Notch 2, where activation of Notch 2 not only led to 
increased tumorigenicity, but increased LSF expression.  These data combined indicated 
that LSF is an oncogene in hepatocellular carcinoma.  Ideally one would be able to 
identify small molecules capable of inhibiting LSF activity for HCC.  Traditionally, 
however, inhibitors of transcription factors have been difficult to identify. Nonetheless, 
compounds capable of inhibiting LSF were recently identified. 
Factor Quinolinone Inhibitors 
A screen of 110,000 compounds identified small molecules that directly inhibited 
LSF DNA binding activity as ascertained in a fluorescent polarization assay combining 
fluorescently labelled DNA with purified LSF.  Named “Factor quinolinone inhibitors”, 
or FQIs, many of these compounds were synthesized (Grant et al., 2012).  The 
prototypes, FQI1 and FQI2, also inhibited LSF activity in a LSF-dependent luciferase 
reporter assay, showing their ability to inhibit LSF activity within cells. 
Both in vitro and in vivo, FQIs inhibited LSF DNA binding as detected by the 
electrophoretic mobility shift assay (EMSA) as well as chromatin immunoprecipitation 
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(ChIP) in an LSF inducible cell line.  Further evidentiary support for LSF specificity 
emerged when FQIs were found to be incapable of inhibiting the DNA-binding or 
transcriptional activation mediated by other classes of transcription factors including Sp1, 
Oct1, E2F3, USF, and p53 (Grant et al., 2012).  The three-dimensional structure of the 
LSF DNA binding region has been predicted to be quite similar to that of p53, a 
transcription factor that binds DNA in similar fashion as a homo-tetramer (Kokoszynska 
et al., 2008).  This intriguing report prompted the investigation as to whether FQIs could 
inhibit p53 binding to one of its direct targets, p21.  Grant et al. indeed confirmed that 
FQIs did not impact the ability of p53 to activate p21 gene expression.  These data 
provided confidence that FQI inhibition was specific to LSF.   
Evaluation of the FQIs in HCC cells resulted in significant growth inhibition 
which was translated in vivo in a mouse xenograft model (Grant et al., 2012).  
Particularly compelling data were also generated in an endogenous liver cancer model in 
transgenic mice that expressed c-Myc downstream of an albumin promoter, which 
developed cancer when administered a carcinogen N-nitrosodiethylamine (DEN).  FQI1 
or FQI2 treatment resulted in remarkable prevention or reduction of the endogenous liver 
cancer (Rajasekaran et al., 2015).  In both in vivo circumstances, evaluation of normal 
rapidly dividing cell populations, popular off target activities of the anti-mitotic drug 
modalities, were unchanged.  Evaluation of liver injury markers to identify potential toxic 
consequences of the FQIs indicated that the liver was not negatively impacted in the 
subcutaneous mouse xenograft model (Grant et al., 2012; Rajasekaran et al., 2015).  
These data established a stark contrast to other anti-mitotic compounds evaluated in 
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preclinical contexts (Chan et al., 2012) as toxicities to the non-tumor cell populations, in 
the case of FQIs, were undetected.  These findings led to speculation that LSF could be 
the ‘Achilles heel’ to HCC with a robust anti-tumor activity that was specific to the HCC 
cell population, a case meeting the requirements of oncogene addiction (Shlomai, 2012; 
Weinstein, 2008; Weinstein and Joe, 2008).  The clean toxicity profile of compounds 
inhibiting LSF could be due to many reasons.  First, LSF may not in fact be required for 
normal cell division, as it is ubiquitously expressed only at low levels in normal cells.  It 
may also be redundant in normal cells whereas the HCCs are oncogene addicted.  Finally, 
some properties of the compounds themselves may render the exposure of the compounds 
higher in HCC cells than normal cells thus achieving a high therapeutic index.    
 
Targeting Transcription Factors 
Targeting transcription factors regulating pathways implicated in human 
disease has been an attractive therapeutic goal, especially for cancer.  As previously 
mentioned, tumor cells can escape molecular targeted therapies, resulting in the 
initial efficacy of a compound to vanish in a patient over time (Llovet et al., 2015; 
Torrecilla and Llovet, 2015; Villanueva and Llovet, 2011).  Targeting an entire 
pathway could potentially abrogate the tumor cells’ ability to adapt and prove more 
efficacious, as approaches that neutralize pathway redundancy are more difficult for 
a cancer cell to overcome.  However, transcription factors in general have been 
difficult to target by small molecule inhibitors as they are intrinsically disordered 
within their protein and DNA binding sites and lack stable tertiary and/or 
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secondary structure under physiological conditions in vitro (Dunker and Uversky, 
2010).  Further, many human TFs have small DNA binding pockets making them 
difficult to target.  In contrast, LSF has a relatively large DNA binding domain which 
could provide support for the rationale of why FQIs successfully inhibit LSF DNA 
binding (Dunker and Uversky, 2010; Yan and Higgins, 2013).  
Clearly, anti-tumor activity of FQIs requires further evaluation to understand why 
LSF is indeed required for hepatocellular carcinoma survival.  Early studies expressing a 
dominant negative LSF in a highly tumorigenic cell line reduced tumor cell growth, 
however, did not obliterate tumor formation.  This could simply be due to the endogenous 
LSF that remained partially active, or it could be that the dominant negative LSF did not 
alter LSF protein-protein interactions that could play a role in HCC cell survival, and 
possibly their proliferation.  To confirm that the FQI inhibition of LSF was the sole 
reason for its anti-tumor activity, and also to understand why HCC cells were dependent 
on LSF, a dual approach was taken to interrogate the molecular requirement for LSF.  
These studies led to the following novel results: 1) identification of LSF as a mitotic 
regulator in HCC cells, 2) demonstration that reducing LSF activity either with FQI1 or 
RNAi technology resulted in similar mitotic defects, including a prometaphase/metaphase 
delay, increased time for progression through mitosis, improper cell division, and 
production of multi-nucleated cells, 3) determination that loss of LSF activity led to a 
dose dependent reduction of Aurora Kinase B and Cdc20 levels, 4) establishment of an 
additional, non-transcriptional role for LSF in regulating mitotic progression in HCC 
cells, and finally, 5) further evidence of the lack of toxicity of FQI1 and FQI2 in mice, by 
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evaluating  hematopoietic cell types in whole blood.  In total, the work in this thesis 
further validates the promise of FQIs, or the targeting of LSF, for treatment of 
hepatocellular carcinoma patients, as LSF is a required mitotic regulator in this cancer 
type.   
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CHAPTER TWO 
Materials and Methods 
2.1 Cell lines, culturing, and cell cycle synchronization  
QGY-7703 cells (obtained from Devanand Sarkar’s laboratory, Virginia Commonwealth 
University) were cultured at 37oC in 10 % CO2 in DMEM (Dulbecco’s Modified Eagle’s 
Medium; Corning Cellgro) supplemented with 10% Fetal Bovine Serum (FBS; Atlanta 
Biologicals).  Cells were propagated in T-75 flasks (Corning).  Cells were split 1:10 using 
0.25 % Trypsin (Gibco) once cells were at 85 % to 90 % confluence.  Cells were frozen 
in 5 % DMSO (Sigma) in DMEM containing 10% FBS at passage 2 after a thaw.  After a 
thaw, cells were not passaged greater than 10 times to maintain the consistency of the cell 
line.  
QGY-7703 cells were plated at 0.45-0.9 x106 cells per 35 x 10 mm tissue culture 
plate in complete medium (DMEM+10% FBS), at 0.250 x 106 cells per well in a 6 well 
plate, and at 5,000 cells per well in a 96 well plate on Day 1 for each experiment.  All 
protocols were initiated 24 hours post plating unless otherwise specified.   
For synchronization, cells were then treated with freshly prepared 2 mM 
thymidine (Sigma) in complete medium for 18 hours, washed twice with 1xPhosphate 
Buffered Saline (PBS) acquired from ThermoFisher Scientific (1.5 mM Potassium 
Phosphate monobasic (KH2PO4), 137 mM Sodium Chloride (NaCl), 0.9 mM Calcium 
Chloride (CaCl2), 0.5 mM Magnesium Chloride (MgCl2-6H20), 2.7 mM Potassium 
Chloride (KCl) and 8.05 mM Sodium phosphate dibasic) and incubated with complete 
medium for 6 hours. The complete medium was then removed and 2 mM thymidine in 
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complete medium was added to the cells for second 18-hour incubation.  Cells were 
washed with 1xPBS twice and released from the G1/S block in complete medium.  For 
preparation of the 2 mM thymidine solution, thymidine was measured on an analytical 
scale, diluted into the appropriate amount of complete medium, and sterile filtered using 
a Corning vacuum top filter. 
For certain assays, the Factor Quinolinone Inhibitors were added after the first 
incubation with 2 mM thymidine and that concentration was maintained during the first 
release, the second block, and at the second release.  Alternatively, FQI1 was added into 
complete medium only at the second release.  For all siRNA experiments, the thymidine 
block was started 24 hours post transfection with siRNA.  At each release 20 μM of 
thymidine was added into complete media for certain studies investigating RNAi 
mediated LSF knockdown or FQI1 treatment.   
For all synchronization experiments, cells were then collected either at the final 
G1/S block, or at times after release from the second block, in order to investigate time 
points representative of the cell cycle phases: DNA Synthesis (S), Gap 2 (G2), Mitosis 
(M), and Gap 1 (G1).  For most analyses, the following protocol was used in order to 
ensure that rounded, mitotic cells were included at the point of cell harvest.  The media 
was first transferred into a 50 ml BD Falcon tube, then the cells were washed with 1xPBS 
which was then transferred into the same 50 ml Falcon tube to include all unattached 
cells.  In order to remove the attached cells, 0.25% trypsin was added to each well/plate 
and incubated for 5 minutes at 37oC in 10% CO2.  The media/PBS from the BD Falcon 
tube was added to its designated well to collect the trypsinized cell population and then 
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transferred back to the BD Falcon tube. The harvested cells were then treated for the 
appropriate analyses.   
 
2.2 siRNA transfection to achieve specific gene knockdown  
Cells were plated either in 100 mm x 20 mm culture dishes, 6 well, or 96 well Costar plates with 
no coating, or in 6 well glass plates (MatTek Corporation) specifically acquired for time lapse 
imaging.  Cells were plated on Day 0 at cell numbers ensuring that the cells would be between 
40-60 % confluent on day 2.  The confluence was essential as plating at too low a confluence 
resulted in toxicity due to the amount of lipid transfection reagent per cell.  On Day 1, the cells 
were transfected using RNAimax (Life Technologies).  The Imax reagent was diluted 1:25 into 
OptiMEM (Gibco) and incubated for 5 minutes at room temperature.  The siRNAs were also 
diluted into OptiMEM (Gibco).  All the dilutions were performed in 50 ml BD Falcon Tubes.  
After 5 minutes, the RNAimax/OptiMEM was carefully added to each siRNA dilution in a 1:1 
fashion.  The solution was then carefully swirled by hand to ensure that the integrity of the 
lipoplex was not compromised. Following a 10-minute incubation at room temperature, the lipid 
formulated siRNA was added to each well/plate according to the instructions provided by Life 
Technologies.  0.5 ml of siRNA/lipid was added to 2 ml of complete media in a 6 well plate, 2 ml 
to 8 ml of complete media in 10 mm plates, and 0.05 ml to 0.1 ml in a 96 well plate, respectively.  
The plates were then placed in the 37°C incubator at 10% CO2 for the rest of the study.  
Transfection efficiency was measured by fluorescent microscopy 24 hours post transfection by 
cellular uptake of the Cy3 labeled siRNA control sequence.   
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2.3 Preparation of FQIs  
FQI1 was synthesized by the Schaus laboratory at Boston University.  Solid FQI1 was 
stored at -20 °C for no more than 5 months.  FQI1 was suspended with DMSO (analytical 
grade from Sigma) and aliquoted for storage at -20 °C for no more than 1 month to a 
concentration of 20 mM.  Aliquots were then diluted to a 2 mM concentration into 
DMSO immediately before addition to cells in culture.  The final DMSO concentration 
added to the cells in any group was 0.5%.   
2.4 Reagents 
Table 2.1 Taqman Probes from Life Technologies 
Taqman probes were acquired from Life Technologies in order to determine relative gene 
expression levels.    
 
Human Gene 
Target Probe Information 
Catalog 
Number 
Aurora Kinase B HS009645858 M1 4331182 
Bub1 HS01557695 M1 4331182 
Cyclin A Hs00171105m1 4331182 
Cyclin B Hs01565448 g1 4331182 
Cdc20 HS00426680 M1 4331182 
Cdh1/FZZD HS00393592 M1 4331182 
GAPDH Not provided 4326317E 
LBP1a HS00232691 M1 4331182 
LSF HS00232185 M1 4331182 
Mad2 HS00365651 M1 4331182 
 
Table 2.2 Probe Information for Affymetrix Quantigene Kit 
The probes included below were acquired from Affymetrix from those currently in stock 
that successfully targeted the genes of interest in human samples.  The probes utilized in 
this body of work are listed below.   
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Human Target 
NCBI Accession Number  
(If required) Catalog number 
Aurora Kinase B   SA-10088 
Cdc20   SA-11364  
GAPDH  SA-10001  
TFCP2 NM_005653.3  QG0052 
18S   SD-10001  
 
 
Table 2.3 Reagent and Kit Product Information 
The following kits were acquired and utilized to investigate various aspects of the impact 
of LSF activity reduction in human cells.  The manufacturer’s protocol was strictly 
followed unless otherwise specified.  All kits were used prior to expiration date and 
stored according to protocol guidelines. 
Reagent/Kit Company 
Catalog 
Number 
Senescence kit Cell Signaling 9860 
FlowCellect™ Bivariate 
Cell Cycle Kit 
EMD Millipore Corporation FCCH025103 
Cell Titer Blue Promega G8081 
Thymidine Sigma Aldrich T1895-10G          
γH2AX Kit EMD Millipore Corporation FCCH025142 
Cell Cycle Kit EMD Millipore Corporation 4500-0220 
Apotoxglo assay Promega G6321 
 
Table 2.4 Antibody Information 
The following antibodies were acquired and utilized in the experiments conducted in this 
work.  They were chosen based on user ratings and those predicted for success for either 
immunocytochemistry or western blotting.  They all target, or were predicted to target the 
human protein.  The host species in which the antibody was derived was carefully 
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considered when co-staining was required.  Polyclonal antibodies were chosen if that 
option was available on candidates that fit the previously described criteria. 
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   Dilution 
Antibody 
Catalog 
Number 
Company 
Immuno-
fluorescence 
Western 
Blot 
Alpha tubulin AB7750 Abcam 50 - 
Aurora Kinase B AB2254 Abcam - 500 
Cyclin A AB38 Abcam - 200 
Cyclin B1 AB72 Abcam - 500 
Cdc20 AB26483 Abcam - 500 
γH2AX 9718S 
Cell 
Signalling 50 - 
phosphorylated-Histone 
3 (Serine 10) AB5176 Abcam - 1000 
phosphorylated Histone 
3 (Serine 28) AB5169 Abcam - 1000 
LBP1a ABE181 Abcam - 500 
LSF ABE180 Abcam 100 1000 
Gamma Tubulin AB11316 Abcam 50 - 
α-Tubulin 10002 Sigma - 1000 
Anti-rabbit Alexa 488 AB150069 Abcam 200 - 
Anti-mouse Alex 647 AB150111 Abcam 200 - 
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Donkey anti mouse 
IR800 926-32212 LI-COR,Inc. - 5000 
Donkey anti rabbit 
IR800 926-32213 LI-COR,Inc. - 5000 
 Goat anti rabbit IR680 926-68073 LI-COR,Inc. - 5000 
Goat anti mouse IR680 926-32214 LI-COR,Inc. - 5000 
 
2.5 Phase contrast and fluorescent microscopy.  
 Cells were imaged using an Axiovert 40 CFL (Zeiss) microscope for both phase 
contrast as well as fluorescent imaging in cultured cells. Paraformaldehyde fixed cells 
were analyzed using a Zeiss Axioimager M1 microscope utilizing both 63x and 100x 
magnifications to analyze mitotic progression based on both DNA staining by DAPI 
(Invitrogen) and actin staining by Alexa Fluor 488 Phalloidin (Thermo Fisher Scientific 
Inc. product number A12379) or with anti-antibodies detecting Alpha Tubulin or Aurora 
Kinase B.    
2.6 Cell flow cytometry 
 Attached cells were harvested with 0.25% Trypsin (Gibco) at pre-determined time 
points and combined with the media supernatant containing non-attached cells.  Cells 
were centrifuged at 23 x g for 5 minutes.  They were re-suspended in 1xPBS at a 
concentration of 1x106 cells per ml and centrifuged at 23 x g for 5 minutes.  Cell pellets 
were re-suspended in 150 µl of 3.33x PBS and 350 µl of 100% ethanol.  Cell solutions 
were fixed overnight at 4°C.  Cells were stored no later than one week at 4°C prior to 
analysis.  Cells were centrifuged at 22 x g for 5 minutes.  The PBS/ethanol solution was 
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decanted without compromising the integrity of the cell pellet.  Cells were washed with 
1xPBS and centrifuged at 23 x g for 5 minutes.  1xPBS was removed and Guava cell 
cycle reagent (EMD Millipore), which contains propidium iodide to determine the DNA 
content, was added at a ratio of 200 µl per 2x105 cells.  Cells were stained for 30 minutes 
at room temperature in the dark.  Cell solutions were transferred into 50 ml BD Falcon 
FACS tubes with straining caps (BD Falcon).  Samples were stored at 4°C in the dark for 
no more than 1 week prior to analysis on the BD Dickenson FACS Calibur. 
2.7 Immunofluorescence  
22 mm x 22 mm non-coated glass coverslips (Fisher Scientific) were placed in 
sterile 6 well Costar tissue culture plates in a sterile recirculating tissue culture hood.  The 
coverslips were submerged in 70% ethanol for 2 minutes.  70% ethanol was removed by 
suction and wells/coverslips were allowed to dry in the hood.  Once 70% ethanol was 
fully evaporated, UV light was utilized to sterilize the coverslips and wells for 10 
minutes.  Cells were plated on the coverslips.  For analysis, media was removed and the 
cells were placed in 2 ml of 4% paraformaldehyde for 10 minutes.  Cells were washed 
twice with 1xPBS.  Coverslips with cells were treated with 0.1% Triton X-100 (Thermo 
Fisher Scientific Inc.) for 10 minutes to permeabilize the cell membrane.  Coverslips 
were then incubated in 1% Bovine Serum Albumin (Sigma Aldrich) freshly prepared in 
1xPBS for 1 hour to block nonspecific interactions, followed by incubation with primary 
antibody alone or in combination with a second primary antibody at the indicated dilution 
(Table 2.4) containing 1% Bovine Serum Albumin overnight at 4°C.  Cells were washed 
three times with 1xPBS.  Secondary antibodies were added at a pre-determined dilution 
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(Table 2.4) and incubated for 2 hours at room temperature in dark.  Cells were washed 3 
times with 1xPBS.  The corner of the coverslip was blotted on a paper towel to remove 
excess 1xPBS.  Cells were then mounted using Anti-fade DAPI Mounting Medium 
(Invitrogen) or Permount mounting solution. Cells were dried overnight in the dark.  
Coverslips were sealed on glass slides with clear nail polish.  
2.8 Immunoblotting  
 Cells were lysed in RIPA buffer (125 mM Tris HCl, 150 mM NaCl, 0.1% NP-40, 
1.0% Sodium deoxycholate, 1.0% SDS, pH 7.6) containing ROCHE protease cocktail 
phosphatase inhibitors (Sigma Aldrich 4693159001) at the manufacturer’s recommended 
concentrations, prepared no greater than 1 week prior to the experimental end.  Lysates 
were placed on ice for 10 minutes then mixed by vortexing for 10 seconds.  Protein 
concentrations were determined by the Pierce BCA protein kit using a BSA standard 
prepared at concentrations from 25 to 2000 μg/ml. Equivalent protein concentrations 
were boiled for 10 minutes in 4x SDS Laemmli buffer (277.8 mM Tris-HCL pH 6.8, 
44.4% (v/v) glycerol, 4.4% lithium dodecyl sulfate, 0.02% bromophenol blue with 355 
nM β-mercaptoethanol; Bio-rad).  The final concentration of the SDS Laemmli buffer 
was 2x.   Lysates were loaded onto 10 or 15 well 4-20% Mini-PROTEAN® TGX™ 
Precast gradient gels (Bio-rad, product number 456-1096). The proteins were transferred 
to a PVDF membrane using the Bio-rad wet transfer apparatus for 30 minutes at 90 volts 
or the iblot system from Invitrogen according to the manufacturer’s protocol.  Ponceau 
red (Sigma) staining confirmed proper protein transfer.  The dual labeled molecular 
weight ladder (Bio-rad #13-032) with blue and red dye allowing visualization in both 600 
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and 800 channels available with the Licor odyssey was utilized in each experiment.  
PDVF membranes were incubated for 1 hour in odyssey blocking buffer (LI-COR 
Biosciences cat# 927-40000). The odyssey blocking buffer was PBS-based with 0.1% of 
sodium azide.  Primary antibodies were incubated at pre-determined concentrations (see 
Table 2.4) in PBS/Odyssey Blocking buffer overnight at 4°C.  Membranes were washed 
three times in 1xPBS 0.01% Tween 20 for 20 minute intervals.  Membranes were then 
incubated in a 1/5,000 dilution of appropriate secondary antibody (or antibodies) at room 
temperature for 2 hours.  Membranes were washed three times in 1xPBS in 20 minute 
increments.  PVDF membranes were then imaged using the Licor Odyssey (Boveia and 
Schutz-Geschwender, 2015).  Infrared detection quantitated each band on an individual 
pixel basis using western analysis tools in the Image Studio program.  This system 
allowed quantitation from each channel separately following the capture of single image, 
on an individual pixel basis (Boveia and Schutz-Geschwender, 2015).  Additionally, the 
background signal is subtracted from the area immediately surrounding the band being 
analyzed.    
2.9 RNA analysis: bDNA assay from Affymetrix 
RNA quantification was executed using a hybridization based assay, Quantigene 1.0 
and/or 2.0 systems, available from Affymetrix.  Probes were designed by Affymetrix 
according to NCBI accession numbers, or sequences were used according to previously 
developed probes for the gene of interest. The probe concentration for the assay was 
determined using a standard curve for each probe on untreated cell lysates plated at the 
10,000 cells per well in at 96 well plate at day 1 with cell lysates harvested 24 hours later.  
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The cell concentration was kept constant and the probe concentration was chosen based 
on the standard curve.  Media was removed by suction and 100 μl of the Affymetrix lysis 
buffer with proteinase K (Promega), added to the buffer immediately prior to the lysis 
step, was then added to each well.  Plates were placed on a shaker for 30 minutes at 56°C.  
Lysates were frozen at -20°C until analysis.  The manufacturer’s protocol was followed.  
Fluorescent signal was determined by 30 second reads on each well using the Victor plate 
reader (PerkinElmer).  Each target gene was normalized to a ubiquitous control gene.  
GAPDH, ACTB, and 18S rRNA were utilized as the ubiquitous control genes (see Table 
2.2).  
2.10 Measuring Gene Expression with RT-qPCR 
RNA isolation using the QIAzol reagent (trizol based chemical from Qiagen) was 
performed by adding the reagent either to growing cells immediately following a 1xPBS 
wash, or to frozen cell pellets collected after a 1xPBS wash and snap frozen at -80°C. 
Alternatively, RNA was isolated from samples using the Qiagen RNAeasy kit following 
the manufacturer’s instructions. RNA concentrations were determined using a Nanodrop 
spectrophotometer (ThermoFisher Scientific). The RNA concentrations were adjusted to 
25 ng/µl where 250 ng was then used to make cDNA using a Reverse Transcription kit 
from Applied Biosystems (catalogue number 4368814).  All probes for RNA 
quantification were acquired from Taqman gene expression system utilizing dual labeled 
probes which allowed for analysis of gene expression. TaqMan® gene expression assays 
consist of a pair of unlabeled PCR primers and a TaqMan® probe with a FAM™ or 
VIC® dye label on the 5' end, and minor groove binder (MGB) non-fluorescent quencher 
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(NFQ) on the 3' end. RNA from samples of interest was reverse transcribed into cDNA, 
and the synthesized cDNA served as a template for real-time PCR. Target gene 
expression was normalized to the GAPDH ubiquitous control in each well utilizing a dual 
label system where the control probe targeting GAPDH RNA was labeled with FAM and 
the probe targeting the gene of interest was labeled with VIC.  Ct values were measured 
using a Roche Light Cycler 480.  The following formula was used to determine relative 
gene expression:  2- (Ct Target)/2-(Ct Control). 
2.11 Caspase activity and viability 
 Caspase activity, viability, and cytotoxicity were measured using the Apo Tox-
GloTM kit (Promega).  The kit measured viability and cytotoxicity using substrates that 
were cleaved by live cell proteases or dead cell proteases, respectively, resulting in the 
emission of a fluorescent signal at different wavelengths (Niles et al., 2007). Specifically, 
the live-cell protease activity is restricted to intact viable cells and is measured using a 
fluorogenic, cell-permeant, peptide substrate (GF-AFC). The substrate enters intact cells 
where it is cleaved by the live-cell protease activity to generate a fluorescent signal 
proportional to the number of living cells. This live-cell protease becomes inactive upon 
loss of cell membrane integrity and leakage into the surrounding culture medium. A 
second, fluorogenic cell-impermeant peptide substrate (bis-AAF-R110) is used to 
measure dead-cell protease activity, which is released from cells that have lost membrane 
integrity. Because bis-AAF-R110 is not cell-permeant, essentially no signal from this 
substrate is generated by intact, viable cells. The live- and dead-cell proteases produce 
different products, AFC and R110, which have different excitation and emission spectra, 
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allowing them to be detected simultaneously.  Additionally, the kit measured the 
cleavage of Caspase 3/7 substrates by luminescence. Cells were cultured with FQIs or 
transfected with siRNA following plating of 2x105 cells per well in 96 well pates 
(Corning), and the Apoptoxglo kit was utilized using manufacturer’s instructions. The 
substrates for both live and dead cell proteases were added to wells with 100 μl of 
complete media. The plate was mixed on a lab rotator orbital shaker at a speed of 300 
units for 1 minute. The plate was incubated for 30 minutes at 37°C 10% CO2 prior to the 
measuring the luminescence or fluorescence on the VersaMaxTM plate reader (Molecular 
Devices). 
2.12 Viability determined by mitochondrial activity 
Cell Titer Blue (Promega) was utilized to measure cell viability via the ability of the cell 
to convert a redox dye into a fluorescent end product.  Cells were plated on day 1 on a 6-
well plate with 250,000 cells per well, on day 2 when the cells reached about 40% 
confluence they were treated with FQIs, vehicle, or transfected with siRNA utilizing 
RNAiMax transfection reagent (Invitrogen).  At selected time points, cell titer blue was 
added to the experimental wells at a volume of 500 μl into 2 ml of complete media for 6 
well costar plate and 20 μl into 100 μl of complete media for a 96 well costar plate.  Once 
the reagent was added, the plates were shaken for 1 min.  The cells were then incubated 
at 37°C with 10% CO2 for 1 to 4 hours.  The fluorescent signal was detected on a 
VersaMaxTM plate reader (Molecular Devices) exciting at 560 nM and measuring 
fluorescence emission at 590 nM.   
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2.13 Isolation of primary mouse hepatocytes. 
Primary mouse hepatocytes were isolated according to the protocol in Severgini et al. 
2012.  Once isolated, the hepatocytes were plated in 6 well plates with sterilized 
coverslips.  The cells were allowed to adhere to the coverslips for 4 hours, and then the 
cells were treated with FQI1 or vehicle.  The coverslips were collected at various time 
points, fixed for 20 min in 4% paraformaldehyde, washed twice with 1xPBS and stored in 
1xPBS at 4°C.  The cells were either stained with DAPI and Phalloidin or with 
Hematoxylin and Eosin prior to imaging. 
2.14 Ex vivo maintenance of primary mouse hepatocytes 
Primary hepatocytes isolated according to 2.13 were plated in 6 well plates at 500,000 
cells per well and maintained in Williams Media (ThermoFisher Scientific cat#1217901) 
supplemented with hepatocyte maintenance supplement pack (ThermoFisher Scientific 
cat#CM4000).  Specifically, cell culture plates were coated with 0.1% rat tail collagen 
(Sigma) 24 h before plating cells. After isolation, cell number and viability were 
determined. The cell pellet was re-suspended by gently pipetting up and down in the 
appropriate volume of 37 °C plating medium [Dulbecco’s Modified Eagle’s Medium, 2% 
bovine serum albumin (BSA, Sigma-Aldrich), Hepatocyte Plating/Thawing and 
Maintenance Supplement (ThermoFisher Scientific cat#C3000), 0.1% rat tail collagen 
(Sigma-Aldrich)].  Cells were seeded gently and incubated in a tissue culture incubator 
set at 37 °C, 5% CO2. After 4.5–5 h, cells were washed once with 1xPBS and 2 ml of 
maintenance medium was added to each well.  At this time FQI1 or vehicle control was 
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added to the media at a final concentration of 5 µM.  Phase-contrast pictures were taken 
with an Axiovert 40 CFL (Zeiss) microscope. 
2.15 Generation and LSF knockdown of QGY-7703 mEmerald Alpha-Tubulin and QGY-
7703 YFP Histone H2B cell lines 
Calcium Phosphate Transfection of HEK-293  
Packaging Cells (GP2-293 packaging cells; Clontech) were cultured at 37oC in 5% CO2 
in DMEM (Dulbecco’s modification of Eagle’s Medium (Corning Cellgro) supplemented 
with 10% FBS (Atlanta Biologicals), 6 mM L-Glutamine (Cellgro), and 1 mM sodium 
pyruvate (Cellgro). Since L-Glutamine degrades over time at 4oC, the media was re-
supplemented with L-glutamine when the cells began to exhibit slow growth. Cells were 
grown on 10 cm tissue culture plates coated with 0.1% collagen (extracted from rat tails; 
gift from the Bradham laboratory) for 30 minutes at 37oC and washed twice with PBS. To 
begin, 5x106 GP2-293 cells were plated on a 10 cm collagen coated tissue culture plate. 
The next day, the cells were transfected with 10 μg of pVSV-G expression plasmid 
(Clontech) and 10 μg of a pBABE vector containing a gene for YFP-tagged histone H2B 
protein and a gene encoding G418 resistance (gift from Jagesh Shah laboratory, Harvard 
Medical School) via calcium phosphate method (Kingston, et al., 2003). Five hours post 
transfection, the DNA-containing media was removed, and the plates were washed once 
with 1x PBS. Then, 10% sterile glycerol in DMEM was added to the plate and left to 
incubate at room temperature for 1.5 minutes. The glycerol/DMEM was then removed, 
the plate was washed once more with 1x PBS, and 10 mL of the supplemented DMEM 
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was added to the plate. [Performed by Mark Roberto of the Hansen laboratory at Boston 
University.] 
Preparation of virus-containing media and Infection of QGY-7703 cells 
Two days after transfection of the packaging cell line with the retroviral vector, the media 
from the plate of GP2-293 cells was collected into a 50 mL conical tube. The media was 
then filtered using a 45 μm syringe filter (Pall Corporation) in order to remove any GP2-
293 cells, and 8 μg/mL polybrene was added. The virus-containing supernatant was then 
transferred to a 10 cm plate of QGY-7703 cells that were at 60-70% confluence. QGY-
7703 cells were cultured at 37oC in 5% CO2 in DMEM (Dulbecco’s modification of 
Eagle’s Medium (Corning Cellgro) supplemented with 10% FBS (Atlanta Biologicals).  
The following day, the virus-containing media was replaced with 10 mL of DMEM + 
10% FBS + 500 μg/mL G418 anti-biotic (Gibco). The G418-containing DMEM was 
replaced every 3 days for about 10 days until the majority of cells expressed the YFP-
histone fusion protein. Presence of the fluorescent protein was checked using an Endow 
GFP/EGFP Bandpass filter (Chroma) in an Olympus IX50 inverted fluorescent 
microscope, exciting the protein at 514 nm and detecting subsequent emission at 527 nm. 
[Performed by Mark Roberto of the Hansen laboratory at Boston University.] 
The QGY-7703 cells were also infected with a lentivirus to express the mEmerald Alpha-
tubulin, selected in 5 μg/ml Blasticidin, and sorted by FACS to enrich for positive cells. 
[Performed by Dr. Kelly George of the Shah Laboratory at Harvard Medical School.] 
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 siRNA Knockdown of LSF and/or LBP1a in Asynchronous QGY-7703 Cells Expressing 
Fluorescently Tagged H2B 
Fluorescently tagged H2B-QGY7703 cells were plated on 6-well glass plates (MatTek) at 
5x104 cells/well. The next day, the cells were transfected with a siRNA against firefly 
luciferase GL3 at a 20 nM concentration or siRNA against LSF at either a 10 nM or 20 
nM concentrations by using 70 μL of RNAiMax (Invitrogen) per plate with a final 
volume of 2.5 mL DMEM with transfection mixture. The cells were incubated at 37OC 
with the transfection mixture for 48 hours, after which the mixture was removed and the 
cells were washed twice with 1x PBS. Fresh DMEM + 10% FBS was then added to each 
well. The cells were imaged by time lapse microscopy the next day (72 hours post-
transfection), or two days later (96 hours post-transfection).  
 
Double and single thymidine block synchronization of fluorescently tagged QGY-7703 
cells after siRNA Knockdown 
The fluorescently tagged H2B-QGY7703 cells were synchronized by using a single 
thymidine block. Two days after the cells were transfected with either control siRNA 
against luciferase or siRNA against LSF, LBP1a, or the combination of the two, the 
siRNA-containing media was removed and cells were washed twice with 1x PBS. The 
media was then replaced with 2 mL of DMEM containing 2 mM thymidine. After 18 
hours, the media was removed, the cells were washed once with PBS, and 2 mL of 
DMEM was added to the cells. Following 6-7 hours, the DMEM was removed and 
replaced with 2 mL of DMEM containing 2 mM thymidine. After 16-24 hours, the media 
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was removed, the cells were washed twice with 1x PBS, and 2 mL of complete media 
was added to the cells with or without 20 μM thymidine. The cells were imaged by time 
lapse microscopy at 48 hours after transfection.  Additionally, some experiments were 
executed using a single thymidine block.  There, the cells were transfected with siRNA, 
24 hours later 2 mM thymidine was added for 24hours.  The cells were then released 
from the block following a 1XPBS wash and imaged.   
 
2.16 Time lapse microscopy 
Single thymidine block synchronization of QGY-7703 Cells Expressing Fluorescently 
Tagged H2B after siRNA knockdown 
QGY-7703 cells with H2B labeled with YFP or with alpha tubulin labeled with 
mEmerald were plated at 250,000 cells per well in 6 well glass plates acquired from 
MatTek Corporation. The cells were placed in the 37°C 10% CO2 incubator overnight.  
For siRNA studies, the cells were transfected on day 2 with RNAiMAX at 1:25 dilution 
into OptiMEM (Gibco).  The siRNA was diluted in OptiMEM at appropriate 
concentrations and mixed 1:1 with the RNAimax/OptiMEM solution; 500 µl of the 
siRNA/Lipid mix was added to 2 ml of complete media. Following 10 minute incubation 
at room temperature, the lipid/siRNA mixture was added to the 6 well plates. The cells 
were placed in the 37OC 10% CO2 incubator overnight.  Twenty-four hours later the 
media was removed and 2 mM of sterile filtered thymidine in Complete media was added 
to each well.  The cells were placed in the 37OC 10% CO2 incubator overnight.  Cells 
were washed with 1xPBS and were imaged in the CO2 independent medium (Leibovitz's 
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L-15 without phenol red) on a Nikon TA10 Eclipse with a 20X objected with a heated 
environment (37°C).  
Treatment of QGY-7703 Cells Expressing Fluorescently Tagged H2B with FQI1 
QGY-7703 cells with H2B labeled with YFP or with alpha tubulin labeled with 
mEmerald were plated at 500,000 cells per well in 6 well glass plates acquired from 
MatTek Corporation. The cells were placed in the 37OC 10% CO2 incubator overnight.  
Vehicle control or FQI1 was added at final concentrations of 0.9, 1.8, or 3.6 µM in CO2 
independent medium (Leibovitz's L-15 without phenol red).  Cells were imaged 
immediately after adding FQI1 in on a Nikon TA10 Eclipse with a 20X objective with a 
heated environment (37°C).  
Measuring mitotic times 
Images were acquired for cells, treated with either FQI1 or transfected with siRNAs, 
every four minutes at 7-10 positions per condition for at least five hours.  Length of 
mitosis was measured from nuclear envelope breakdown to anaphase.  Nuclear envelope 
breakdown as demonstrated by disordered condensed chromosomes was used to 
demarcate entry into mitosis.  Anaphase was determined as the first image in which sister 
chromatid separation is apparent (for normal anaphases) or when a furrow begins to form 
over the chromosomes. The pictures were then compiled into a video at a speed of five 
frames per second.  Imaging and photo compilation was carried out by Dr. Kelly George 
of the Shah Laboratory at Harvard Medical School.  
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2.17 Analysis of γ H2AX to assay for double stranded DNA breaks 
Levels of γ-H2AX were analyzed by both flow cytometry and immunofluorescent 
microscopy.  Immunofluorescence staining for γH2AX was performed in similar fashion 
to all immunofluorescence imaging previously discussed using an anti γH2AX antibody 
from Abcam at a 1:50 dilution.  Images were gathered using the methodology described 
in 2.2 and 2.3.  These cells analyzed following siRNA transfection of FQI1 treatment 
were either asynchronous or synchronized using a double thymidine block.   
γH2AX staining was also measured by flow cytometry using a kit from EMD Millipore 
(17-344).  The cells were treated with FQI1 or siRNA knockdown (2.1-2.3).  Cell 
samples were collected and washed in 1xPBS.  The cell pellets were then fixed and 
permeabilized with overnight incubation in a 70% ethanol solution prior to staining and 
detection.  Histone H2A.X phosphorylated at serine 139 was detected by the addition of 
the anti-phosphorylated-Histone H2A.X, FITC conjugate.  Cells were then analyzed by 
flow cytometry to quantitate the number of cells staining positive for phosphorylated 
Histone H2A.X. 
2.18 β-Galactosidase activity to determine cellular senescence 
QGY-7703 cells synchronized with a double thymidine block with either FQI1 treatment 
or LSF knockdown in 6 well plates were washed once with 1xPBS.  The cells were then 
stained for β-galactosidase using the activity kit from Cell Signaling Technologies.  The 
Senescence β-Galactosidase Staining Kit is designed to conveniently provide reagents 
needed to detect β-galactosidase activity at pH 6, a known characteristic of senescent 
cells not found in presenescent, quiescent or immortal cells.  The cells were fixed using 
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the fixation buffer including in the Cell signaling Technology kit.  The staining reagent 
was prepared according to the manufacturer’s protocol and the pH was adjusted to 6.0 
using 1 M HCl.  The cells were then washed twice with 1xPBS and 1 ml of the staining 
solution was added to each well in 6 well plates.  The plate was sealed with aluminum 
foil and incubated overnight at 37°C.  Cell images were gathered following the overnight 
incubation on a phase Axiovert 40 CFL (Zeiss) microscope.  The number of positive 
cells, as determined by blue staining, was determined in comparison to cells without blue 
signal.  Intensity of signal was not measured.  
2.19 Blood collection and analysis 
C57BL6 male mice (Charles River Laboratories) were acquired at approximately 8 weeks 
of age.  Animals were kept on normal diet and light cycling conditions. Mice were dosed 
intraperitoneally with FQI1, FQI2 or vehicle control (DMSO) injected into each animal at 
40 µl/gram.  Both the vehicle and FQI injections contained 5% DMSO.  One group of 
animals were dosed with 40 µl/gram of Saline as an additional control.  The 8 mg/kg dose 
was injected daily for 5 days.  Blood was collected utilizing the retro-orbital eye bleed 
procedure 24 hours post the final dose.  For this procedure, the mice were anesthetized 
using isoflurane.  Heparin coated capillary tubes (Fisher Scientific) were inserted into the 
posterior corner of the mouse eye; the tube was inserted at a 45-degree angle to 
approximately 1 cm and rotated until the blood from the retro-orbital sinus was released.  
Approximately 200 µl was collected from the left eye each mouse according to the 
IACUC protocol for blood collection.  The blood was collected either in Becton 
Dickinson (BD) serum separator tubes or with BD plasma tubes coated with EDTA.  
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Serum samples were kept at room temperature for 1 hour and then spun in a micro-
centrifuge at 22 x g at room temperature for 10 minutes.  Serum was transferred to 1.5 ml 
micro-centrifuge tubes for storage at -80°C until samples were processed.  Whole blood 
samples were collected and held at room temperature with mixing every 5 min to ensure 
EDTA was properly distributed to avoid clotting. The whole blood and sera samples were 
analyzed using an ADVIA® 120 Hematology System from Siemens. All procedures were 
conducted in accordance with IACUC procedures.  
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CHAPTER THREE  
FQI1 Treatment for short intervals causes reversible mitotic defects with minimal 
transcriptional consequences 
 (Figures 3.2, 3.3d, and 3.4a include data published in Rajasekaran et al.) 
Introduction 
 Hepatocellular carcinoma represents approximately 70-85% of the primary liver 
cancers, and is one of the major causes of death worldwide (Bruix, 2011; Bruix and 
Sherman, 2011; Wang et al., 2002).  Risk factors include, but are not limited to, viral 
infection, toxins, and alcohol.  HCC, a disease which slowly progresses over decades, 
presents with both non-specific symptoms and a lack of biomarkers which often lead to 
late diagnosis.  One third of patients diagnosed may qualify for potential curative, yet 
invasive treatments, including surgical resection and liver transplantation.  Those who 
have progressed into late stage disease do not qualify for such curative treatments leaving 
patients with only palliative treatment options as systemic therapies are limited.  Current 
systemic therapeutic options are subpar as Sorafenib, the only approved molecular 
therapy, extended patient survival, at best, only 11 months (Bruix and Sherman, 2011; 
Llovet et al., 2015).  New molecular therapies, which have demonstrated promising anti-
tumor activity in preclinical models, have yet to match (or improve upon) Sorafenib, 
leaving a large population with a severe unmet medical need. 
 The ubiquitously expressed, evolutionarily conserved transcription factor LSF is 
overexpressed in HCC, with increased expression positively correlating with disease 
severity in clinical samples (Fan et al., 2011b; Yoo et al., 2010).  LSF expression, which 
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is at relatively low levels in hepatocytes, is necessary and sufficient for HCC 
tumorigenicity in vivo as expressing LSF induced tumorigenicity in a HCC line and 
expression of a dominant negative LSF inhibited both subcutaneous tumor growth and 
metastasis formation in xenograft mouse models.  These data implicated LSF as an 
oncogenic transcription factor in hepatocellular carcinoma. 
A small molecule inhibitor of LSF (in the Factor Quinolinone Inhibitor (FQI) 
family), was identified from a screen of 110,000 compounds utilizing a fluorescent 
polarization assay designed to detect molecules able to directly inhibit LSF DNA binding 
(Grant et al., 2012).  FQI1 and FQI2 were identified from the screen and confirmed as 
inhibitors of LSF in several assays including a LSF transcriptional activation in a 
luciferase reporter assay and a LSF- DNA binding electrophoretic mobility shift assay 
(EMSA).  In addition, the molecules proved capable of inhibiting LSF DNA binding to a 
target gene, POLA1, in vivo as ascertained by chromatin immunoprecipitation (ChIP) in a 
tagged-LSF inducible cell line (Grant et al., 2012).  The first compound identified (FQI1) 
was demonstrated to be specific for LSF as it was not capable of inhibiting the DNA-
binding activity of other classes of transcription factors, including E2F3, Oct1, or SP1.  
Further, FQI1 treatment did not impact the transcriptional activation by p53 or USF 
(Grant et al., 2012).  These data collectively indicated strongly that LSF is specifically 
targeted by both FQI1 and FQI2 resulting in the inability to transcriptionally regulate 
their direct targets.  Further, treatment of HCC cells with FQI1 and FQI2 caused loss of 
viability as determined by reduced mitochondrial activity and an increased level of 
apoptosis.  In vivo, FQI1 and FQI2 inhibited HCC tumor growth in both a subcutaneous 
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HCC xenograft mouse model, and more recently, in an endogenous mouse liver model 
(Rajasekaran et al., 2015).  Taken together, these data indicate that FQI1 or FQI2 
inhibition of LSF results in hepatocellular carcinoma cell death in preclinical models 
suggesting that LSF small molecule inhibitors may provide therapeutic benefit to the 
HCC patient population.   
Transcription factors are generally believed to be undruggable and few bona fide, 
specific transcription factor inhibitors have been identified to date despite a great deal of 
effort both in academic and industrial settings (Yan and Higgins, 2013). Given the 
proposed unusual mechanism of action of FQI1 and 2, confirming that their observed 
biological effects are specifically and solely due to inhibition of LSF, as well as 
identifying the mechanism of HCC death resulting from FQI1 treatment are important to 
provide clarity around their therapeutic potential for HCC. 
Previous reports have shown that LSF is required prior to the G1/S transition for 
cell cycle progression (Powell et al., 2000; Saxena et al., 2010).  Expression of a 
dominant negative mutant of LSF resulted in apoptosis during S phase, as thymidylate 
synthase, regulated by LSF, was not as substantially induced; this phenotype was rescued 
with supplementation of exogenous thymidine.  The dominant negative LSF utilized for 
these studies, a double amino acid substitution mutant of LSF named Q234L/K236E, was 
unable to bind DNA (Santhekadur et al., 2012a; Shirra et al., 1994).  These results 
suggested that LSF regulation of G1/S progression in HCC cells may be responsible for 
the FQI1/FQI2 anti-tumor activity.   
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To elucidate the molecular requirement of LSF in HCC cell survival, I evaluated 
the impact on cell cycle progression by FQI inhibition of LSF in QGY-7703 cells.  Here, 
I show that treatment of synchronized HCC cells with FQI1 starting at the G1/S border 
results (during the subsequent mitosis) in a prometaphase arrest followed by cell death.  
This is evidenced by cell cycle arrest following the completion of DNA synthesis, 
followed by multi-nucleation and/or cell death.  Accumulation of cells at prometaphase is 
reversible if the compound is removed from the HCC cells after a short prometaphase 
block, suggesting that this phenotype is not related to LSF-mediated transcription.  
Together, these data indicate that LSF is required for proper mitotic progression in 
hepatocellular carcinoma cells and that this may significantly involve non-transcriptional 
regulation by LSF. 
Results 
The LSF inhibitor FQI1 causes dose dependent inhibition of cellular division and loss of 
viability following Caspase 3/7 activation 
To investigate whether LSF was required for HCC cell cycle progression, QGY-
7703 cells were synchronized at the G1/S border and released in the presence of FQI1 or 
vehicle (Illustration 3.1).  The half maximal concentration for growth inhibition of QGY-
7703 cells was reported to be 1.3 µM (Christadore, 2013).  This was consistent with the 
G150s generated in two human tumor cell lines ranging from 0.79 to 6.3 µM (Grant, et al 
2012).  The concentrations were chosen to bracket the half maximal concentration, with 
3.6 μM demonstrating maximal growth inhibition (Christadore, 2013).  Measurement of 
cell numbers following release (Figure 3.1a) revealed a dose dependent reduction in total 
 
 
50 
cells upon treatment for 10 hours with FQI1. The experimental conditions chosen should 
result in the cell population doubling at approximately 8 hours after release, the amount 
of time needed for the cells to complete both DNA synthesis and mitosis.  Indeed, the 
control cells increased in number by 2-fold, consistent with the expected division rate.  In 
contrast progression through cell division was inhibited in a dose dependent manner with 
FQI1 treatment.  Specifically, at the highest FQI1 concentration of 3.6 µM, the cells still 
had not progressed through cell division 8 hours after release from the G1/S block.  At 
the lower FQI1 concentrations, however, cell division was able to occur in at least a 
subset of the cells at 1.8 µM, and in most of them at 0.9 µM.    
To determine if the lack of cell division upon FQI1 treatment was due to cell 
death, apoptosis and cell viability assays were conducted in parallel.  Caspase 3/7 
activation (which occurs early in the apoptotic pathway) was measured at 6, 24, and 48 
hours post release from a G1/S block (Figure 3.1b).  Enzyme activity increased in a dose 
dependent manner and was elevated even at 6 hours, at which point the control cells 
would have been predicted to complete DNA synthesis. However, cell viability was not 
impacted until later, after 24 h (at 24 h, treated cells still retained full viability, data not 
shown).  FQI1 concentrations that increased caspase 3/7 activity also decreased viability 
at 48 h, as measured by a reduction in intracellular live cell protease activity that is lost 
upon cell membrane disruption (Figure 3.1c).  Together, these data indicate that while 
cells treated with FQI1 initiate cell death pathways early following release from a G1/S 
block, phenotypic programmed cell death is delayed.  The loss of cell viability is 
consistent with previous reports showing reduced mitochondrial activity by an MTT 
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assay, TUNEL staining and Annexin V staining (the latter two being indicative of 
apoptosis).  TUNEL staining was documented after 48 hours of incubation with 10 µM 
FQI1 in asynchronous HCC cell populations (Grant, et al 2012).  Annexin V staining and 
caspase 3 activity were assayed in asynchronous QGY-7703 cells after 24 hours of 
incubation with 2 µM FQI1 or FQI2 (Rajasekaran et al 2015).  Because Annexin V 
staining measures apoptotic signaling through the flipping of phosphatidylserine in the 
plasma membrane to the cell surface, one of the earliest responses in the apoptotic 
pathway, it is not surprising that this occurred within 24 hours of incubation even in the 
asynchronous population.   
 
FQI1-mediated inhibition of cellular division in HCC cells results from mitotic defects 
The observation of cellular death following the inhibition of cellular division 
suggested that LSF was required for cell cycle progression.  To determine at what point 
LSF was required for HCC cell cycle regulation we evaluated cell cycle progression in 
G1/S synchronized HCC cells released in presence of 2 or 5 µM of FQI1 or vehicle.  Cell 
cycle progression was analyzed by cellular DNA content using flow cytometry.  Because 
tumor cells in general, and QGY-7703 in particular, are aneuploid, DNA content as 
ascertained by flow cytometry does not reflect a true 2n.  Given the aneuploid nature of 
the cells, I aligned the cell populations with non-replicated DNA at the 2n peak, with 4n 
representing a successful round of DNA synthesis (Figure 3.2).  Utilizing this protocol, 
successful synchronization of the cells at the G1/S border was demonstrated by the peak 
of cellular DNA at 2n immediately prior to release (compare Figures 3.2a and b).  
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Subsequent cell cycle progression following the release (0 hours) of control cells results 
in a doubling of DNA content to G2/M levels at 7 hours, followed by a return to G1 
levels 3 hours later (Figure 3.2c).  Unexpectedly, unlike the vehicle-treated cells, the 
FQI1-treated cells remained at 4n DNA content at the 10-hour time point.  At 17 hours 
post release, the 5 µM FQI1 treated cells remained arrested, except for a small population 
with sub-G1 DNA content, indicative of cell death.  A lower concentration of FQI1 also 
resulted in accumulation at 4n DNA shortly after control cells had exited mitosis (10 
hours), however, seven hours later when controls were still in G1 three populations were 
observed:  a population of cells with 4n DNA content, a population with sub G1 DNA 
content, and a population that appears to have re-entered G1.  The mixed populations 
observed with the lower concentrations of FQI1 are consistent with a partial inhibition of 
LSF activity at those doses. 
The observation of both a cell proliferation defect along with an accumulation at 
4n DNA content indicated that the impact of FQI1 inhibition on the cells likely occurred 
after completion of DNA synthesis, however, whether the cells had actually entered 
mitosis remained unclear.  To investigate this, I measured both Cyclin A and B levels in 
FQI1 treated cells that had entered mitosis at 6-7 hours after G1/S (Figure 3.3).  In 
normal cells Cyclin A and B levels change during mitosis as Cyclin Dependent Kinase 1 
(CDK1) associates with different cyclins at different points to phosphorylate key targets.  
Cyclin A levels degrade in late prophase whereas levels of Cyclin B are maintained 
through mitosis until anaphase (Casimiro et al., 2012; Malumbres, 2007; Sherr and 
Roberts, 1995, 2004).  While cyclin A gene expression at 8 hours after G1/S release was 
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unaltered by FQI1 treatment (Figure 3a), Cyclin A protein levels were reduced at both 0.9 
and 1.8 μM relative to the controls (Figure 3b,c).  This result was particularly striking as 
the control cells at that point had an elevation of Cyclin A protein, these results suggest 
that as opposed to the control cells that had successfully gone through mitosis, the treated 
cells remained in mitosis (Figures 3.3b and c). However, the cells treated with 5 µM 
FQI1 surprisingly had comparable Cyclin A levels in comparison to the control, which 
combined with the DNA profiling data (Figure 3.2) suggested that these cells were 
arrested earlier (e.g. G2 or early mitosis) than the cells treated at the lower FQI1 
concentrations.  To determine whether the cells had progressed at least to late G2 by 7 
hours after G1/S release, Cyclin B expression was also measured. The vehicle treated, 
control cells show an initial increase in Cyclin B expression when the cells are about to 
enter mitosis (7 hours), which is then reduced at 10 hours after the G1/S release 
(consistent with the cellular DNA profiles) indicating mitotic exit and G1 re-entry at this 
time (Figure 3.3d).  In contrast, the Cyclin B protein levels remained elevated at 10 and 
17 hours in both of the FQI1-treated samples. Together, these data suggest that the FQI1 
treated cells are arrested at in late G2/early mitosis.  However, since Cyclin B RNA 
levels in FQI1 treated cells at 7 hours after G1/S was comparable to that of the control, 
the persisting, higher protein levels must result from the G2/mitotic arrest, rather than 
from transcriptional dysregulation (Figure 3.3e).  Collectively, these data are suggestive 
of a G2/mitotic arrest in FQI1 treated cells where the higher concentrations result in a 
delay in late prophase whereas at the lower concentrations there is an arrest following 
mitotic entry.   
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To investigate further the apparent mitotic defect caused by FQI1, cells were 
imaged for progression through mitosis by visualizing their cellular morphology as 
determined by staining for alpha tubulin and DNA.  Eight hours after release from the 
G1/S block, FQI1-treated cells revealed increased numbers of cells in prometaphase 
whereas the vehicle-treated cells were in final stages of mitosis or interphase (Figure 
3.4a). These cells, analyzed at 63x magnification, were deemed to be arrested in 
prometaphase as the DNA had condensed, however, the chromosomes were not aligned 
as expected in metaphase.  FQI1 treatment for 48 hours led to a reduced number of cells 
in comparison to the control (not shown).  The cells remaining were multi-nucleated 
(Figure 3.4b).  When progression of synchronized HCC cells was followed over time, 
those treated with 5 µM FQI1 that had entered mitosis at 6 hours after release from the 
G1/S block, were predominantly in prometaphase, whereas the vehicle-treated cells that 
had entered mitosis were predominantly in metaphase (Figure 3.4c).  At later timepoints, 
the control cells had divided and eventually were again observed in metaphase, whereas 
the FQI1-treated cells were both lower in cell number and generally multi-nucleated, as 
indicated by the arrows at 19 hours (Figure 3.4c 16.5, 19, and 23 hours).   
Higher magnification (100x) of cells treated for 7.5 to 9 hours with FQI1 and 
imaged for both α-tubulin and DNA revealed additional phenotypes: occasional cells with 
multi-asters (cells with more than two microtubule structures known as asters), and cells 
in prophase (defined by rounded cells with non-condensed DNA), in addition to cells in 
prometaphase (rounded cells with condensed DNA that had not formed a metaphase 
plate) (Figure 3.5a and b).  Image quantitation revealed that FQI1 treatment resulted in an 
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increasing proportion of cells in prophase, particularly with those that display protrusions 
(Figure 3.5b) and correlated with increasing FQI1 concentrations at 9 hours post release 
(Figure 3.5d).  The increase in both prophase and prometaphase cells was the most 
prominent phenotype of FQI treatment (Figure 3.5d, e, and f). These findings are 
consistent with the analysis of DNA content by flow cytometry where the FQI1 treated 
cells showed a cell cycle arrest at 4n levels of DNA (Figure 3.2).  An additional FQI-
induced phenotype was multi-aster prometaphase cells, whose proportion increased in 
particular at higher FQI1 concentrations and later time points, approaching 20% at 3.6 
µM FQI1 (Figure 3.5g).  It is noteworthy that the extent of the multi-aster prometaphase 
phenotype may have been underestimated due to limitations of analyzing selected time 
points in fixed cell populations. 
Finally, multi-nucleation, a phenotype resulting when a cell exits mitosis in the 
absence of bipolar separation of its chromosomes, was observed following in 80% of the 
cells after incubation with 5 μM FQI1 (Figures 3.4b and c, 3.5c).  Both the prophase and 
prometaphase arrest and the accumulation of cells with 4n DNA content are consistent 
with the maintenance of elevated levels of Cyclin B expression at 7, 10 and 17 hours after 
release from the G1/S block in the presence of the LSF inhibitor (Figure 3.3e) as Cyclin 
B expression is elevated during mitosis, but degraded prior to mitotic exit.  Together, the 
data indicate that FQI1 treated cells are accumulating in mitosis whereas the control cells 
re-enter the cell cycle at G1.   
Short term incubation with FQI1 does not impact transcription of key mitotic genes 
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Given that LSF is a transcription factor and previous studies indicated that FQI1 
and FQI2 could inhibit LSF DNA-binding activity, we hypothesized that direct 
dysregulation of mitotic gene transcription might be the mechanism of the observed FQI1 
mediated prometaphase arrest. To investigate this hypothesis, we looked a gene 
expression changes via qPCR across cells treated with various concentrations of FQI1 
versus control cells.  In particular, expression levels of both Aurora kinase B and Cdc20 
(two genes that are required for prometaphase and mitotic exit) in the presence of FQI1 
were comparable to levels in control cells (Figures 3.6a-c, e-g).  Unexpectedly, the 
highest FQI1 concentration, unlike that observed at lower concentrations, was absent of 
phosphorylated Histone 3, a crucial event for mitotic onset.  However, these findings are 
consistent with the increased Cyclin A expression shown in Figure 3.3c and large number 
of prophase cells (Figure 3.5e and f) indicating that at 8 hours the cells treated with 5 μM 
FQI1 are delayed from entering prometaphase.  Regardless, the lack of expression 
changes in genes encoding mitotic regulators (Figures 3.3 and 3.6) suggested that the 
FQI-induced prophase/prometaphase arrest might not be the result of changes in 
transcription but possibly that of translation, phosphorylation or protein: protein 
interactions.   
Short-term FQI1-mediated mitotic arrest in QGY-7703 cells is reversible 
In order to independently test whether LSF transcriptional activity was involved 
in any of the mitotic phenotypes, a washout experiment was performed in which FQI1 
treated cells were arrested and then the compound removed.  If FQI1 induced cellular 
phenotypes by blocking transcriptional induction of key genes during cell cycle 
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progression (prior to mitotic entry), the phenotypes would not be reversible after a mitotic 
block had been established, as transcription is inhibited during mitosis and would not be 
able to reinitiate (Delcuve et al., 2008; Gottesfeld and Forbes, 1997; Long et al., 1998).  
However, if the mitotic phenotypes were reversible by washing out FQI1, it would 
strongly suggest that the effects were independent of the transcriptional activity of LSF 
and due to other mechanisms.   
  To this end, QGY-7703 cells synchronized at the G1/S border (Figure 3.7a) were 
initially released back into the cell cycle in the presence or absence of 5 μM FQI1 for 10 
hours.  A group treated with 5 μM FQI1 for 10 hours was washed with 1xPBS whereas 
all other groups were incubated further with either FQI1 or vehicle.  Thirteen hours after 
the wash, the cell cycle distributions of the different populations were compared by DNA 
flow cytometry profiles (Figure 3.7b-d).  As expected (Figure 3.2), the vehicle-treated 
cells exhibited cells throughout the cell cycle (Figure 3.7b) while the cells treated 
continuously with FQI1 remained in an arrested mitotic state (Figure 3.7c).  Interestingly, 
the FQI1-treated cells that had been briefly washed 10 hours post release to remove the 
compound resulted in cells in all stages of the cell cycle (Figure 3.7d), clearly 
demonstrating reversibility of the FQI1 phenotype. Consistent with these data, phase 
contrast images demonstrated that the population in which FQI1 was washed out was 
similar to the vehicle control cells (Figure 3.7g, e), with most cells flattened and firmly 
attached to the surface of the plates. In contrast, cells treated with FQI1 for the duration 
of the study (Figure 3.7f) exhibited rounded morphology typical of a mitotic cell arrest, 
as described previously in this chapter.   
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Discussion 
The finding that LSF promotes oncogenesis of HCC prompted previous 
preclinical studies regarding the potential utility of LSF small molecule inhibitors in 
treatment of HCC. These studies demonstrated that FQI1 and FQI2, which inhibit LSF 
DNA-binding activity, both in biochemical assays and in cellular contexts, induce HCC 
cell death in vitro and inhibit tumor growth. (Grant et al., 2012; Rajasekaran et al., 2015).  
Strikingly, at concentrations that significantly inhibited tumor growth, no general toxicity 
was evident.  Based on these data, it was important to better characterize the mechanism 
by which FQI1 caused HCC cell death, its specificity of action, and its relationship to 
LSF inhibition. 
LSF has long been appreciated to play a role in mammalian cell cycle, with 
previous studies mainly focused on G1/S transition (Powell et al., 2000; Saxena et al., 
2010), however it remained unclear if cell cycle defects were the trigger by which FQI1 
treatment induced cell death.  To investigate this mechanism of FQI1 further, three 
approaches were taken:  A flow cytometry based characterization of cell cycle and 
apoptotic effects of different concentrations of FQI1 (supplemented with investigating 
levels of activated caspase and selected protein markers of mitosis); a microscopy based 
characterization of cellular morphological effects of FQI1 treatment, and finally a 
compound washout experiment to investigate the mechanism of the observed FQI1 
effects.  Interestingly the effects of FQI1 on cell cycle arrested HCC cells at prophase and 
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prometaphase and occasionally caused multi-aster formation prior to cell death or the 
appearance of multi-nucleated cells. 
FQI1 treatment of synchronized QGY 7703 cells resulted in Caspase 3/7 
activation, followed by loss of viability and subG1 content of cellular DNA (Figure 3.2). 
These data, while consistent with previous reports, also suggested that FQI1 treatment 
resulted in a defect in mitosis. Specifically, the defect was most significantly in prophase 
and prometaphase. In addition, these data show that the loss of viability occurred well 
after mitotic arrest.  The observations including a prometaphase arrest, elevated cyclin B 
levels and observations of multi-nucleated cells prior to cell death suggest that death 
through mitotic slippage may be occurring.  The process by which cells escape mitosis 
when they cannot satisfy the SAC requires the ubiquitination and/or proteolysis of cyclin 
B and is known as mitotic “slippage” (Brito and Rieder, 2006; Brito et al., 2008; Hunt et 
al., 1992; Yang et al., 2009).  Consistent with this notion, at 17 hours (Figure 3.3d), the 
cyclin B levels appear to be diminishing in the FQI1 treated cells in comparison to earlier 
time points.  Further evaluation would be need to determine whether cyclin B degradation 
has triggered mitotic slippage. Slow degradation of cyclin B can occur in mitotic arrest 
induced by microtubule depolymerizing agents (Dai et al., 2004; Xu et al., 2010), an 
interesting potential parallel given the appearance of multi-asters suggests microtubule 
disruption in FQI1 treated cells.  Elevated levels of Cyclin B in FQI1 treated G1/S 
synchronized cells 10 hours post release from G1/S (Figure 3.3) are consistent with the 
observation of a mitotic defect as Cyclin B must be degraded, or Cdk1 inactivated in 
some other manner, prior to mitotic exit (Guadagno and Newport, 1996; Irniger, 2002).  
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In Rajesekaran et al., FQI1 inhibition of LSF resulted in a prometaphase arrest (presented 
in Figure 6) and was associated with increased Cyclin B.  Here, the data indicate that the 
increased expression of Cyclin B protein levels is actually a consequence, and not 
causative of the prometaphase arrest, as Cyclin B RNA levels were not altered as would 
have been anticipated if the gene were a direct target of LSF as a transcription factor.  It 
is not surprising that Cyclin B protein levels would be elevated as the cells arrested in 
prometaphase.  It is only once cells have reached anaphase that Cyclin B protein is 
degraded by the Anaphase Promoting Complex.    
These results are quite distinct from those of (Powell et al., 2000) where a 
dominant negative version of LSF demonstrated apoptosis in S phase.  The differences in 
phenotypes could represent disparate mechanisms of action of the agents utilized.  
Dominant negative LSF disrupts the ability of LSF to bind DNA and activate 
transcription, however, interactions with other protein cofactors may be left intact.  Of 
course, endogenous LSF may still have been active in the dnLSF evaluation confounding 
the results.  The small molecule on the other hand also prevents LSF DNA binding, but 
may interfere with other activities of LSF creating more of a null phenotype.  
Alternatively, a trivial explanation for the difference in phenotypes could be that separate 
cell lines were utilized in the experiments. Indeed, whereas dominant negative LSF 
expression abolished thymidylate synthase expression in the cells in which it caused S 
phase death, it diminished, but did not eliminate, thymidylate synthase expression in 
HCC cells (Yoo et al., 2010; Yoo et al., 2009).  FQI1, on the other hand, may be a more 
robust inhibitor, in that it appears to cause similar phenotypes (accumulation of cells with 
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4n DNA content) in multiple cell types, including the HCC Hep3b and Huh7 cells 
(Rajasekaran et al., 2015).  The phenotypes observed by microscopy were entirely 
consistent with the DNA profiling, showing rounded cells with and without condensed 
DNA that had not formed a metaphase plate indicative of a prophase/prometaphase arrest 
(Figure 3.5a, b, d and e).  Also consistent was the elevated levels of Cyclin B expression 
at 7, 10 and 17 hours after release from the G1/S block in the presence of the LSF 
inhibitor (Figure 3.3a), as Cyclin B is elevated during mitosis.  
Since Cyclin B RNA levels were unaffected by FQI1 treatment, I examined 
expression of other potential LSF targets whose dysregulation could cause prometaphase 
arrest.  Aurora B Kinase inhibition also causes accumulation of cells in prometaphase due 
to incomplete kinetochore attachment, subsequently resulting in multi-nucleation and 
apoptosis (Kallio et al., 2002; Wang et al., 2006).  Additionally, a coactivator of the 
Anaphase promoting complex (APC), Cdc20, is required for proteolysis of Cyclin B. 
However, a Cdc20 deficiency would most likely arrest the cells immediately before 
anaphase rather than in prometaphase.  Under these conditions, in which cells were 
incubated with FQI1 only starting at the G1/S border, neither RNA nor protein levels of 
these two genes were altered.  Further, phosphorylation of Histone 3 on Serine 10, which 
is catalyzed substantially by Aurora kinase B, was not reduced.  Surprisingly, 
phosphorylation of Histone 3 on Serine 10 was diminished when cells were treated with 5 
µM of FQI1, the same concentration at which Cyclin A protein levels are not reduced.  
These data indicate that at sufficiently high FQI1 concentrations, LSF may have an 
additional role required for mitotic progression that is crucial in prophase.   
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In the absence of identifying specific mitotic regulatory genes whose expression 
was altered by short-term FQI1/2 treatment, a general scheme was developed to test 
whether or not the mitotic defect was due to transcriptional regulation.  Transcription 
mediated by RNA polymerase II does not generally occur during mitosis (Delcuve et al., 
2008; Gottesfeld and Forbes, 1997; Long et al., 1998) thus expression of mitotic genes 
occurs during G2 and S phases, but not in mitosis.  If transcriptional dysregulation were 
the main driver of the FQI1-mediated mitotic defect, removing FQI1 at the time of arrest, 
when cells are in mitosis with condensed chromosomes, would not be reversible.  The 
cells would not recover, as LSF-mediated transcriptional events could not resume. 
Interestingly the results demonstrated that the mitotic defect in HCC cells was reversible 
upon removal of the LSF inhibitor (FQI1) within a few hours of inducing the mitotic 
block, allowing proper cell cycle progression to G1.  In these experiments, the cells were 
synchronized at the G1/S border to allow specific interrogation of the impact of FQI1 
incubation on different cell cycle stages, and FQI1 was added only at the time of release 
from this cell cycle block at G1/S.  Although FQI1 has been demonstrated to inhibit LSF 
DNA-binding activity (Grant et al., 2012), the question remains as to whether FQI1 
would be able to compete off pre-bound LSF from the DNA. If not, FQI1 may be unable 
to inhibit LSF-mediated gene expression under these circumstances.  Overall, these data 
support a role for LSF, the target of FQI1, in regulating prometaphase to metaphase 
transition through a non-transcriptional means.   
However, these results open the question of whether FQI1 has targets besides 
LSF.  FQI1s do inhibit LSF family members, but only the close paralogs: LBP1a/b and 
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LBP9.  FQIs do not inhibit the Grainyhead proteins (T. Grant and U. Hansen, 
unpublished), more distant family members to LSF.  If specific knockdown of LSF by 
RNAi result in a similar phenotype, it would confirm the role for LSF in mitosis in HCC 
cells.   
The elucidation of a potential mitotic role for LSF was unanticipated. Powell et al. 
(Powell et al., 2000) demonstrate that expression of dominant negative LSF resulted in 
apoptosis in S phase due to reduction of thymidylate synthase levels, however, all these 
experiments were performed in cells synchronized prior to S phase, defects later in the 
cell cycle, as in mitosis, would not have been observed.  Alternatively, the non-
transcriptional role uncovered by reversibility of the prometaphase arrest by FQI1 
removal may suggest a regulatory role for LSF in proper mitotic progression through 
protein-protein interactions. It is possible that the dominant negative LSF would maintain 
all protein-protein interactions and not be defective in this regard. 
The collective evidence supporting that FQIs specifically target LSF and LSF 
paralogs indicates that the anti-tumor activity observed in preclinical tumor models is 
likely not a result of an off target effect.  FQI1 was previously identified to inhibit LSF 
DNA binding and shown not to inhibit transcriptional activity of other transcription 
factors including p53, a transcription factor predicted to be structurally similar to LSF. 
Further, FQIs did not impact transcriptional activation of the Grainyhead family members 
(Trevor Grant, Ulla Hansen, unpublished observations), transcription factors that have 
similar DNA binding domains but have diversified from the LSF subfamily of factors 
(Traylor-Knowles et al., 2010).  Finally, compound structure-activity relationships (SAR) 
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demonstrated a linear relationship between the G150 and the IC50 generated using the LSF 
activity assay.  This high degree of correlation indicates that FQI inhibition of LSF 
resulted in growth inhibition (Christadore, 2013).  These data, among others, provide 
confidence that FQI1 and FQI2 specifically target LSF, in comparison to other 
transcription factors.   
In summary the results in this chapter indicate that by a non-transcriptional 
mechanism, FQI1 inhibition induces a prophase/prometaphase arrest prior to cell death, 
and suggest that this may occur by interfering with an LSF protein-protein requirement 
for proper mitotic progression.  Further work is needed to evaluate what key interactions 
LSF may have with proteins required for spindle formation, DNA condensation, or 
microtubule-kinetochore attachments, or to eliminate the alternative hypothesis, that the 
mitotic defect is a secondary event characteristic to the compound, rather than to LSF 
itself.   
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Figures 
Illustration 3.1 FQI Incubation in Synchronized HCC Cells (Short incubation) 
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Figure 3.1   Treatment of QGY-7703 cells with FQI1 inhibits cell division, activates 
Caspase 3/7 and results in loss of cell viability in a concentration-dependent manner. 
(a) QGY-7703 cells were synchronized at the G1/S border and released in presence of the 
indicated concentrations of FQI1. The averages of total cell counts at 0 and 10 hours after 
release from the G1/S block are shown.  Standard deviations represent 3 independent 
experiments.  Absence of error bars due to data being averaged from 2 independent 
experiments.   (b) QGY-7703 cells were synchronized at the G1/S border and released in 
the presence of increasing amounts of FQI1, or in the presence of only vehicle or no 
treatment as controls. Cells were analyzed for Caspase 3/7 activity at the indicated times 
after release by directly measuring cleavage of a luminogenic caspase 3/7 substrate.  Data 
are depicted as percent of the activity in the vehicle-treated cells. Dashed line represents 
control cells (100%).  Standard deviations represent technical triplicates. Data are 
representative of two independent experiments.  (c) Caspase 3/7 activation and cell 
viability were measured by a luminogenic caspase 3/7 substrate (as in b) and by cleavage 
by intracellular protease(s) of a fluorogenic permeant peptide (Promega Apotoxglo kit), 
respectively, at 48 hours post incubation with FQI1 or vehicle. Standard deviations 
represent technical triplicates. Loss of viability was observed at 1.8 µM and 3.6 µM 
FQI1, concomitantly with increased Caspase 3/7 activity. Statistical significance was 
determined using a Student T Test; * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 
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Figure 3.2    Treatment of synchronized QGY-7703 cells with FQI1 results in 
accumulations of cells with G2/M and/or subG1 DNA content.   
HCC cells were synchronized at the G1/S border and released in the presence of 
increasing amounts of FQI1 or vehicle. Cells stained with propidium iodide were 
analyzed at 7, 10, and 17 hours following release to evaluate DNA content.  10,000 
events were assayed per condition.  The area measures the DNA content per event.  (a) A 
parallel untreated asynchronous population of cells shows the expected distribution of 
cellular DNA across phases of the cell cycle.  (b)  Synchronized cells were collected 
immediately prior to the time of release, confirming appropriate synchronization at G1/S.  
(c)  Cells released in presence of 2 or 5 μM FQI1 were analyzed at the indicated time 
points and directly compared with the cells treated with vehicle to evaluate cell cycle 
progression. 
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Figure 3.3 Cyclin B protein expression is increased and maintained in QGY-7703 
cells treated with FQI1. 
Synchronized HCC cells were collected at the indicated time points after release from a 
G1/S block in the presence or absence of FQI1. (a) RNA was isolated for gene analysis 
by Taqman.  CCNA1 RNA levels were normalized to levels of GAPDH RNA in QGY-
7703 cells released in the absence or presence of FQI1 for 7 hours.  (b) Immunoblot for 
cyclin A1 and β-actin (as a loading control) of lysates collected at 8 hours post release 
from a G1/S block in presence of 0.9, 1.8 or 5 μM of FQI1 or vehicle as a control.  (c) 
Quantitation of cyclin A1 protein expression was determined using the Odyssey Licor 
detection system.  Data are depicted as the area of pixels determined for Cyclin A1 
normalized to that for β-actin.  (d) Immunoblots of cyclin B1 and β-actin from cell 
lysates collected at 0, 7, 10 and 17 hours after release from a G1/S block in presence of 2 
or 5 µM FQI1 or vehicle.  The data are representative of 3 independent experiments. (e) 
CCNB1 RNA levels normalized to those of GAPDH in QGY-7703 cells 8 hours post 
G1/S release with increasing FQI1 concentrations. Data are from a single experiment. 
The results are representative of two independent experiments.  
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Figure 3.4    Treatment of QGY-7703 cells with FQI1 results in prometaphase arrest 
and subsequent multi-nucleation. 
HCC cells were synchronized at the G1/S border and released in presence of 5 µM FQI1 
or vehicle. (a) Fixed HCC cells stained with DAPI and an antibody against alpha tubulin 
were analyzed on a Zeiss axioimager at 63x magnification. DAPI staining reveals a 
prometaphase arrest in the FQI1-treated QGY-7703 cells 8 hours post release from a 
G1/S block, as shown by the arrows. (b)  Hematoxylin and Eosin staining of 
asynchronous QGY-7703 cells treated with 5 μM of FQI1 or vehicle for 48 hours at 63x 
magnification.  (c) DAPI staining for synchronized cells treated with DMSO or 5 µM 
FQI1 and analyzed at 20x magnification.  Samples were collected at 0, 3.5, 6, 8, 16.5, 19 
and 23 hours post release from a G1/S block in presence of DMSO or FQI1.  Insets 
represent individual cells in more detail.  Arrows represent cells in metaphase or 
prometaphase, respectively, at the 6 hour time point, and multi-nucleated cells at the 19-
hour time point.   
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Figure 3.5    Treatment of synchronized HCC cells results in a concentration-
dependent increase of cells in prometaphase as well as mitotic anomalies such as 
multi-asters and prophase cells with protrusions. 
HCC cells were synchronized at the G1/S border and released in presence of vehicle or 
increasing concentrations of FQI1 or FQI2. HCC cells, fixed and stained for α-tubulin 
and DNA.  (a, b) Representative images of cells analyzed using a Zeiss Axioimager 7.5 
hours post release from the G1/S block, showing examples of (5µM) FQI1-mediated 
phenotypes including multi-aster (a, bottom right) and cells in prometaphase/metaphase 
(a, bottom left).   Examples of prophase cells with and without protrusions (b, bottom 
right).  All images were taken at 100x magnification. (c) Representative image of a multi-
nucleated cell observed post treatment with 5 µM FQI1 in synchronous cells 24 hours 
post release. (d) Quantification from 75-100 total cells 7.5 hours post release from a G1/S 
block that were in interphase, prometaphase, metaphase and cytokinesis, as determined 
by DNA and alpha tubulin characteristics. There are no phenotypes shown for the highest 
concentration of FQI2 (3.7 µM), because at this time point, all cells remained in 
prophase.  (e) Quantification from the same population of 75-100 total cells as in (d), 
analyzed by DNA and alpha tubulin morphologies indicating cells containing prophase 
cells, with and without protrusions, and multi-asters analyzed 8 hours post release from a 
G1/S block.  (f) Quantification from 75-100 total cells analyzed by DNA and alpha 
tubulin morphologies indicating cells containing interphase, prophase, prometaphase, 
metaphase, and cytokinesis, fixed for imaging at 9 hours post release from a G1/S block. 
(g) Quantification from 75-100 total cells analyzed by DNA and alpha tubulin 
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morphologies indicating cells containing multi-asters, at 9 hours post release from a G1/S 
block.  Data are representative of 2 quantitation experiments.  
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Figure 3.6. FQI1 addition to synchronized HCC cells at the G1/S transition does not 
alter subsequent expression of Aurora B Kinase or Cdc20 prior to mitosis. 
 
Synchronized HCC cells were released from a G1/S block in the presence or absence of 
FQI1 at the indicated concentrations. Cell lysates were prepared 9 hours post release from 
the G1/S block.    (a)  Aurora kinase B RNA levels were determined using bDNA 
(Affymetrix) and normalized to those of beta actin within each lysate.  Error bars 
represent standard deviation of two independent experiments. (b) Immunoblots of Aurora 
kinase B and β-actin. Data are representative of greater than 4 experiments.  (c) 
Immunoblot measuring phosphorylation of Histone 3 Serine 10 on lysates collected 9 
hours post release. (d) Protein expression was quantitated using the Odyssey Licor 
detection system.  Data are depicted as the area of pixels determined for Aurora Kinase B 
normalized to the area of pixels detected for β-actin.   (e) Gene expression determined 
using bDNA (Affymetrix) of CDC20 RNA levels were normalized to ACTB RNA within 
each lysate.  Error bars represent standard deviation of technical triplicates. Data are 
representative of two independent experiments. (f) Immunoblots of CDC20 and β-actin in 
lysates collected 9 hours post release from a G1/S block.  Each lysate was probed for beta 
actin as a loading control.  Data are representative of 3 experiments.  (g) Data are 
depicted as the area of pixels determined for Cdc20 normalized to the area of pixels 
detected for the beta actin loading control.   
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Figure 3.7    The prophase/prometaphase arrest mediated by short-term FQI1 
treatment of synchronized HCC cells is reversible.   
Synchronized QGY-7703 cells were released in the presence of 5 µM of FQI from a G1/S 
block.  Ten hours after the release, the cells were washed and then either incubated with 
media alone or re-incubated with media in the presence of 5 µM FQI1.  Samples were 
collected 24 hours post release.  Fixed cells were stained with propidium iodide to 
analyze DNA content.  (a) Synchronized cells harvested immediately prior to release 
from the G1/S block.  Cellular DNA profiles 10 hours post release for (b) vehicle control 
and (c) cells released with 5 µM FQI1.  Cellular DNA profiles 24 hours post release for 
(d) cells treated throughout only with vehicle (e) cells treated throughout with 5 µM FQI1 
and (f) cells treated initially with 5µM FQI1 for 10 hours, but then incubated in the 
absence of FQI1.  Phase contrast images of QGY-7703 cells treated with (g) vehicle 
control, (h) 5 µM FQI1 treated cells and (i) cells treated with 5 µM FQI1 at release, 
washed, and incubated with complete media 10 hours post release.  This is representative 
of two independent experiments. 
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CHAPTER FOUR  
The transcription factor LSF regulates mitotic progression in hepatocellular 
carcinoma cells  
  
Contributions 
Kelly George generated mEmerald Tubulin QGY-7703 cells, the time lapse imaging data, 
and analysis for mitotic time determinations 
Mark Roberto generated the YFP H2B QGY-7703 cell line 
 
 
Introduction 
Primary liver cancer is the fifth most common cancer worldwide and the third 
leading cause of cancer mortality (Bruix, 2011; Bruix and Sherman, 2011; Llovet et al., 
2015; Marengo et al., 2016; Torrecilla and Llovet, 2015; Wang et al., 2002).  
Hepatocellular carcinoma (HCC) represents approximately 70-80% of primary liver 
cancer cases (Bruix, 2011; Bruix and Sherman, 2011; Llovet et al., 2015; Marengo et al., 
2016; Torrecilla and Llovet, 2015).  The leading risk factors, worldwide, include 
Hepatitis, both B and C, and alcoholism.  More recently metabolic syndrome and obesity 
have resulted in Non-Alcoholic Steatohepatitis (NASH) development, another precursor 
to HCC.  Today, one million individuals in the US alone are afflicted with NASH 
(Marengo et al., 2016), a condition for which there are no approved treatments, and  
therefore put large numbers of individuals at risk for developing hepatocellular 
carcinoma (Zoller and Tilg, 2016).  Regardless of the disease etiology, each HCC case 
follows a lengthy disease progression with the majority of patients developing fibrosis, 
with a percentage of those patient’s livers progressing to cirrhosis and eventually to frank 
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carcinoma.  The factors that cause some patients to progress rapidly while others slowly 
or never are unknown and are currently under intense investigation.  However, a major 
risk factor for HCC is cirrhotic liver (Bruix and Llovet, 2003; Llovet, 2006).  Patients 
with HCC are often diagnosed in the late stages, with few meeting the requirements for 
invasive procedures, such as surgical resections, with the majority qualifying for mere 
palliative treatments (Bruix and Sherman, 2011).  Further, hepatocellular carcinoma 
patients, in general, have not responded to standard chemotherapeutics.  Sorafenib, a 
small kinase inhibitor shown to target vascular endothelial growth factor receptors, 
platelet derived growth factor receptors and Raf kinases (originally approved for renal 
cell carcinoma) has demonstrated modest improvement in survival rates in HCC patients 
suggesting that molecularly targeted therapies may be helpful in mitigating the disease 
(Torrecilla and Llovet, 2015). The improvement in overall survival rates with this 
treatment, however, is subpar and patients suffer with significant side effects leaving the 
hepatocellular carcinoma patient population with a large unmet medical need.  
 LSF was identified as an oncogene in hepatocellular carcinoma by virtue of being 
necessary and sufficient, in the background of a non-tumorigenic, but tumor-primed 
hepatocyte cell line, for HCC tumor growth in mouse xenograft models.  Dominant 
negative LSF expression reduced tumor growth, and conversely, LSF overexpression in a 
non-tumorigenic HCC cell line resulted in increased tumorigenicity (Yoo et al., 2010).  
Small molecule inhibitors of LSF, Factor Quinolinone Inhibitors (FQIs), were identified 
from a compound screen in a fluorescent polarization assay where FQIs inhibited the 
DNA binding of purified LSF.  Additionally, FQIs have no effect on the DNA binding 
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activity of transcription factors from multiple structural classes, including Oct1, E2F3, 
and Sp1 (Grant et al., 2012).  Specific inhibition of LSF with these FQIs resulted in 
growth inhibition of HCC cells in vitro and in vivo as initially ascertained in a 
subcutaneous mouse xenograft HCC tumor model (Grant et al., 2012). More recently, 
FQIs were shown to inhibit growth and apparently cause regression in a mouse 
endogenous liver tumor model (Rajasekaran et al., 2015).  In all cases, inhibition of HCC 
tumor growth was accompanied with no signs of toxicity, as assessed by liver injury 
markers or histopathology of tissues with rapid cell turnover, suggesting a case of 
oncogene addiction of HCC to LSF.   
Oncogenic transcription factors are promising therapeutic targets given that they 
regulate tumorigenic pathways.  Transcription factors, in general, have been notoriously 
difficult to target with small inhibitors as their DNA binding pockets are commonly small 
and the proteins themselves are intrinsically unstructured, a feature allowing binding site 
promiscuity (Dunker and Uversky, 2010; Yan and Higgins, 2013).  The DNA binding 
pocket of LSF, however, is uncharacteristically large (Kokoszynska et al., 2008; Shirra et 
al., 1994).  Identification of the transcription factor LSF as an oncogene in HCC and the 
significant inhibition of tumor growth upon LSF inhibition with no observed toxicity 
indicate that LSF holds great promise as an HCC therapeutic target (Grant et al., 2012; 
Santhekadur et al., 2012b; Yoo et al., 2010).  The molecular role by which LSF is 
necessary for HCC survival, however, has yet to be identified.  Targeting a transcription 
factor has been challenging, therefore clarifying the mechanism by which inhibition of 
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LSF leads to hepatocellular carcinoma cell death would further support the candidacy of 
FQIs as a molecular therapy.   
Initial studies (Rajasekaran et al., 2015) revealed that short term FQI1 treatment 
in HCC cells caused cells to accumulate at prometaphase, suggesting that inhibition of 
LSF activity resulted in a mitotic defect.  Furthermore, reversibility of the phenotype 
through FQI1 removal at the time of mitotic arrest revealed a non-transcriptional role for 
LSF in mitosis (Chapter 3). Previous investigations that indicated a transcriptional role 
for LSF in cell cycle progression during the G1/S transition were performed by 
overexpressing a dominant negative LSF mutant (Powell et al., 2000)(). These studies, 
with a very distinct type of inhibitor, did not investigate mitotic progression. Since FQI1 
was initially identified based on its ability to inhibit LSF DNA-binding and 
transcriptional activation potential, its ability also to apparently inhibit non-
transcriptional functions of LSF suggests that FQI1 treatment results in a null phenotype 
for LSF.   
To both fully evaluate the hypothesis that LSF regulates mitosis and investigate 
whether or not the mitotic arrest was due to perturbation of an off target of FQI1, we 
interrogated LSF activity in HCC cells using RNAi technology to recapitulate the LSF 
null phenotype.  Titrating LSF activity with either FQI1 or siRNA in HCC cells resulted 
in similar mitotic phenotypes, indicating that LSF is the major target of FQI1. 
Surprisingly, we did not fully recapitulate the persistent prometaphase arrest observed 
upon short-term FQI1 treatment (Chapter 3. (Rajasekaran et al., 2015)), but instead 
observed a similar phenotype of prometaphase/metaphase delays leading to lengthening 
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of times to progress through mitosis.  In addition to the delay, mitotic phenotypes 
included defective cell division and multi-nucleation.  At the mechanistic level, in 
contrast to the short-term FQI1 treatment, long-term inactivation of LSF by both 
approaches did reveal specific RNA and protein reduction of key mitotic regulators. In 
particular, both Aurora Kinase B, a major mitotic kinase, and Cdc20, a major component 
of the proteolysis complex, were downregulated upon LSF inhibition. Thus, this study 
also shows that LSF controls gene expression of mitotic proteins.   
 
Results 
Identification of potent and durable siRNAs targeting LSF and LBP1A expression.   
To optimize transfection conditions for the HCC cells, a control siRNA targeting 
the luciferase transcript was synthesized with a Cy3 fluorescent tag.  This allowed visual 
confirmation of a successful transfection.  The luciferase targeting siRNA is an excellent 
control siRNA, as it is a non-targeting siRNA in the QGY-7703 cells in that they do not 
express the luciferase gene.  Thus, complications from knockdown of additional targets 
of non-interest are eliminated.  The fluorescent distribution following transfection with 
this tagged siRNA (Figure 4.1a) reveals efficient uptake, with approximately 90% of the 
cells depicted in the phase contrast image (Figure 4.1b), overlapping the fluorescent 
signal.  The degree of background fluorescence was measured at the same exposure using 
LSF siRNA-transfected cells (Figure 4.1, c and d), where no fluorescent tag was 
included.  
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To identify potent molecules targeting LSF or LBP1A, multiple siRNAs targeting 
each were synthesized.  In order to recapitulate the findings generated by the FQIs in 
HCC, it was imperative to also investigate the other widely-expressed LSF family 
member, LBP1A, since FQI1 also inhibits the activity of LBP1A (T. Grant and U. 
Hansen, unpublished results).  Therefore, to interrogate the mechanism of FQI1 anti-
tumor activity, the role of LBP1A, if any, in HCC cell proliferation must also be 
investigated.  The siRNAs (designed using algorithms generated to reduce off target 
hybridization by either the sense or antisense strand) were chemically modified and 
included a 21/23 design (21 nucleotides on the guide strand and 23 complementary 
nucleotides with an overhang on the 3’ end of targeting strand, a siRNA scheme 
previously shown to result in potent and durable knockdown (Zimmermann et al., 2006).   
Specifically, 24 siRNAs designed to target LSF were synthesized and screened in a two 
dose screening paradigm to identify potent molecules.  siRNAs were transfected into both 
Hep3B (Figure 4.1e) and QGY-7703 (Figure 4.1f) cells at concentrations of either 2 or 10 
nM.  Hep3b and QGY-7703 are both HCC cell lines that overexpress LSF (Grant et al., 
2012; Yoo et al., 2010), with QGY-7703 cells those utilized to create the subcutaneous 
xenograft model that was responsive to FQI1 treatment.  Normalized LSF transcript 
levels from these transfections are depicted as the percentage of LSF RNA levels in HCC 
cells treated with LSF siRNA compared to the levels in cells treated with the non-
targeting luciferase control siRNA.  Multiple siRNAs were determined to be potent, as 
defined by inducing a minimum of 80 percent target knockdown at 10 nM and greater 
than 50 percent knockdown at 2 nM.  In particular, siRNA 9 and 22, henceforth referred 
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to as LSF siRNA and as LSF siRNA 2 respectively, were chosen and utilized for all 
subsequent experiments in this chapter and the Appendix.  Additionally, 8 siRNAs 
targeting LBP1A were designed and synthesized using the same design scheme, and 
screened at a 20 nM dose in QGY-7703 cells (Figure 4.1i).  Relative gene expression 
levels showed significant knockdown of the LBP1A transcript; siRNA 28 was chosen for 
investigating the impact of LBP1A knockdown in QGY-7703 cells.   
Previous reports (Hubner et al., 2010) have described an off target effect with 
certain siRNAs, which resulted in nonspecific reductions in MAD2 mRNA and protein 
levels.  Given the critical importance of MAD2 in mitosis, siRNAs targeting LSF or 
LBP1A were transfected into HCC cells, and RNA was isolated 72 hours after the 
transfection to evaluate Mad2 transcript levels.  Transfection with either the siRNA 
targeting LSF or LBP1A (Figures 4.1g, h and j) did not reduce Mad2 transcript levels 
when directly compared to cells transfected with the control siRNA, demonstrating that 
they were specific and effective.  
 
Both RNAi-mediated knockdown of LSF and FQI1 treatment inhibit HCC cellular 
division prior to cell death 
In order to investigate potential cell cycle defects in QGY-7703 cells we first 
evaluated cellular proliferation.  QGY-7703 cells synchronized at the G1/S border (0 
hours) were treated with increasing concentrations of FQI1 or siRNAs targeting LSF, as 
they were released into S phase.  Since FQIs inhibit the activity of both LSF and LBP1A 
(T. Grant and U. Hansen, unpubl. results), siRNAs against both were included for 
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evaluation.  A detailed protocol schematic is depicted in Illustration 4.2.  The success of 
this protocol depended on durability of LSF knockdown, given the long half-life of LSF 
protein (Hansen et al., 2009).  20 nM LSF siRNA resulted in ~90% LSF RNA reduction 
at 72 hours, and 95% reduction at 96 hours (Figure 4.2a).  As expected given the half-life 
of 24 hours, levels of LSF protein decreased more slowly than those of the transcript, 
with maximum decline of protein being achieved at ~48 hours after transfection (Figure 
4.2c).  With this degree of durability of RNA knockdown, LSF protein knockdown was 
able to persist through the entire course of the experiment (Figures 4.2d).  The double 
thymidine block synchronization protocol spanned approximately 48 hours and could not 
be initiated on the day of siRNA transfection as the combination resulted in severe 
toxicity.  Similarly, expression of LBP1A RNA after transfection with 20 nM LBP1A 
siRNA yielded 96% knockdown at 24 hours post transfection- a level of knockdown that 
was maintained as far out as 96 hours post transfection (Figure 4.2b).  These results 
demonstrate potent and long-lasting knockdown of both LSF and LBP1A with the 
siRNAs.   
To attempt to recapitulate effects of FQI1, we tested the impact of decreased 
protein levels of LSF, LBP1A or the combination of both.  A single cell division of HCC 
cells treated with one or more siRNAs was monitored by arresting cells at the G1/S 
border and then releasing them to continue cell cycle progression.  After the 
synchronization protocol, cell populations that had been transfected with LSF siRNA, at 
any concentration or in combination with LBP1A, had fewer cells. Upon release from the 
G1/S block, populations treated with LSF siRNA did not divide.  In contrast, control cells 
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substantially completed the first mitosis and cellular division, as did cells treated with 
LBP1A siRNA. Phase contrast images of synchronized QGY-7703 cells treated with 
control or LSF siRNAs (Figure 4.2 h,i) are consistent with reduced total cell counts 
following LSF knockdown.  Note that many of the LSF siRNA-treated cells are rounded 
up, a phenotype of mitotic cells.  These data suggest that LSF alone, but not LBP1A, is 
necessary for timely HCC cellular division at the first mitosis following reduction in 
protein expression.   
To determine if FQI1 treatment, which inhibits LSF activity, would mirror the 
reduction in cellular division observed upon loss of LSF protein, a similar 
synchronization experiment was performed in the presence of FQI1.  QGY-7703 cells 
were treated with FQI1 at 0.9, 1.8, and 3.6 µM, or vehicle, for 24 hours immediately 
following the first thymidine block and continually thereafter, including release in the 
presence of FQI1 from the G1/S block at the same concentration as the initial incubation 
(Illustration 4.1).  In previous growth inhibition assays, 1.3 µM of FQI1 resulted in half 
maximal growth inhibition in the QGY-7703 cell line (Christadore, 2013).  Therefore, 
concentrations were chosen in order to flank the GI50 concentration. Figure 4.2g shows 
that with progressively increasing FQI1, there is an increasingly pronounced decline in 
cell division. Phase contrast images of synchronized QGY-7703 cells treated with control 
(Figure 4.2j) or with 1.8 µM of FQI1 (Figure 4.2k) are consistent with the reduced cell 
number reflected in total cell counts.   Again, many cells in the FQI1 treated group are 
rounded up.   
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To determine if the LSF knockdown or FQI1 treatment resulted in cell death, the 
viability of the treated cells was assayed using multiple methods (Figure 4.3).  
Asynchronous HCC cells were treated either with FQI1 or LSF siRNA, and the Trypan 
Blue positive cells were counted. Trypan blue staining occurs only if the cell membrane 
is compromised, as in dying cells.  By this measurement, 20 nM of LSF siRNA or 3.6 
µM of FQI1 resulted in reduced percentage of viable cells (Figure 4.3a and 4.3b).  FQI1 
treatment resulted in reduced viability at the 24 hour time point whereas the cells with 
RNAi mediated LSF knockdown do not show signs of reduced viability until 96 hours 
following transfection.  The differential timing in viability loss is consistent with the 
modalities (small molecule and siRNA) utilized to inhibit LSF as most small molecules 
are anticipated to interact with their targets fairly rapidly upon incubation whereas the 
reduction of LSF levels by siRNAs takes 48-72 hours. When cell viability was measured 
by mitochondrial functionality in synchronized cells, 3.6 µM of FQI1 or 20 nM of LSF 
siRNA resulted in approximately 40% reduction of viability or reduced cell number when 
assayed 24 hours post release from a G1/S block (Figure 4.3c).  Reduced mitochondrial 
activity may simply reflect reduced cell number, rather than cell death at this time point, 
as the cells do not proliferate upon LSF inhibition (Figure 4.2 f and g).  To determine 
whether cells were dying as a consequence of LSF knockdown or FQI1 treatment, and 
whether this immediately followed inhibition of cellular division, synchronized HCC 
cells incubated with various concentrations of LSF targeting siRNA or with various FQI1 
concentrations were assayed for apoptosis by measuring Caspase 3/7 activity (Figure 
4.3e).  Both LSF knockdown and LSF small molecule inhibition (Grant et al., 2012) 
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resulted in induction of apoptosis by 48 hours, with caspase activity undetectable as the 
cells entered the first mitosis.     
 
LSF knockdown or inhibition in QGY-7703 cells results in multiple cellular phenotypes 
including cell cycle delay in G2 or M and cellular senescence 
To elucidate how LSF knockdown inhibited cell division, cellular DNA content 
was measured in synchronized QGY-7703 cells after LSF inhibition, focusing on times 
spanning when cells would normally progress from the G1/S transition through mitosis 
and re-entry into G1.  Because HCC cells are generally aneuploid, the DNA content as 
ascertained by flow cytometry would not be a true 2n or 4n.  However, for ease I aligned 
the cell populations with non-replicated DNA at the 2n peak, with 4n representing 
successful DNA synthesis.   
The QGY-7703 cells were transfected with increasing amounts of LSF siRNA, 
from 0 to 20 nM, and compared to cells transfected with highest amount of control 
siRNA.  All cell populations showed the expected profile of cellular DNA, predominantly 
at the G1/S border, after synchronization (Figure 4.4, 0 hours).  Control cells were in S 
phase at 3.5 hours after release from the block, in G2 or mitosis at 8 hours, and back in 
G1 phase by 18 hours, having divided.  However, with levels of LSF diminishing from 
RNAi activity during the course of the synchronization procedure, at the end of the 
double thymidine block procedure a subpopulation of all the LSF siRNA-treated cells no 
longer was able to progress into DNA replication, but instead was arrested with 2n DNA.  
The remainder of the cells continued to progress through the cell cycle.  Consistent with 
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the viability and caspase activity assays, subG1 DNA populations (Figure 4.4), indicative 
of apoptosis, were observed by flow cytometry in all the LSF siRNA-treated samples, but 
not significantly in the control cells. These data indicate that whereas gradual LSF 
knockdown generates a population of cells that no longer progresses into S phase, the 
remaining cells do progress from G1 into mitosis, accompanied by some cell death 
thereafter.   
Synchronized QGY 7703 cells in which LBP1A was knocked down showed no 
apparent difference in cell cycle progression, as compared to the control cells (Figure 
4.5).  These results are consistent with the analysis of cellular division (Figure 4.2f) 
where cell progression of cells with LBP1A knockdown was comparable to the siRNA 
control group. 
In order to compare cell cycle phenotypes generated by LSF small molecule 
inhibitors with those produced by RNAi treatment, QGY-7703 cells were also treated 
with FQI1 during the synchronization protocol (Illustration 4.1). At the lower 
concentrations of 0.9 and 1.8 µM, the FQI1-treated cells were initially delayed in 
returning from G2/M to G1, remaining with 4n DNA content, compared to the control 
cells that had re-entered G1 (Figure 4.9, 8.5 h), an observation consistent with previous 
studies (Chapter 3, Christadore, 2010, (Rajasekaran et al., 2015)).  At 16 hours, some of 
these FQI1-treated cells had either divided (2n DNA) or initiated cell death (subG1 DNA 
content). At the highest FQI1 concentration, cells also were delayed with 4n DNA 
content, but the entire population converted to subG1 content by 16 hours post release 
from the G1/S block (Figure 4.6).    
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The surprising inability of cells to progress into S phase after synchronization 
coupled with LSF inhibition led to the hypothesis that the decreasing LSF levels during 
the previous cell division might have caused defects leading in G1 to senescence. To test 
this hypothesis, β-galactosidase activity, indicative of senescent cells (Debacq-Chainiaux 
et al., 2009), was measured. QGY-7703 cells were synchronized as before by a double 
thymidine block in the presence of 0 to 3.6 µM of FQI1, LSF siRNA at 20 nM, or the 
appropriate controls.  Cells were fixed at the time when control cells were approximately 
at mitotic entry and the levels of β galactosidase activity, which is indicated by blue 
staining upon phase contrast microscopy (Figure 4.7 a-j), were imaged.  Reduction in 
LSF levels or inhibition of its activity resulted in significantly greater numbers of cells 
expressing β-galactosidase activity compared to control samples. Quantitation of the 
number of cells analyzed as well as the number of cells positive for β galactosidase 
activity with LSF knockdown resulting in 88% of β-galactosidase-positive cells 
compared to 24% in the control group.  Increasing FQI1 treatment resulted in 47% and 
72% in the 1.8 and 3.6 µM groups, respectively, whereas the vehicle control group and 
0.9 μM FQI1 group had 6 and 4 percent of a positive cell population.  The observed 
increase in β-galactosidase-positive cells with reduced LSF activity correlates with the 
analysis of DNA content by flow cytometry, as fewer cells continue progression through 
the cell cycle with increasing siRNA or FQI1 concentrations (Figures 4.4 and 4.6).  
Furthermore, increasing FQI1 or LSF siRNA concentration positively correlated with the 
percentage of β galactosidase-positive cells (Figure 4.7 k and l). These data demonstrate 
that reduced LSF levels or activity during previous cell cycles can predispose cells to 
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senescence.  In contrast to data with short-term incubation of FQI1 (Chapter 3), here, 
when cells are incubated with FQI1 throughout the entire synchronization process there is 
a population that remains at 2n upon cell cycle release, albeit a minor percentage of the 
cells analyzed.  This is especially apparent in the 3.6 µM treated group and is consistent 
with the observation of senescence in the FQI treated cells (Figure 4.6).   
 
Cell cycle progression defects in QGY-7703 cells upon LSF inhibition do not result from 
DNA damage  
LSF has previously been shown to be necessary for appropriate cell cycle 
progression at the G1/S transition, due to its requirement for upregulation of thymidylate 
synthase expression (Powell et al., 2000).  Indeed, in the non-HCC cells previously 
examined, the requirement for LSF at this transition was eliminated by exogenous 
addition of low levels (20 µM) of thymidine (Powell et al., 2000).  However, in HCC 
cells, the requirement for LSF in expressing adequate thymidylate synthase is not as 
severe.  In particular, the enzyme levels were not abolished upon inhibition of LSF (Yoo 
et al., 2009).  Furthermore, addition of thymidine did not affect FQI1-mediated reduction 
in cell viability, indicating that altered thymidylate synthase expression is not the 
mediator of FQI-mediated cell death (Grant et al., 2012).  To determine whether 
reduction in thymidylate synthase expression might impact the senescent or cell cycle 
phenotypes, thymidine was added to synchronized cells at the time of release from the 
G1/S block for QGY-7703 cells treated with either LSF siRNA or FQI1.  Cell cycle DNA 
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profiles generated from flow cytometry were indistinguishable in the presence or absence 
of 20 µM of thymidine (data not shown). 
Nonetheless, to test directly whether S phase defects potentially caused by 
deficiency in LSF function might be responsible for the defects prior to G1 re-entry, 
DNA damage was monitored using antibodies to phosphorylated H2AX (γ-H2AX).  We 
assayed this by two separate techniques:  flow cytometry and immunofluorescence.  Cells 
treated with LSF siRNA were imaged by fluorescent microscopy at multiple time points 
following release of synchronized cells from a G1/S block; cells harvested at time points 
representing completion of DNA synthesis (4 hours) and re-entry into G1 (16 hours) 
showed comparable γ-H2AX staining (Figure 4.8 a, right) to those treated with control 
siRNA (Figure 4.8a, left).  Similarly, cells treated with FQI1 (Figure 4.8b, left) have 
similar profiles as compared to the control cells treated only with vehicle, exhibiting a 
small population with positive γ-H2AX staining (Figure 4.8b, right).  At the later time 
point, 16 hours, it is noteworthy that both groups with reduced LSF activity do have 
increased γ-H2AX staining in comparison to the control cells at the same time point, but 
this would be long after the mitotic defects occurred, and consistent with induction of 
apoptosis in such cells.  To confirm the results obtained by flow cytometry, a similar 
experiment was performed, however, the synchronized cells were then analyzed for γ-
H2AX signal by immunofluorescence at 8 hours post release (Figure 4.8 c and d).  A 
positive control was included (Figure 4.8c, bottom) where UV-irradiated HCC cells 
showed strong γ-H2AX staining.  Both the siRNA (Figured 4.8c) and FQI1 (Figure 4.8d) 
treated groups had comparable levels of phosphorylated H2AX as did controls, and 
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dramatically reduced levels compared with the positive control (Figure 4.8c bottom).  
Evaluation of asynchronous HCC cells treated with either LSF siRNA (Figure 4.8e) or 
FQI1s (Figure 4.8f) did result in increased γ-H2AX in both cases, however, this occurred 
approximately 24 hours following the documented aberrant mitosis, indicating that a 
defective mitosis, rather than any defects during initial progression through DNA 
synthesis, was responsible for the DNA damage (Orth et al., 2012).  Overall, these data 
indicate that LSF knockdown or inhibition does not induce double stranded DNA breaks 
prior to mitotic entry, consistent with LSF being required more directly for regulation of 
proper progression through G2 or M in hepatocellular carcinoma cells. 
 
Reduced LSF Activity Results in a Prometaphase Arrest, Cell Division Defects, and 
Multi-Nucleation 
To further investigate the consequences of mitotic delay and aberrant cell division 
induced by LSF inhibition, synchronized cells treated with LSF targeting siRNA or FQI1 
along with their respective controls were phenotypically analyzed at time points when 
control cells had exited mitosis by visualizing fixed cells for LSF, α-tubulin, and DNA 
(Figures 4.9a, c).  Both LSF loss and FQI1 treatment resulted in cells persisting in 
prometaphase, with those that exited from faulty mitoses leading to various phenotypes 
including multi-nucleation (Figure 4.9a, c). These data combined show that inhibition of 
LSF activity, by either method, results in persistence of mitotic cells much later than 
normal, with a prometaphase (Figure 4.9b, d) delay followed by aberrant cell division.  
Representative images gathered from immunofluorescent analyses (Figures 4.10-4.12) 
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show that synchronized cells with reduced LSF activity resulted in a prometaphase delay 
(Figure 4.10), defective cytokinesis (Figure 4.11) and multi-nucleation (Figure 4.12).  
These data are consistent with our previous findings indicating that high concentrations 
of FQI1 induce a profound prometaphase arrest in HCC cell lines (Chapter 
3;(Rajasekaran et al., 2015)).   
 
Expression of Aurora kinase B and Cdc20 is significantly down regulated upon LSF 
knockdown or inhibition in HCC cells 
Given that inhibition of Aurora kinase B can result in prometaphase delay, 
cytokinesis defects, and multinucleation (Andrews, 2005; Ditchfield et al., 2003; Vader 
and Lens, 2008), and that ChIP-seq data in an LSF inducible system identified multiple 
binding sites both within the Aurora Kinase B promoter and in presumptive enhancer 
regions (Gene Chin, Sriharsa Pradhan, Ulla Hansen, unpublished results), I determined 
whether loss of LSF activity would impact expression of key mitotic regulators such as 
Aurora kinase B. QGY-7703 cells treated with LSF siRNA or control siRNA were 
analyzed for expression of multiple mitotic regulators at various time points from G1/S to 
M.   
In order to investigate the delay in mitosis observed by immunofluorescent 
microscopy, expression of key drivers of mitotic entry, Cyclin A and Cyclin B, was 
examined first in synchronized QGY-7703 cells.  Eight hours after release of cells from a 
G1/S block, at which time the control cells should have completed mitosis and re-entered 
G1, Cyclin B levels were significantly decreased by both siRNA and FQI1 treatments in 
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a dose dependent manner (Figure 4.13a and 4.14a, respectively).  Cyclin A levels were 
also reduced correlating with reduced LSF activity suggesting that cells had completed 
late prophase and, unlike the controls, had not re-entered G1 (Figures 4.13 and 4.14).  
Interestingly cyclin B protein levels under this experimental design were inconsistent 
with those published (Rajasekaran et al., 2015) and those reported in Chapter 3 of this 
thesis where cyclin B protein levels remained elevated in the presence of FQI1.  This 
difference is due to distinct experimental protocols.  The studies here included incubation 
of HCC cells with FQI1 for an extended time, whereas in the previous experiments 
(Chapter 3) cells were incubated with FQI1 only after release from the G1/S block.  
Consistent with this interpretation, whereas Cyclin B RNA levels were not affected by 
the short-term incubation with FQI1 (Chapter 3 and (Rajasekaran et al., 2015)), when 
FQI1 treatment was extended RNA levels diminished in line with the protein levels 
(Figure 4.15j).  However, Cyclin B RNA levels in the cells treated with LSF siRNA was 
comparable to those in the control at the same time point (Figure 4.15k).  The apparent 
discrepancy between the siRNA and FQI1 results may be due to a timing difference 
between the two technologies utilized to deplete LSF activity where LSF knockdown, 
and its impact on downstream regulation may occur earlier than with the FQI1 treatment.  
In addition, many of the siRNA-treated cells by this protocol appear not to progress back 
into G2 or M upon release from G1/S, which may dilute any differences in cell cycle-
dependent RNA expression. 
Upon examination of Aurora kinase B expression, both LSF siRNA and FQI1 
treatments reduced protein expression of Aurora Kinase B (Figures 4.13a and 4.14a, 
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respectively).  Consistent with this observation, phosphorylation of direct targets of 
Aurora Kinase B, Serines 3 and 28 on Histone 3 (pH3 S10 and pH3 S28), were also 
reduced when either LSF levels or activity were diminished by siRNA or FQI1, 
respectively (Figures 4.13a and 4.14a).  Because RNAseq studies in HEK293 cells 
implicated LSF regulation of APC/C proteins, Cdc20 was also evaluated (Gene Chin, 
unpublished).  Cdc20 protein expression was also reduced in a dose dependent manner 
(Figures 4.13a and 4.14a), with decreasing LSF expression or activity resulting in 
decreasing Cdc20 expression.   
To determine whether the changes in Aurora Kinase B and/or Cdc20 levels were 
potentially transcriptional in nature, the relative RNA levels of both genes were measured 
following LSF inhibition or knockdown.  Gene expression of both AURB and CDC20 
was indeed down-regulated; and correlated to the degree of LSF protein decreased by 
RNAi knockdown (Figures 4.15 a-d) or via treatment with increasing concentrations of 
the LSF inhibitor, FQI1 (Figure 4.15 f,g). As expected, Cdc20 levels increased as the 
control cells progressed through the cell cycle with peak levels at mitosis (Inbal et al., 
1999) (Figure 4.15c, g), however, cells with LSF loss had significantly reduced levels at 
all time points indicating that Cdc20 was no longer being transcriptionally activated 
during G2.  Although Aurora Kinase B RNA levels normally also increase during G2 due 
to transcriptional activation (Kimura et al., 2004), in the untreated QGY-7703 cells 
Aurora Kinase B gene expression (Figures 4.15a, f) did not show a substantial increase as 
the cells entered mitosis.  This is likely due to the constitutive overexpression of Aurora 
Kinase B in HCC cells (Sistayanarain et al., 2006; Tanaka et al., 2008; Yasen et al., 
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2009).  Nonetheless, both LSF siRNA and inhibitor led to decreased AURKB expression. 
Overall, both methods of reducing LSF activity resulted in a significant loss of expression 
of CDC20 and AURKB.    
LSF knockdown or FQI1 treatment results in increased mitotic time, due to a 
prometaphase/metaphase delay followed by aberrant cellular division 
Given the complexity of multiple phenotypes, it was critical to analyze the 
phenotype and fate, cell by cell, of those that continue cell cycle progression beyond 
G1/S in the absence of or inhibition of LSF. QGY-7703 cells stably expressing 
fluorescently labeled histone H2B or α-tubulin (YFP-H2B and Emerald-α-tubulin, 
respectively) were generated. H2B labeled cells allowed visualization of the DNA 
structure and α-tubulin labeling allowed visualization of spindle formation, kinetochore 
attachment, and cytokinesis. Synchronized QGY-7703 YFP-H2B cells were transfected 
with siRNAs targeting LSF, LBP1A, both LSF and LBP1A, or a non-expressed control.  
For these experiments, a single thymidine block protocol was chosen for synchronization 
(Illustration 4.3), as the double thymidine block protocol resulted in monotonically fewer 
cells being released through S phase and ultimately into mitosis upon treatment with 
increasing amounts of LSF siRNA (Figure 4.4 and data not shown).  Using a single 
thymidine block, a larger percentage of cells reached mitosis. Representative time lapse 
images of cells treated with the highest concentration (20 nM) of either LSF targeting 
siRNA or control highlight dramatic changes in mitotic progression.  The control cells 
exhibit normal mitosis with progression through prometaphase, metaphase, anaphase and 
telophase in a timely manner (Figure 4.16a).  However, the cells with diminished LSF 
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levels exhibit a prometaphase/metaphase delay followed by cell division defects (Figure 
4.16b). Upon quantitation, the time required for each cell to progress through mitosis, 
measured from the start of nuclear envelope breakdown (NEB) to anaphase, was 
dramatically increased in the cells with reductions in LSF (Figure 4.16c).   
Counterintuitively, the lower concentrations of LSF siRNA resulted in longer times for 
mitotic progression.  
LBP1A knockdown alone resulted in only a subtle increase in mitotic time. Taken 
together with the cell viability and DNA profiling data (Figures 4.3 b and c; 4.5) this 
minor increase does not significantly impact either proper HCC cellular mitotic 
progression or cellular division. Further, no abnormal mitotic phenotypes were observed 
in the time-lapse studies of cells with LBP1A knockdown.  LBP1A siRNA (10 nM) 
added in combination with LSF siRNA (10 nM) diminished the effect on mitotic 
progression compared to 10 nM LSF siRNA alone (Figure 4.16c), which may relate to 
the lesser effect of 20 nM LBP1a siRNA alone.  
Upon examining the outcomes for individual cells treated with LSF siRNA as 
they progressed through mitosis, major defects were observed. Most striking was an 
extended delay in prometaphase and/or metaphase (representative images in Figure 4.16 
b, e and f).  On a cell-by-cell basis, this was often followed by aberrant cellular division 
(Figure 4.16 b, g-j).  Figure 4.16 e and f show the same cell delayed in 
prometaphase/metaphase with 4.16e exhibiting a prometaphase phenotype and 4.16 f 
exhibiting a metaphase phenotype.  Figure 4.16 g represents a cell arrested in 
prometaphase in which the DNA condensed into a near-apoptotic state, whereas Figure 
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4.16i and j display a cell that, following a prolonged prometaphase/metaphase arrest, 
divided in a multi-polar fashion without separating into two daughter cells. Quantitation 
indicated a significant increase in both the prometaphase/metaphase and aberrant cellular 
division phenotypes over a range of degrees of LSF knockdown (Figure 4.16d).  In 
addition, some cells remained in prometaphase-metaphase by the end of the analysis (e.g. 
Figure 4.16 g,h); thus it is not certain that these cells would exit mitosis at all.    
Asynchronous H2B YFP QGY-7703 cells were also treated with increasing 
concentrations of FQI1 and imaged by time-lapse microscopy.  Synchronization was not 
regarded as necessary in this case, as time-lapse imaging allowed the tracking of 
individual cells as they pass through mitosis and FQI1 addition to asynchronous cells was 
hypothesized to relatively rapidly interact with LSF following addition.  At the highest 
concentration (3.6 µM), representative images show cells that apparently arrested in 
prometaphase with no observable transitioning to metaphase throughout the 640 minutes 
of imaging (Figure 4.17c).  This was in stark contrast to control cells, which progressed 
through mitosis within the normal timespan (Figure 4.17a).  Cells treated with half the 
maximal concentration of FQI1 (1.8 µM) were delayed in prometaphase and/or 
metaphase, with cells subsequently progressing through defective cellular division 
(Figure 4.17b).  Upon quantitation, mitotic time (time from nuclear envelope breakdown 
(NEB) to anaphase) increased with increasing concentrations of FQI1 (Figure 4.17d).  
The time was indeterminable for cells treated with 3.6 µM of FQI1, as the cells never 
reached anaphase during the course of the experiment.  Overall, phenotypes were similar 
to those documented with LSF siRNA treatment (compare Figure 4.16e with Figure 
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4.17d). By following individual cells as they progressed through mitosis, it became 
apparent that cells delayed progression either in prometaphase (e.g. Figure 4.17f) or 
metaphase (e.g. Figure 4.17g), and subsequently exited mitosis aberrantly (Figure 4.17h, 
i). A recurring consequence was multi-nucleation upon mitotic exit (Figure 4.17i).   
Lastly, Figure 4.18 d and e are representative images where upon reduced LSF activity, 
regardless of the method utilized, appearance of cellular protrusions was evident.  As to 
whether loss of LSF directly leads to the membrane protrusions or whether this 
observation is secondary to the mitotic arrest is unknown. 
Discussion 
LSF, a ubiquitously expressed transcription factor, is an oncogene in human 
hepatocellular carcinoma (Santhekadur et al., 2012b; Yoo et al., 2010). Recent studies 
have shown that small molecule inhibitors directly targeting LSF inhibited HCC cell 
proliferation in vitro and tumor growth in vivo (Grant et al., 2012; Rajasekaran et al., 
2015).  These inhibitors, FQI1 and FQI2, both resulted in significant anti-tumor activity 
in an endogenous liver model with no signs of toxicity at the doses required for tumor 
inhibition (Grant et al., 2012; Rajasekaran et al., 2015).  Together, these data indicate that 
LSF is an exciting therapeutic candidate for HCC patients.  The recent reports used 
Factor Quinolinone Inhibitors as a tool to inhibit LSF activity showing robust anti-tumor 
activity, and were consistent with earlier observations of a dominant negative LSF 
reducing HCC tumorigenicity (Yoo et al., 2010).  However, although the data support 
specific targeting of the transcription factor LSF by FQIs, this result was surprising given 
 
 
113 
the generally encountered difficulties in targeting transcription factors with small 
molecules (Yan and Higgins, 2013).   
Here, the combinatorial use of small molecule inhibitors that eliminate LSF DNA 
binding with RNAi technology which specifically reduces LSF synthesis was utilized to 
confirm FQI1 specificity.  The data show that titrating LSF activity by either small 
inhibitors or LSF activity resulted in extensive mitotic defects prior to cell death.  These 
data provide definitive evidence both that the FQI1-induced mitotic defects previously 
published are not a secondary effect of FQI1, and that LSF regulates mitosis in 
hepatocellular carcinoma cells.  
Eliminating LSF activity inhibited HCC cellular division and resulted in the 
duplicated DNA remaining in one cell prior to cell death.  Analysis of cell cycle 
progression revealed a population of cells undergoing mitotic delay prior to cell death 
through apoptosis, as well as a population of senescent cells.  The mitotic delay, 
particularly in prometaphase or metaphase, was highlighted by time lapse microscopy, 
upon inhibition of LSF activity by the two independent approaches.  Mitotic time, 
measured as the amount of time from NEB to anaphase, was similarly boosted upon 
increasing either FQI1 or LSF siRNA concentrations.  Strikingly, the lower siRNA 
concentrations produced greater delays in mitotic progression than higher siRNA 
concentrations.  One interpretation of this result is that LSF targets multiple mitotic 
components, and higher levels of LSF inhibition may be required to solidify the 
mechanism of prometaphase arrest.   
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Presence of DNA damage as cells enter mitosis can result in mitotic delay 
(Ganem and Pellman, 2012).  However, this was ruled out by two types of controls. First, 
misregulation of thymidylate synthase was not the cause of the mitotic defects because 
supplementation of these cells with exogenous thymidine in order to circumvent a 
thymidylate synthase deficiency did not impact the phenotype (Grant et al., 2012).  
Second, staining for double stranded DNA breaks indicated that minimal, if any DNA 
damage occurred under these conditions prior to mitotic progression. 
Key phenotypes observed in the HCC cells with LSF depletion included: cellular 
senescence, prometaphase/metaphase arrest, cell division defects and multi-nucleation.  
To identify potentially relevant LSF targets, we assayed expression of key mitotic 
proteins that generate similar phenotypes when inhibited, showing that levels of both 
Aurora kinase B and CDC20 decrease when LSF is inhibited by either siRNA or small 
molecule inhibitors.  Notably, phenotypes previously documented for agents that inhibit 
Aurora Kinase B are consistent with all those described for LSF inhibition in Chapters 3 
and 4 (Kim et al., 2011; Le et al., 2013; Poon, 2013; Sistayanarain et al., 2006; Vader and 
Lens, 2008).  In addition, reduction of Cdc20 levels also results in increased mitotic times 
(Huang et al., 2009; Irniger, 2002). Cdc20 is required for proteolysis of key mitotic 
regulators, including securin, and is a prerequisite for the promotion of anaphase and 
mitotic exit.   
When Cdc20 is depleted with siRNA, cells remain in mitotic distress for lengthy periods, 
and die in mitosis (Huang et al., 2009; Irniger, 2002).  The increase in mitotic time with 
the reduced Cdc20 expression jive with a strategy that has been proposed as promising 
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for anti-tumor therapies (Gascoigne and Taylor, 2008, 2009; Kimura et al., 2013).  
Overall, that both Aurora Kinase B and Cdc20 are down regulated at the mRNA and 
protein levels when LSF is diminished begs the question as to whether LSF directly 
activates expression of these two target genes during G2.  This hypothesis is being 
actively pursued in the Hansen laboratory.         
The mitotic phenotypes prove that LSF is required for mitotic progression in HCC, and 
that Aurora Kinase B and Cdc20 expression are downstream from LSF.  The mechanism 
by which LSF regulates these targets remains to be determined.  However, ChIP-seq data 
generated in a non-HCC cell line revealed multiple LSF DNA binding sites in Aurora 
Kinase B regulatory regions (Gene Chin, unpublished results) raising direct regulation as 
a possibility.  In addition, separate analyses of clinical HCC samples have shown 
increased LSF (Fan et al., 2011a; Gu et al., 2015; Yoo et al., 2010) and Aurora Kinase B 
expression, albeit independently, that positively correlate with HCC disease severity.   
These observations are consistent with our data that LSF regulates Aurora Kinase B 
expression, albeit whether the interaction is direct or indirect remains to be proven.  The 
indirect hypothesis is that Aurora Kinase B and Cdc20 reductions are a secondary 
consequence of a mitotic defect initiated through another form of regulation, perhaps 
such as a non-transcriptional mechanism suggested from results in Chapter 3.  Whether 
the interaction is direct or indirect,  however, the observed phenotypes including cellular 
senescence, prometaphase/metaphase delay, aberrant cell division, multi-nucleation and 
cell death, are all consistent with Aurora Kinase B inhibition/knockdown (Andrews, 
2005; Ditchfield et al., 2003; Vader and Lens, 2008).    
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The mitotic phenotypes generated by either LSF knockdown or FQI1 treatment 
were similar in many respects, although not identical. With FQI1 treatment, cell division 
defects included a unique chromosome alignment (shaped like a boomerang) and the 
highest FQI1 concentration resulted in a complete prometaphase arrest.  In contrast, 
diminishment of LSF protein levels (even at siRNA concentrations as high as 20 nM) did 
not result in a complete arrest in mitosis, but instead mitotic slippage to aberrant cell 
divisions.  The differences in phenotypes may simply be due to LSF RNAi knockdown 
not completely ablating LSF, whereas high concentrations of the small molecule inhibitor 
may well inhibit LSF completely.  Alternatively, since FQI1 inactivates, but does not 
remove LSF from the cell, it may only inhibit some of LSF functions.   
Finally, FQIs also inhibit LSF paralogs, including the ubiquitously expressed 
LBP1a (Trevor Grant and Ulla Hansen, unpublished).  Therefore, to accurately 
recapitulate the FQI1 phenotype to confirm target specificity we perturbed LSF and 
LBP1a levels, both alone and in combination.  Our results, however, show that LBP1A 
has only limited impact indicating that LBP1A is likely not involved in producing the 
LSF-related mitotic phenotypes.  In fact, individual loss of LBP1A did not affect cellular 
division or induce death of the HCC cells.  The one noted consequence of LBP1A 
knockdown, however, was a small, but statistically significant, increase in the amount of 
time required to progress from NEB to anaphase.  This prolonged mitosis did simply not 
result in aberrant phenotypes or cell death.   
These findings support the notion that LSF is a strong clinical candidate to treat 
the afflicted hepatocellular carcinoma population, a patient population increasing globally 
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with a strong unmet medical need.  Aurora Kinase B inhibitors, initially clinical 
candidates with great promise, have dwindled in the clinic as off target effects and 
minimal efficacy have plagued the trials (Chan et al., 2012). Targeting LSF, an oncogenic 
transcription factor, could have greater impact on the HCC patient population.  FQIs were 
non-toxic in preclinical tumor models and this work now implicates LSF as being 
upstream of a major mitotic kinase, APC/C member, Cdc20, whose knockdown in tumor 
cells with induced mitotic delay, has been hypothesized to having an advantage in 
targeting and killing tumor cells (Huang et al., 2009).  Together, the interrogation of LSF 
by multiple means, including the two described here, has corroborated the clinical 
candidacy for this target, as well as revealing a previously unknown role in mitotic 
regulation.  Targeting an oncogenic transcription factor that is necessary for 
hepatocellular proliferation and survival could have a significant impact on a significant 
disease population.   
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Figures 
Illustration 4.1 FQI1 Treatment in Synchronized HCC Cells (Long Incubation) 
 
Illustration 4.2 siRNA Transfection in Synchronized HCC Cells-Double Thymidine 
Block 
 
Illustration 4.3 siRNA Transfection in Synchronized HCC Cells-Single Thymidine 
Block 
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Figure 4.1 Lipid transfection of siRNA in HCC cells results in efficient knockdown 
of LSF and LBP1A   
(a-d) QGY-7703 cells plated in 100 mm x 20 mm dishes were transfected using 
Invitrogen RNAimax with either 20 nM of control siRNA or TFCP2 targeting siRNA.  
The Control siRNA was tagged with Cy3 to follow cellular uptake.  Images were taken 
on a Zeiss microscope at a 40x magnification approximately 24 hours following lipid 
transfection. Cy3 channel images of Control siRNA-Cy3 transfected (a) or LSF siRNA 
transfected (c) cells, Phase contrast images of Control siRNA-Cy3 transfected (b) or LSF 
siRNA transfected (d) cells. Images in (a) and (c) were taken at the same length of 
exposure.  (e,f) Twenty-four candidate siRNAs targeting TFCP2, the gene encoding LSF, 
were identified.  Each siRNA was transfected using RNAimax into two different HCC 
cell lines - Hep3B (e) and QGY-7703 (f), at 20, 10, or 2 nM.  LSF RNA harvested at 24 
hours post transfection was quantified using a hybridization-based bDNA assay 
(Affymetrix).  LSF RNA levels were normalized to those of an internal control gene, 
GAPDH, and are depicted as percentages of LSF RNA levels in the control siRNA-
treated cells.  (g, h) Mad2 RNA harvested at 72 hours (g,h) and 96 hours (h) post 
transfection was quantified using the Taqman gene expression system.  Relative gene 
expression was determined by normalizing MAD2 RNA levels to those of an internal 
control, GAPDH.  Mad2 gene expression was not altered following treatment with the 
siRNA targeting LSF.  This finding was consistent across 2 independent experiments for 
the lead siRNA chosen.  (i) Eight candidate siRNAs designed to target LBP1A were 
transfected into QGY-7703 cells at 20 nM.  Expression at 72 hours post transfection of 
UBP1, the gene encoding LBP1A, was determined using a Taqman qPCR assay. LBP1A 
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RNA levels were normalized to those of GAPDH and are depicted as percentages of 
LPB1a RNA levels in the control siRNA-treated cells. (j) Relative MAD2 RNA levels 72 
hours post transfection in asynchronous QGY-7703 cells treated with control siRNA or 
the each of the 8 siRNAs targeting LBP1A. 
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Figure 4.2 Division of synchronized HCC cells is abrogated upon inhibition of LSF.  
siRNAs targeting LSF, LBP1A or a non-expressed target were transfected into to QGY-
7703 cells at 20 nM. (a-b) LSF and LBP1A mRNA levels were detected using a Taqman 
gene expression assay. Remaining (a) LSF RNA and (b) LBP1A RNA levels were 
measured at 24, 48, 72 and 96 hours post transfection.  Relative RNA levels, normalized 
to those of GAPDH, are depicted as percentages of the levels in the control siRNA-
treated cells. (c-e) Representative immunoblots of LSF and beta tubulin are shown for (c) 
lysates collected at 24, 48 hours post transfection during cell synchronization or (d) 
lysates collected following synchronization and release from the final G1/S block for 0, 4 
and 8 hours. (e) LBP1A protein expression measured 24, 48 and 72 hours post 
transfection.  α-Tubulin was used as a loading control.  Control siRNA was transfected at 
20 nM and analyzed 24 hours post transfection.  LBP1A siRNA was transfected at a 10 
nM concentration. (f) siRNAs targeting LSF or both LSF and LBP1A were transfected 
into QGY-7703 cells at 10 or 20 nM.  Cells were synchronized using a double thymidine 
block as depicted in Illustration 4.2 and counted at 0 or 16 hours following release from 
the G1/S block. (f-g) QGY-7703 cells were synchronized using Illustration 4.1 or 4.2. 
The total cell number had increased 1.5-fold in comparison to the total cell number 
measured at 0 hours.  The control cells may contain less than 2-fold the number of cells at 
0 hours due to cell loss during washing of the cells upon change of media for release 
from the G1/S block.  However, such loss would have been consistent across all 
populations.  (f) Cells treated with siRNAs targeting either control, LSF, LBP1a, or LSF 
and LBP1a in combination.  (g) Cells were treated with vehicle control, 0.9, 1.8 or 3.6 
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µM FQI1 and counted at 0 and 16 hours following a release from a G1/S block. Standard 
deviation represented of 3 biological experiments. (h-k) Synchronized QGY 7703 cells 
were transfected with 20 nM Control siRNA (h) or 20 nM LSF siRNA (i) or treated with 
1.8 µM FQI1 (j) or vehicle (k).  Phase contrast images were taken at 96 hours post release 
from the G1/S block at a magnification of 20x.   
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Figure 4.3    LSF knockdown and FQI1 treatment in HCC cells results in reduced 
cell number and induction of caspase activity 
(a-b) Asynchronous QGY-7703 cells were (a) transfected with siRNA targeting either 
LSF or a control, or (b) treated with 3.6 µM of FQI1 or vehicle.  The cells were analyzed 
at 24, 48, 72, 96, and 120 hours post treatment for cell viability/number by Trypan blue 
staining.  Fifty individual fields were quantitated for the number of trypan blue positive 
cells; which is depicted as a percentage of the cell count for those 50 fields.  Data 
represent 3 independent experiments.   (c) Viability, as determined by cell permeability 
(Trypan Blue), of asynchronous QGY 7703 cells treated with 20 nM of control siRNA or 
siRNAs targeting either LSF or LBP1A.  Data were generated 120 hours post transfection 
and include 3 independent experiments.  (d) QGY-7703 cells were transfected with 
control siRNA targeting either LSF or a control, or treated with 3.6 µM of FQI1 or 
vehicle.  The cells were synchronized at the G1/S border and released. Cells were 
analyzed 48 hours after release for cell viability using cell titer blue (Promega).  Standard 
error bars were derived from 3 independent experiments. (e) Synchronized QGY-7703 
cells were analyzed for caspase activation at 8 and 48 hours post release in presence of 20 
nM of LSF or 3.6 µM of FQI1.  Compiled data from all three time points depicted as 
percent of the vehicle control.  Standard deviation derived from two independent 
experiments.  Statistical significance was determined using a Student T Test; * P<0.05, ** 
P<0.01, *** P<0.001, **** P<0.0001 
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Figure 4.4   Synchronization of HCC cells after LSF knockdown reveals two distinct 
phenotypes: a static 2n DNA population and a population progressing from 2n to 4n 
DNA content transitioning to a subG1 population. 
QGY-7703 cells were synchronized at the G1/S border post transfection with 20 nM 
control siRNA or 5, 10, or 20 nM LSF siRNA (Illustration 4.2). At 0, 3.5, 8 and 18 hours 
after release from the block, cells were fixed and stained with propidium iodide for 
analysis of DNA content by flow cytometry.  Data are representative of greater than 4 
experiments.    
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Figure 4.5    Synchronization of HCC cells after LBP1A knockdown does not impact 
cell cycle progression. 
QGY-7703 cells were synchronized at the G1/S border 24 hours post transfection with 
LBP1A or control siRNA at 20 nM (Illustration 4.2). At 0, 4, and 8 hours post release, 
cells were fixed and stained with propidium iodide for analysis of DNA content by flow 
cytometry.  (a) Untreated cells were synchronized and analyzed at 0 hours. Synchronized 
HCC cells transfected with (b) control siRNA or (c) siRNA targeting LBPA1a.  Data are 
representative of 3 independent experiments. 
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Figure 4.6 Synchronized HCC cells treated with FQI1 reveal a G1/S population, and 
accumulation at 4n 
FQI1-treated QGY-7703 cells were synchronized at the G1/S border using a double 
thymidine block (Illustration 4.1). Cells were incubated with 0.9, 1.8, or 3.6 µM of FQI1 
or vehicle.  At 0, 4.5, 5.5, 8.5, and 16 hours post release from the G1/S block, cells were 
fixed and stained with propidium iodide for analysis of DNA content by flow cytometry.  
These data are representative of at least 3 independent experiments.  
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Figure 4.7 LSF removal or inhibition in synchronized HCC cells results in cellular 
senescence  
FQI1-treated QGY-7703 cells were synchronized at the G1/S border using a double 
thymidine block. Cells were incubated with 0.9, 1.8, or 3.6 µM of FQI1 or vehicle 
(Illustration 4.1), or with Control or LSF siRNA (Illustration 4.2), and then fixed and 
stained for β-galactosidase activity at 8 h after release from the G1/S block. Phase 
contrast images were taken at 20x magnification.  Representative images are shown for 
cells treated with (a) 20 nM Control siRNA, (b) 20 nM LSF siRNA, (c) Vehicle (DMSO) 
or (d, e and f) 0.9, 1.8, and 3.6 µM of FQI1, respectively.  Images in (a-f) are 
representative of 3 independent experiments. (g-j) Representative images are shown from 
three independent experiments evaluating LSF siRNA at dose levels including 5, 10, and 
20 nM in comparison to control siRNA at 20 nM.  (k,l) The correlation of increasing 
FQI1 concentrations or increasing siRNA concentrations with the number β-galactosidase 
positive cells is depicted as a percentage of the control for each individual experiment.  
75 cells were analyzed per condition.  Statistical significance was determined using a 
Student T Test; * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 
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Figure 4.8 γ-H2AX levels remain minimal prior to mitosis in synchronized QGY-
7703 cells treated with either LSF knockdown or FQI1 treatment. 
(a) QGY-7703 cells were treated with LSF siRNA or control siRNA at 20 nM and 
synchronized with a single thymidine block, as indicated in Illustration 4.3. Cells were 
collected at 4 and 16 hours post release from the G1/S block, fixed, and probed with an 
anti γ-H2AX antibody directly conjugated Alexa 488 to measure double stranded DNA 
breaks. In addition, the cellular DNA was stained with propidium iodide.  Data were 
analyzed by flow cytometry.  (b) QGY-7703 cells were synchronized with a single 
thymidine block at the G1/S border following incubation with 1.8 µM FQI1 or vehicle 
and then released.  γ-H2AX staining in FQI1 treated cells versus vehicle was analyzed as 
in (a) at 4 and 16 hours post release from the G1/S block.  The percentage of cells in the 
indicated gate is shown in each panel at the top.  (c,d) Cells treated as in (a) and (b), 
respectively, were stained with anti-γ-H2AX antibody but analyzed by 
immunofluorescence at 63x magnification 8 hours post release from a G1/S block.  All 
images were taken at the same exposure.  Representative images are displayed in (c) for 
control siRNA (left) and LSF siRNA (right), and an ultra-violet treated control (bottom 
left) and in (d) for vehicle (left) and 1.8 µM FQI1 treated cells (right). (e) Asynchronous 
QGY-7703 cells treated with LSF siRNA or control were collected at 24 and 48 hours 
post treatment and stained for anti-γ-H2AX.  (f) Asynchronous cells treated with 0.9, 1.8 
or 3.6 μM of FQI1 were collected at 24 and 48 hours post treatment and stained for anti-
γ-H2AX.  Representative images are shown for each time point.  
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Figure 4.9 Immunofluorescent analysis of synchronized HCC cells with LSF 
knockdown or FQI1 treatment reveal multi-nucleation and cell division defects 
(a,b) QGY 7703 cells were synchronized at the G1/S border following transfection with 
LSF or control siRNA at 20 nM, and then released to progress through the cell cycle, as 
depicted in the schematic at the top.  Cells were fixed and probed with an anti-LSF (red) 
and anti-alpha tubulin (green) antibody and stained with DAPI (blue) at multiple time 
points to analyze mitotic figures.  Images were analyzed at 16 hours post release at 63x 
magnification. 89-102 individual cells were analyzed within each group.  (a) 
Representative images 16 hours post release revealing cells still in 
prometaphase/metaphase, aberrant cell division and multi-nucleation in cells with LSF 
knockdown as well as examples of normal mitotic figures in the control siRNA group 
including metaphase and telophase at earlier time points. (b) Quantitation of mitotic cells 
as well as observations of apoptosis determined by fragmented nuclei and multi-
nucleation. 100 individual cells were analyzed within each group at 16 hours post release.  
(c,d) QGY 7703 cells were synchronized at the G1/S border following incubation with 
vehicle control or FQI1 at concentrations of 1.8 or 3.6 µM and then released (Illustration 
4.1).  QGY 7703 cells were fixed and probed with an anti-LSF antibody, anti-α-tubulin 
antibody and then stained with DAPI to analyze mitotic figures.  Images were analyzed at 
16 hours post release at 63x magnification. 100 individual cells were analyzed within 
each group.  (c) Representative images 16 hours post release revealing signs of aberrant 
cytokinesis, and multi-nucleation in the FQI1 treated cells.  (d) Quantitation of cellular 
phenotypes.  98-107 individual cells were analyzed within each group.   
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Figure 4.10 Immunofluorescent analysis of FQI1 and siRNA treated HCC cells 
reveals prometaphase/metaphase arrest 
Synchronized HCC cells were treated with either 20 nM of LSF siRNA or 1.8 μM FQI1.  
Cells were collected 8 hours post release from the final G1/S block and stained for α-
tubulin and DNA. DNA is shown in FQI1 treated or LSF siRNA treated cells on bottom 
(b,d), Alpha-Tubulin staining shown on top (a,c). Representative images of a 
prometaphase-metaphase delay are shown. 
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Figure 4.11 Immunofluorescent analysis of FQI1 and siRNA treated HCC cells 
reveal aberrant cell division 
Synchronized HCC cells were treated with either 20 nM of LSF siRNA or 1.8 μM of 
FQI1.  Cells were harvested 16 hours post release and stained for α-tubulin and DNA. 
DNA is shown in FQI1 treated or LSF siRNA treated cells on the right (b,d,f), α--tubulin 
staining is shown on the left (a,c,e). Representative images of cells exhibiting an aberrant 
cell division are shown. 
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Figure 4.12 Immunofluorescent analysis of FQI1 and siRNA treated HCC cells 
reveals multinucleated cells 
Synchronized HCC cells were treated with either 20 nM of LSF siRNA or 1.8 μM of 
FQI1.  Cells were harvested 16 hours post release and stained for α-tubulin and DNA. 
DNA is shown in FQI1 treated or LSF siRNA treated cells on bottom (b,d), alpha-tubulin 
staining shown on top (a,c). Representative images of multinucleated cells are shown. 
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Figure 4.13 Protein expression of Aurora Kinase B, Cdc20, and Cyclin B is 
decreased in synchronized HCC cells upon reduction of LSF protein levels 
QGY-7703 cells transfected with siRNA were synchronized and harvested 8 hours post 
release from a G1/S block. Cell lysates were probed for a variety of proteins involved in 
mitosis. (a) Immunoblot images of lysates collected 9 hours post release from a G1/S 
block for LSF, Cyclin A, Cyclin B, Cdc20, Aurora Kinase B, pH3 Ser10, and pH3 Ser28.  
Beta actin levels were used to control for differential loading. Quantitation of the levels 
of (b) Aurora Kinase B and (c) Cdc20 normalized to beta actin levels.  Data are 
representative from 3 independent studies.  Statistical significance was determined using 
a Student T Test; * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 
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Figure 4.14 Protein expression of Aurora Kinase B, Cdc20, and Cyclin B are 
significantly reduced in synchronized HCC cells treated with FQI1 
FQI1 treated QGY 7703 cells were synchronized at the G1/S border using a double 
thymidine block. Cells were incubated with 0.9, 1.8, or 3.6 µM of FQI1 or vehicle 
control.  Lysates were probed for proteins of interest. (a)  Western blot images for lysates 
collected 9 hours post release from a G1/S block for LSF, Cyclin A, Cyclin B, Cdc20, 
Aurora Kinase B, and pH3 S10.  Beta actin levels were used to control for differential 
loading.  Quantitation of the levels of (b) Cdc20 and (c) Cyclin B, (d) Aurora B Kinase, 
(e) Phosphorylated Histone 3 Serine 10 normalized to Beta Actin levels.  Data are 
representative of 2-4 independent experiments.  Standard error calculated where data 
were averaged from 3 independent studies.  Statistical significance was determined using 
a Student T Test; * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 
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Figure 4.15 Aurora Kinase B and Cdc20 gene expression is reduced in HCC cells 
upon inactivating LSF with either LSF siRNA or FQI1 
(a-d) QGY-7703 cells transfected with siRNA were synchronized and released as 
indicated in Illustration 4.2. Cells were harvested between 0 and 8 hours post release 
from a G1/S block. RNA was isolated for gene expression analysis by qPCR using 
Taqman probes. The relative levels of gene expression were determined by normalizing 
RNA levels to those of GAPDH as an internal control.  (a) Aurora Kinase B gene 
expression measured at 0, 4, and 8 hours post release from a G1/S block.  Standard error 
is based on 4 biological replicates for the 8 hour time point.  (b) Aurora Kinase B 
expression normalized to siRNA control 8 hours post release from a G1/S block 
following treatment with 5, 10, 20 nM of LSF siRNA, 10 nM LBP1A or 10 nM of both 
LSF and LBP1A siRNA.  (c) Cdc20 gene expression was determined on samples treated 
with the various siRNAs alone or in combination 0, 4, 6 and 8 hours post release from the 
G1/S block.  Standard error is based 4 biological replicates for the 8 hour time point (d) 
Cdc20 expression determined on samples treated with siRNA targeting a control, LSF, 
LBP1A or a combination at 8 hours post release from a G1/S block. Concentrations were 
20 nM for the control siRNA, 5, 10, or 20 nM for LSF siRNA, or a combination of with 
10 nM of LBP1A siRNA and 10 nM of LSF siRNA.  Standard error is based on 2 
biological experiments for the 0 and 4 hour time points, and 4 biological experiments for 
the 8 hour analysis.  (e-g) FQI1-treated QGY-7703 cells were synchronized at the G1/S 
border using a double thymidine block, according to Illustration 4.1. Cells were incubated 
with either 1.8 µM of FQI1 or vehicle starting at the release from the first G1/S block and 
maintained throughout the remainder of the time course. Samples were harvested at 0, 4, 
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and 8 hours post release from the final G1/S block and RNA for gene expression was 
analyzed by qPCR using Taqman probes. Relative levels of gene expression were 
determined by normalizing RNA levels to those of GAPDH as an internal control. RNA 
levels are depicted for (e) LSF, (f) Aurora Kinase B (g) Cdc20 following incubation with 
either 1.8 µM FQI1 or vehicle.  Standard error of the mean was derived from 4 
independent experiments.  Gene expression for Cyclin A (h,i) or Cyclin B (j,k) was 
determined at 8 hours post release from the G1/S block for samples treated either with 
0.9, 1.8 or 3.6 µM FQI1 vs vehicle control (h,j), or with 20 nM control siRNA or 20 nM 
LSF siRNA (i,k).    SEM derive from 2 independent experiments.  Statistical significance 
was determined using a Student T Test; * P<0.05, ** P<0.01, *** P<0.001, **** 
P<0.0001 
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Figure 4.16 LSF knockdowns in synchronized HCC cells results in increased mitotic 
time with prometaphase/metaphase delay and cell division defects 
Synchronized QGY-7703 cells expressing YFP-labeled H2B were analyzed utilizing time 
lapse microscopy.  Cells were transfected with 20 nM of either control siRNA, or siRNA 
targeting LSF, LBP1A, or LSF and LBP1A in combination. Cells were treated with a 
single thymidine block and released prior to imaging (Illustration 4.3). (a-b) 
Representative images of cells treated with control siRNA (a) or with LSF siRNA (b) are 
pictured. Numbers represent minutes from nuclear envelope breakdown.  (c) Quantitation 
of mitotic time determined on 100 cells following nuclear envelope breakdown treated 
with control siRNA or siRNAs targeting LSF or LBP1A separately or in combination.  
Standard error is depicted based on the number of cells analyzed in a single experiment. 
(d) Quantitation of cellular events including numbers of cells entering mitosis, exhibiting 
delay in prometaphase/metaphase, and defects in cell division at the indicated 
concentrations of transfected LSF siRNA.  The controls had neither of the indicated 
defects among the cells counted.  Approximately 120-140 cells were analyzed per 
condition. Statistical significance was determined using a Student T Test; * P<0.05, ** 
P<0.01, *** P<0.001, **** P<0.0001. (e-i) Representative images of individual cells to 
demonstrate mitotic phenotypes in cells transfected with 5 nM LSF siRNA: (e-f) 
prometaphase/metaphase delay, (g-h) cells that never divided within the time course (16 
hours) of the experiment, and (i-j) cells undergoing aberrant cell division.  
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Figure 4.17    FQI1 treatment of HCC cells causes a dose dependent increase in 
mitotic time, prometaphase/metaphase delay and cell division defects  
Asynchronous QGY-7703 cells expressing YFP-labeled H2B were analyzed utilizing 
time lapse microscopy after treatment with increasing concentrations of FQI1.  
Representative images of cells treated with (a) vehicle, (b) 1.8 µM FQI1 or (c) 3.6 µM 
FQI1.  Numbers represent minutes from nuclear envelope breakdown.  (d) Quantitation 
of mitotic time determined on 101 cells following nuclear envelope breakdown treated 
with 0.9 µM or 1.8 µM FQI1 or vehicle.  Standard error is depicted based on the number 
of cells analyzed in a single experiment. Cells treated with 3.6 µM were not included as 
those entering mitosis did not reach anaphase during the overnight imaging period.  (e) 
Quantitation of cellular events including number of cells entering mitosis, delayed in 
prometaphase/metaphase, and exhibiting cell division defects.  120-140 events were 
analyzed per condition. Statistical significance was determined using a Student T Test; * 
P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. (f-i) Representative images of 
prometaphase/metaphase delay and cell division defects, taken of cells treated with 1.8 
µM FQI1.  (f-g) Cells delayed in prometaphase/metaphase; (h-i) cells undergoing 
aberrant cellular division are the same as those in (f-g), although at later times. 
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Figure 4.18 HCC cells delayed in prometaphase/metaphase upon LSF inhibition or 
knockdown often exhibit cellular protrusions  
(a,b) Asynchronous HCC cells expressing mEmerald labeled α-tubulin were analyzed 
phenotypically utilizing time lapse microscopy following treatment with 3.6µM of FQI1 
or vehicle.  Representative images of QGY-7703 cells labeled with mEmerald α-tubulin 
treated with vehicle control (a) or 1.8 µM FQI1 (b) or (c) 3.6 µM FQI1.  The numbers 
represent the time in minutes from nuclear envelope breakdown.  (d) Synchronized HCC 
cells were treated with either 20 nM of LSF siRNA (Illustration 4.3) or 1.8 μM of FQI1 
(Illustration 4.1).  Cells were collected 8 hours after release from the final G1/S block and 
fixed for IF analysis with an anti-α-tubulin antibody and stained with DAPI.  Anti-α-
tubulin staining is shown in vehicle control (d), FQI1-treated (e), or LSF siRNA-treated 
(f) cells.  Arrows indicate the cytoskeletal protrusions.  siRNA control images were 
identical to those in vehicle control (d) (data not shown). 
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CHAPTER FIVE  
LSF inhibition by FQI1 does not impact primary mouse hepatocytes ex vivo nor 
does FQI1 or FQI2 treatment in wild type mice reduce circulating rapidly dividing 
cell populations.   
Introduction 
Current treatments for those afflicted with Hepatocellular carcinoma (HCC) are 
subpar with the majority of patients qualifying for only palliative treatments (Bruix and 
Sherman, 2011; Farazi and DePinho, 2006; Torrecilla and Llovet, 2015).  A minority of 
patients do qualify for invasive therapies including surgical resection or a liver transplant.  
Currently, Sorafenib, a tyrosine kinase and Raf inhibitor initially approved for renal cell 
carcinoma, is the only approved molecular therapy for HCC.  Sorafenib has been shown 
to be efficacious in a subset of HCC patients where 71 patients had stable disease versus 
67 in the placebo control, with only 2 patients showing complete response to 1 observed 
in the control group (Llovet et al., 2008).  Further, the improvement in survival rates was 
subpar leaving the afflicted population with a significant unmet need (Llovet et al., 2008).  
Following the improvement observed with Sorafenib, a large number of molecularly 
targeted therapies were tested in clinical trials (Torrecilla and Llovet, 2015; Villanueva 
and Llovet, 2011).  These drugs include both new agents and agents that have proven 
effective in other types of cancer, including inhibitors of angiogenesis, oncogenic 
signaling pathways, and histone deacetylases (Torrecilla and Llovet, 2015; Villanueva 
and Llovet, 2011).  
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Chemotherapeutics have long been a mainstay of therapy for a broad range of cancer 
types.  The majority of chemotherapeutics demonstrate a robust ability to kill rapidly 
dividing cancer cells, however they also target rapidly dividing non- tumor cell 
populations. These normal cell populations include epithelial cells in both the intestine 
and hair follicles, resulting in two or the more notorious side effects experienced by 
cancer patients (diarrhea and hair loss). Approaches to specifically target cancer cells are 
ongoing with efforts to identify cancer specific receptors or to eliminate the uptake by 
non-carcinogenic cells of cancer therapeutics.  Once a cancer cell population is 
successfully targeted by a drug, regardless of whether it targets one or multiple proteins, 
that tumor cell population could potentially escape rendering the therapy ineffective  
(Bergmann-Leitner et al., 2003; Khong and Restifo, 2002).  Targeting of an oncogenic 
transcription factor would be advantageous as it might be possible with this approach to 
target an entire oncogenic pathway.   
In the last decade, certain molecular targets were identified and hypothesized to be 
cases of oncogene addiction (Pagliarini et al., 2015; Weinstein and Joe, 2008; Weinstein 
and Joe, 2006).  These cases involve the dependence of oncogenic cell proliferation and 
survival on a single target or pathway, which once removed, completely incapacitated the 
tumor cell, inducing cell death. Most importantly, the removal of this protein or pathway 
did not impact the healthy, non-tumor cell populations (Weinstein and Joe, 2008).  The 
concept of therapies targeting an oncogene to which cells have become addicted has been 
tested in clinical trials, however, the results have been mixed with some therapies having 
a positive effect and others having no effect at all (Torti and Trusolino, 2011). The lack 
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of translation in those patients could potentially be due to heterogeneity in the molecular 
signature.  None of these therapies however have targeted transcription factors or whole 
pathways.  The inhibition of an oncogenic transcription factor to which HCC tumor cells 
are addicted is a new approach that could provide a promising therapeutic option HCC, a 
disease with very high unmet medical need. 
 
We have shown that small molecular inhibitors of LSF, FQI1 and FQI2, inhibit 
human hepatocellular tumor growth in a subcutaneous xenograft mouse model (Grant et 
al., 2012).  Animals receiving efficacious doses of FQI1 or FQI2 (that substantially 
reduced tumor growth), resulted in no detectable elevations in markers of liver toxicity.  
Specifically, there were no elevations in alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), or albumin (ALB) following total doses of 10 or 20 mg/kg over 
a 1-week period. Furthermore, histopathological analysis of various tissues, including 
those with rapidly dividing cell populations (such as the epithelial lining of the small 
intestine) did not reveal any observable toxicity one week following treatments (Grant et 
al., 2012).  More recently, FQI1 and FQI2 administration to an endogenous liver cancer 
mouse model also resulted in significant tumor inhibition (Rajasekaran et al., 2015).  In 
that study, there were no gross signs of toxicity in mice dosed with either compound 
using a 4 mg/kg dose for each of the five dosing treatments.  The significant inhibition of 
tumors in vivo combined with the lack of toxicity observed in non-tumor cell populations 
led to a proposal of oncogene addiction (Grant et al., 2012; Shlomai, 2012).  
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As discussed above, a case of oncogene addiction would indicate that LSF is not 
absolutely required for cell survival in non-tumorigenic cells and therefore that LSF 
inhibition would not impact the healthy cell populations.  FQI inhibition of LSF would 
result in a significant advantage in the hepatocellular carcinoma (HCC) patient 
population compared to the currently approved therapeutics that not only target the 
rapidly dividing cancer cell, but could negatively impact rapidly dividing non tumor cells 
in the body. Sorafenib for instance causes lymphopenia, neutropenia, and 
thrombocytopenia as well as diarrhea, nausea, hand-foot skin reaction and fatigue, all 
hallmarks of chemotherapeutics that impact normal cells (Bruix and Sherman, 2011). 
 
In Chapters 3 and 4, I demonstrated that inhibition by FQI1 and FQI2 in 
hepatocellular carcinoma cells resulted in reduced cell viability following significant 
mitotic defects.   Here, I show that FQI1 treatment of primary mouse hepatocytes ex vivo 
did not result in any observable toxicity.  Additionally, I show that intraperitoneal dosing 
of FQI1 or FQI2 administered at dose levels 2 to 4 times those required to inhibit tumor 
growth (Grant et al., 2012; Rajasekaran et al., 2015), did not result in reduction in non-
tumor cell populations analyzed at a time point where toxicity is typically observed (Scott 
Barros-Alnylam Pharmaceutical Toxicology Expert, Personal comm.). 
 
Results 
LSF inhibition is without consequence in primary mouse hepatocytes 
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To determine whether LSF inhibition would result in cell death in normal, non-
carcinogenic and non-dividing hepatocytes, mouse hepatocytes were isolated from 
C57BL6 mice using a rapid two step isolation method and plated for maintenance in 
culture (Chapter 2). The protocol generated a pure population of hepatocytes (Severgnini 
et al., 2012).  Following confirmation of a successful isolation, with the adherent cells 
showing expected cellular morphology (Figures 5.1a and c), cells were incubated with 5 
µM of FQI1 or vehicle.  Cells were collected 24, 48, or 72 hours after FQI1 treatment, 
and stained with both DAPI and Phalloidin allowing visualization of DNA and actin 
filaments to evaluate cellular morphology.  Representative images of vehicle-treated cells 
(top) and 5 µM FQI1-treated cells (bottom) are comparable in cell morphology with no 
discernible differences (Figure 5.1b).  In a separate study a distinct batch of primary 
mouse hepatocytes were treated with vehicle or 5 µM FQI1 for 48 hours, and then stained 
with hematoxylin and eosin.  Representative images (Figure 5.1d) of the vehicle control 
(top) and FQI1 treated cells (bottom) confirm the initial observations that there are no 
discernible differences between the treated or control cells.  
 
FQI1 or FQI2 treatment in mice does not result in weight loss, elevation of liver enzyme 
levels or reduction in circulating whole blood cell populations.     
 
LSF inhibition results in mitotic defects followed by cell death in rapidly dividing 
HCC cells (Chapters 3 and 4); however, in tumor bearing animals dosed with FQI1 or 
FQI2 there was no elevation in liver enzyme levels or cytotoxicity of tissues analyzed by 
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H&E staining (Grant et al., 2012).  This result was surprising given the small inhibitors 
generally have exposure to tissues (including those with dividing cells) outside of HCC 
tumor cells.  It is also unusual for a chemotherapeutic that targets dividing tumor cells to 
have no impact on normal and dividing cell populations. Therefore, I asked whether FQI1 
or FQI2 in vivo is toxic to the rapidly dividing cell populations (assayed via FACS) or 
normal liver cells (assayed by measuring liver enzyme elevations) in peripheral blood. 
Furthermore, I specifically tested early timepoints (24 hours after the final compound 
dose), as previous studies had tested later timepoints at which it was theoretically 
possible that compound effects were missed due to are resolution of any defects.  
Animals were treated with 2 to 4 times the therapeutic dose levels (Grant et al., 2012; 
Rajasekaran et al., 2015) reported to treat HCC xenograft animals or the mice with 
endogenous liver cancer.  Specifically, C57BL/6 male mice were dosed intraperitoneally 
(i.p.) with 8 mg/kg of compound, vehicle or saline daily for five consecutive days with 
four animals per group.  Male mice were used as in the previous studies, because HCC 
occurs with higher frequency in males, both in mice and humans. Body weights were 
recorded prior to the treatment regimen and at end of the study.  No significant difference 
in weight was observed when comparing mice before and after FQI1 or FQI2 exposure, 
in comparison to controls (Figure 5.2). 
Serum was collected 24 hours after the final dose (Table 5.1).  Albumin levels 
were unchanged in treated versus the controls indicating that liver protein levels were not 
elevated significantly in treated animals.  There was no statistical difference between the 
FQI treated animals and the vehicle control group as measured by the Student T Test.  As 
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another measurement of whether any of the liver protein levels in the blood were 
abnormal, the data were compared to the reference standards generated for C57BL/6 
males. The values in all groups were comparable to or lower than those observed in non-
treated C57BL6 males at a similar age range (http://www.criver.com/products-
services/basic-research/find-a-model/c57bl-6n-mouse).  These data confirm that there is 
no liver toxicity.   
Whole blood was also analyzed from each animal 24 hours after the final dose of 
controls or compound, in order to assay for alterations in rapidly dividing blood cell 
populations.  All whole blood cell populations following both FQI1 and FQI2 treatments 
were similar overall as comparable to those of the vehicle control (Table 5.2).  Further, 
the data were comparable to the reference standards generated for C57BL/6 males 
(http://www.criver.com/products-services/basic-research/find-a-model/c57bl-6n-mouse), 
indicating that this dosing regimen did not result in any statistically significant abnormal 
findings.   
 
Discussion 
The robust inhibition of HCC tumor growth in vivo with either FQI1 or FQI2, 
combined with the apparent lack of toxicity from previous studies, suggested that the 
tumor cells could be addicted to LSF.  To properly investigate whether FQI1 or FQI2 
would harm non-tumor cells, the compounds were analyzed in mouse primary 
hepatocytes ex vivo and in untreated C57BL/6 mice in vivo.   
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Evaluation of the cellular morphology of primary mouse hepatocytes ex vivo with 
FQI1 revealed no obvious signs of toxicity consistent with previous observations.  
Specifically, liver enzymes were not elevated and histopathological analysis was 
unremarkable in vivo with subcutaneous xenograft models (Grant et al., 2012).  The lack 
of toxicity of FQI1 on mouse hepatocytes in vivo is promising given that FQI1 and FQI2 
caused cell death of hepatocellular carcinoma cells.  One obvious difference between 
HCC cells and primary isolated hepatocytes, however, is that the isolated mouse 
hepatocytes are not capable of cell division.  Previous studies have documented roles for 
LSF during cell cycle progression, both at the G1/S transition and in mitosis (Chapter 3 
and 4)(Powell et al., 2000).  Thus, one interpretation would be that LSF activity is only 
critical for dividing cells. Nonetheless, it is promising that LSF inhibition does not impact 
non-dividing primary hepatocytes but could potentially benefit HCC patients as the 
rapidly dividing tumor cells are LSF dependent.  A therapy that does not impact normal 
hepatocytes in HCC patients is important as their liver function is already compromised, 
often by non-tumor disease such as cirrhosis, and keeping whatever normal hepatocytes 
they have left is key to both the toxic profile of the therapy but also the ability of the liver 
to possibly regenerate.  One area for further investigation is to determine what role (if 
any) LSF or its family members play in liver regeneration.  
The in vivo examination of the impact of FQI1 and FQI2, at 2-4 times 
therapeutically relevant dose levels, on various mouse cell populations (Figures 5.2 and 
Tables 5.1 and 5.2) are consistent with previous reports with no loss of body weight or 
significant elevation of key liver injury markers.  Here, I evaluated the cell populations 
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24 hours after the final dose levels eliminating the possibility that the liver could recover 
at late time points. Further, for the first time I show that FQI1 and FQI2 doses in vivo do 
not significantly impact various hematopoietic cells populations (summarized in 
Illustration 5.1). Whether FQI1 or FQI2 do not impact these populations because LSF is 
not required in these cells types or because insufficient drug levels have permeated these 
cells populations to result in impairment cannot be determined from these studies.  
However, these data are consistent with the proposed model of LSF in HCC being a case 
of oncogene addiction.     
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Illustration 5.1 
 
In summary, these data support the notion that the LSF requirement in HCC cells 
is a case of oncogene addiction.  LSF inhibition via treatment with FQI1 and 2 
specifically inhibits HCC tumor growth without compromising normal hepatocytes or 
other rapidly dividing cell populations such as blood cells in mouse models (as assayed at 
early or later time points).  Consistent with the tumor model data in vivo, isolated 
primary hepatocytes also appear to be unaffected by treatment with LSF inhibitors.  
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Taken together the data support further investigation of LSF as a target for the treatment 
of HCC and the FQI family of compounds in particular.  
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Figures 
Figure 5.1. LSF inhibition by FQI1 is without consequence in primary mouse 
hepatocytes 
Primary mouse hepatocytes were isolated from wild type C57BL6 mice acquired from 
Charles River Laboratories.  Hepatocytes were isolated, plated, and treated with 5 µM 
FQI1 or vehicle.  Cells were analyzed for morphology 24, 48, and 72 hours post 
incubation with FQI1 treatment.  Representative images above were taken following 
fluorescent staining with DAPI and Phalloidin (a,b) or following fixation and staining 
with Hematoxylin and Eosin (H&E) (c,d).  Images were gathered using a Zeiss 
axioimager at 63x magnification. (a) Representative image of the cells 4 hours post 
plating.   (b) Representative images of cells collected and fixed at approximately 24, 48 
or 72 hours post incubation with vehicle (top) or with 5 µM FQI1 (bottom).  H&E stained 
isolated primary mouse hepatocytes with successful plating 4 hours post isolation (c) or 
treated with (d) vehicle control (top) and with 5 µM FQI1 (bottom) for 48 hours.    
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Figure 5.2. Mice retain expected body weight upon treatment with FQI1 or FQI2 at 
doses that exceed efficacious levels 
C57BL/6 male mice were dosed intraperitoneally (i.p.) daily for 5 consecutive days at 8 
mg/kg of FQI1 or FQI2, or vehicle (DMSO), or physiological saline.  Body weights were 
taken prior to the first dose and 24 hours following the final dose.   n=5 per group.  
Standard error of the mean is depicted.  These data are representative of two independent 
experiments.   
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Table 5.1. Mice treated with higher than efficacious levels of FQI1 or FQI2 have 
comparable liver function readouts in comparison to controls, assayed shortly after 
dosing.   
These data are representative of two independent experiments in which n=4 per group. 
The reference intervals (last row) were generated by Charles River Laboratories 
(http://www.criver.com/products-services/basic-research/find-a-model/c57bl-6n-mouse) 
on at least 123 C57BL6 male mice at 8-10 weeks of age using a Drew Scientific 
HemaVet analyzer. 
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Table 5.2. Higher than efficacious treatments with FQI1 or FQI2 in C57BL6 male 
mice do not alter blood cell distributions or levels in comparison to levels in 
controls. .   
Data are representative of two independent experiments in which n=4 per group. 
Abbreviations include: Red blood cells (RBC), Hemoglobin (HGB), Hematocrit  (HCT), 
Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean 
Corpuscular Hemoglobin Concentration (MCHC), Platelets (PLT), White Blood Cells 
(WBC), Neutrophil  (NEUT), Neutrophil count (NEUT ABS), Lymphocyte  (LYM), 
Lymphocyte count (LYM ABS), Monocyte (MONO), Monocyte Count (MONO ABS), 
Eosinophil  (EOS), Eosinophil Count (EOS ABS), Basophil (BASO), Basophil count 
(BASO ABS), Large Unstained Cells (LUC), Large Unstained Cell Count (LUC ABS), 
Reticulocyte (RETIC), Reticulocyte count (Retic ABS). The reference intervals (last row) 
were generated by Charles River Laboratories (http://www.criver.com/products-
services/basic-research/find-a-model/c57bl-6n-mouse)on at least 123 C57BL6 male mice, 
8-10 weeks of ageusing a Drew Scientific HemaVet analyzer.   
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CHAPTER SIX DISCUSSION  
 
In this body of work, I have investigated the role of LSF in Hepatocellular 
Carcinoma.  I utilized two approaches to understand the requirement for LSF in HCC and 
why inhibition of LSF activity significantly reduced tumor growth in preclinical models, 
as well as to generate additional evidence that the FQI anti-tumor effect was specific to 
LSF inhibition.   
I demonstrated that short incubations with FQIs revealed a non-transcriptional 
based, mitotic interruption resulting in cell death.  The major phenotype was 
prometaphase arrest, followed by multi-nucleation which suggested interruption in proper 
kinetochore-microtubule attachment, an event that can result in mitotic arrest (Hauf et al., 
2007; Hauf et al., 2003).  However, levels of proteins involved in microtubule-
kinetochore attachment and mitotic exit, Aurora Kinase B and Cdc20, were unchanged, 
as were their RNAs.  To rule out that FQI1 impacted Aurora B kinase activity rather than 
expression, phosphorylation of the Aurora Kinase B target Histone 3 was evaluated and 
confirmed as comparable to the control.  I also found that the upregulation of Cyclin B 
protein expression, as documented in Rajesekaran et al (2015), was due solely to mitotic 
arrest as Cyclin B RNA levels were unperturbed in the FQI treated cells.  Furthermore, to 
confirm that the prometaphase arrest was not due to transcriptional misregulation of LSF 
target genes, FQI1 was removed after the arrest, resulting in phenotype reversal.  Since 
transcription of protein-encoding genes (with the possible exception of cyclin B) is not 
believed to occur following mitotic entry, the release from prometaphase arrest must 
therefore be due to an alternative mechanism. 
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Utilization of RNAi interference to ablate LSF expression as well as a “long-term 
FQI incubation protocol” revealed a second mitotic requirement for LSF, implicating 
involvement of mitotic regulators Aurora kinase B and Cdc20.  Both investigative 
approaches revealed consistent phenotypes upon the reduction of LSF activity, including 
prometaphase delay and subsequent cell death and senescence.  Furthermore, the loss of 
LSF activity lengthened passage through mitosis, as determined with time lapse 
microscopy.     
Cellular senescence, prometaphase/metaphase delay, aberrant cell division, and 
multi-nucleation are also all phenotypes previously reported using various methods to 
eliminate Aurora Kinase B expression and/or activity (Andrews, 2005; Carmena et al., 
2012; Ditchfield et al., 2003; Hauf et al., 2007; Hauf et al., 2003; Huck et al., 2010; Kim 
et al., 2011; Sistayanarain et al., 2006; Vader and Lens, 2008).  The connection between 
LSF and Aurora kinase B was supported in that direct substrates of Aurora Kinase B 
were no longer modified, consistent with observed loss of Aurora Kinase B expression 
and/or activity.  
The deduction that short incubation with FQI1 apparently impeded microtubule 
attachment to kinetochores, as indicated by the prometaphase arrest, is intriguing.   
Microtubule-kinetochore attachment requires a multitude of proteins, and is the primary 
process transitioning cells from prometaphase to metaphase.  Aurora Kinase B is a key 
regulator of this process, so it was notable that prometaphase arrest occurred under these 
conditions without decreasing levels of the kinase.  Phosphorylation of Histone H3 on 
Serine 10 was also not reduced in the cells treated with FQI1 for short periods, however, 
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this particular Histone H3 Serine is redundantly targeted by other mitotic kinases.   
Therefore, phosphorylation of other Aurora Kinase B targets should be tested in the 
context of the short incubation protocol.  Regardless, additional work is required to 
understand how loss of LSF activity might impact microtubule-kinetochore attachments 
through a non-transcriptional type of regulation.   
Regarding longer times of inhibition, whether LSF directly regulates Aurora 
kinase B or Cdc20 is unknown and should be examined further.  ChIP-seq against LSF in 
HCC cell lines treated with and without FQI1 would be informative as would an 
evaluation of Aurora Kinase B isoform regulation in circumstances of reduced LSF 
activity.  The latter is of specific interest as upregulation of specific Aurora Kinase B 
isoforms has been described in HCC patients, an observation which positively correlated 
with poor prognosis (Yasen et al., 2009).  
Finally, I have demonstrated that FQI1 and FQI2 are non-toxic to either freshly 
isolated primary mouse hepatocytes or in wild type non-tumor bearing mice following 
consecutive doses of FQIs at levels 2 to 4 times those required for therapeutic benefit in 
pre-clinical models.  Analysis in non-dividing primary mouse hepatocytes did not result 
in observable toxicity, consistent with the lack of elevated liver enzyme levels detected in 
the anti-tumor analysis of FQIs assayed in a subcutaneous mouse xenograft model.  For 
the first time, the studies reported here evaluated the impact of FQI1 or FQI2 on 
hematopoietic cell populations that divide rapidly, and could therefore be susceptible to 
an anti-mitotic therapy.  The results indicated that neither FQI`1or 2 have a significant 
impact on hematopoietic populations. Whether the lack of observed toxicity is because 
 
 
203 
the FQI compounds were not exposed to or did not penetrate these cells types in vivo 
remains unknown.  Proper pharmacokinetic and exposure studies need to be completed.   
However, these data are consistent with  the accumulating evidence that FQI inhibition of 
LSF activity in non-immortalized or non-tumor cell populations is non-toxic, lending 
additional support to the argument that LSF may in fact be the Achilles heel of 
hepatocellular carcinoma (Shlomai, 2012).  The anti-tumor activity of LSF should also be 
evaluated in other cancer types to determine whether inhibiting LSF could provide a 
therapeutic benefit and the impact of LSF knockdown in HCC should strongly be 
considered for further preclinical and possibly clinical evaluation. 
LSF has been shown to be an oncogenic transcription factor in HCC, whose 
activity does not appear to be required for immediate survival of normal cells (Grant et 
al., 2012; Porta-de-la-Riva et al., 2011; Rajasekaran et al., 2015; Santhekadur et al., 
2012a; Santhekadur et al., 2012b).  I report here that LSF is a mitotic regulator for HCC 
cellular progression.  LSF has also been reported to regulate fibronectin in Snail induced 
EMT.  As to whether inhibition of LSF activity would inhibit EMT would be worth 
further investigation given that EMT is the precursor to metastasis.  A more important 
question is whether inhibition of LSF would inhibit metastasis.  It has been shown that 
expression of dnLSF did reduce wide spread tumor formation in an artificial metastasis 
model in vivo (Yoo et al., 2010).  However, whether this is due to the inhibiting tumor 
cell proliferation, inhibition of EMT, or a combination was untested.  This concept should 
be evaluated as this would have enormous implications for LSF as a molecular target for 
a HCC therapy.   
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Identifying potent molecular therapies can be complex and often trials fail due to 
an improper design.  The SHARP trial (designed in 2004 to determine the impact of 
Sorafenib on HCC survival rates) evaluated the compound across various etiologies and 
ethnicities with great success as it reported survival rates to be in the range of 7-11 
months, rates greater than those observed in earlier clinical evaluations (Torrecilla and 
Llovet, 2015).  The increased success was attributed to improved strategies regarding 
clinical trial design for the HCC patient population.  While the data were not stunning, 
the SHARP trial generated information allowing better future study designs for molecular 
therapies to be evaluated in the HCC populations. Unfortunately, a number of recent  
molecularly targeted  therapies (Sunitinib, Brivanib, Erlotinib, Lifnifanib, Everolimus), 
have failed to show a survival benefit (Torrecilla and Llovet, 2015).  One hypothesis set 
forth to explain the failures was that Sorafenib’s “success” was most likely due to a 
balance of targeting cancer cells and the microenvironment, a feature absent from the 
new molecular candidates.  Regardless, alternative molecular therapies have failed, even 
with new information on how to properly evaluate efficacy bringing no new relief to this 
population with an unmet need. 
LSF remains unique among potential HCC clinical targets in that the data 
generated here suggest LSF-mediated mitotic regulation both potentially through non 
transcriptional interactions impacting microtubule-kinetochore attachment and through 
expression of a major mitotic kinase and mitotic proteolysis member.  The inhibition of 
LSF does not appear to impact non-dividing cells as shown with primary mouse 
hepatocytes and in vivo studies.  These data, combined with previous reports, support the 
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anti-tumor activity specific to HCC cells as a case of oncogene addiction (Weinstein and 
Joe, 2008).  Current suggestions to design the ideal HCC molecular target include 
proposals to target oncogenic transcription factors, microtubule regulators (Komlodi-
Pasztor et al., 2011), proteolysis members, and those that enhance EMT (Sekyrova et al., 
2012; Torrecilla and Llovet, 2015).  These are all criteria for which LSF may qualify and 
therefore generate further excitement around the clinical candidacy for LSF.  Given the 
high unmet need in HCC with worldwide primary liver cancer rates on the rise, as well 
as, very limited available safe and effective therapies, the possibility that targeting LSF in 
HCC could represent a major breakthrough is exciting.  Further experiments to validate 
LSF as a target and uncover its full mechanism of action as well as optimization of the 
FQI family of compounds for possible application in clinical studies are clearly 
warranted. 
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APPENDIX I 
siRNAs Targeting LSF, with off target reduction of Mad2, result in HCC cell death 
following decreased mitotic time and reduced expression of both Aurora B kinase and 
Cdc20.   
Introduction 
The ability to robustly knockdown a gene of interest in molecular biology has 
enabled acquisition of significant insight in recent years.  Information generated utilizing 
specific gene silencing has provided mechanistic insights into the functionality of 
proteins of interest that, prior to this technological advance, may have once been deemed 
out of reach.  This is particularly true in the case of transcription factors, which have been 
notoriously difficult to target utilizing small molecular inhibitors due to the smaller size 
of their DNA binding domains coupled with their intrinsic structural instability, a trait 
allowing their promiscuity, enabling binding to various proteins resulting in diverse 
functionality (Yan and Higgins, 2013). However, as with all technologies, proper 
investigational practices must be followed in order to rule out any nonspecific events.  
Identifying siRNAs capable of specific and robust gene silencing can be a rigorous 
exercise.  Generating siRNA sequences that are proficient at accessing the target site is a 
requirement as the structure of native mRNA or co-factor association could inhibit access 
and impact silencing capabilities. Direct hybridization to off-target sequences also must 
be minimized by using algorithms to reduce the probability of this occurring.  Finally, 
rescue experiments should be executed, when feasible, to confirm the restoration of the 
observed phenotype.   
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However, as reported in Hubner et al 2010, results may be misleading if the phenotype is 
inadvertently rescued by another mechanism (Hubner et al., 2010).  Mitotic Arrest 
Deficient 2 (Mad2) is a key member of the spindle assembly checkpoint (SAC) required 
for proper chromosome segregation (Ditchfield et al., 2003).  Mad2 is required for cells 
to transit from metaphase to anaphase. Even minimal levels of Mad2 knockdown can 
result in cell death and multi-nucleation as cells with an inactivated checkpoint and an 
inappropriate spindle attachment inappropriately enter anaphase.  The Hubner et al. 
report showed that transfection of certain siRNAs resulted in non-specific reduction of 
Mad2 expression impacting both its gene expression (mRNA) and protein levels (Hubner 
et al., 2010).  Furthermore, the Mad2 knockdown was not a consequence of direct 
hybridization of the siRNAs to the Mad2 transcript, based on homology predictions, but 
rather of an upstream event in the Mad2 pathway.  This target or mechanism has yet to be 
identified.  The reduction of Mad2 levels occurred with multiple, but not all siRNAs 
suggesting that this observation was a sequence, not target, dependent event that resulted 
in the initial misinterpretation of the role of Plk1-interacting checkpoint helicase (PICH) 
regulating the spindle assembly checkpoint (SAC) (Hubner et al., 2010; Llovet et al., 
2015).  To investigate the phenotype of LSF knockdown in hepatocellular carcinoma, 
multiple siRNAs were designed to specifically target LSF messenger RNA.  A single 
siRNA (LSF siRNA2) was observed to have off-target effects on Mad2.  LSF siRNA2 
was identified as a potent siRNA for reducing LSF expression (Figure 4.1e and f).  
However, additional assessment revealed that Mad2 was also nonspecifically reduced, 
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albeit with different kinetics (a slower rate and to a lesser extent) when compared to the 
predicted target (LSF) of the siRNA, but nevertheless had an impact on the phenotypes 
observed in the experiments.  In particular, knockdown of LSF with siRNA 2 resulted in 
decreased amount of time to transit mitosis, followed by HCC cell death including 
apoptosis and multi-nucleation. These phenotypes are consistent with Mad2 reduction 
(Michel et al., 2004a; Michel et al., 2004b).  LSF siRNA 2 treatment also resulted in dose 
dependent reduction of Aurora B Kinase and Cdc20 protein and RNA.  A comparison of 
cellular consequences of siRNAs specific for only LSF (LSF siRNA) versus LSF plus 
Mad2 reductions (LSF siRNA2) therefore showed overlapping but not identical 
phenotypes.  Both siRNAs caused reduction of Aurora kinase B, reduction of Cdc20, 
multi-nucleation, and apoptosis, however only the specific knockdown of LSF alone 
resulted in an increase in mitotic time (Chapter 4). 
 
Results 
Treatment with LSF siRNA 2 results in cell death following mitotic exit 
A potent siRNA targeting LSF, (duplex 9) LSF 2, was identified from the screen 
described in chapter 4.  HCC cells with LSF knockdown with LSF siRNA 2 revealed cell 
death following progression through the cell cycle.  By phase contrast imaging, the cell 
number was reduced following transfection with LSF siRNA 2 compared to with control 
siRNA (Figure A1.1).  Further, cellular DNA profiles of HCC cells treated with LSF 
siRNA 2 revealed an increasing amount of cells with sub-G1 DNA content in comparison 
to control (Figure A1.2a).  Aurora Kinase B and Cdc20 levels were evaluated, as FQI1 
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inhibition of LSF (Chapter 3) generated phenotypes that were similar to those previously 
reported upon inhibition of AurkB or Cdc20.  To determine if Aurora kinase B or Cdc20 
levels were altered, both RNA and protein expression were evaluated in synchronized 
cells treated with LSF siRNA 2.  The data revealed dose dependent reduction of both 
targets (Figure A1.3).  To confirm loss of the mitotic kinase activity, phosphorylation of 
substrates of Aurora Kinase B, on serine 10 and serine 28 of Histone 3, were also 
examined.  Modification on both of these targets was reduced, concomitant with 
increasing siRNA levels and consistent with the observed reduction in AurkB (Figure 
A1.3).  
 
Due to the reduction in key mitotic proteins Aurora Kinase B and Cdc20, mitotic 
progression was assessed following treatment with LSF siRNA 2 or control.  Mitotic 
phenotypes were analyzed by cellular morphology of the DNA (with DAPI) and mitotic 
spindles (with antibody against alpha tubulin).  The analysis revealed an increased 
number of apoptotic cells as identified by fragmented nuclei, decreased numbers of cells 
in prometaphase and metaphase, and an increased number of multi-nucleated cells in 
comparison to the controls at various time points (Figure A1.4, Tables A1.1 and A1.2). 
For this analysis, 91 to 100 cells were analyzed per condition.  The off center phenotype 
was one in which the condensed DNA was not located in the center of the cell as is 
typically observed prior to microtubule attachment from either spindle pole.  These data 
collectively suggested a reduced number of cells in mitosis following LSF knockdown 
with LSF siRNA 2 as well as incidents of multi-nucleation.  To more fully understand the 
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mitotic impact of LSF siRNA 2 treatment in HCC treated cells, live cell imaging was 
performed with QGY-7703 cells expressing mEmerald-tagged histone H2B, following 
transfection with either control siRNA or LSF siRNA 2.  The LSF siRNA 2-treated cells 
reached nuclear envelope breakdown (NEB) earlier than those treated with control 
siRNA as determined by the time lapse analysis.  Additionally, the LSF siRNA2 treated 
cells exhibited a significant reduction in mitotic time as measured from NEB to anaphase 
(Figure A1.5) with most cells traversing this in 16-24 minutes from NEB to anaphase, as 
compared to 24-36 minutes for the control siRNA treated cells.  Spending less time to 
passage through mitosis is consistent with a reduced number of cells at a given time point 
in prometaphase or metaphase, and increased numbers of cells at a given point exhibiting 
cytokinesis in the cells treated with LSF siRNA 2.  Consistent with these data were the 
DNA profiles of synchronized cells at various time points after release from the final 
G1/S block (Figure A1.6) where the LSF siRNA treated cells appear to progress rapidly 
from 2n DNA content to subG1 content.  Combined with the time lapse results, we 
conclude that the cells progress rapidly through the cell cycle prior to cell death.   
 
A potent siRNA targeting LSF also reduces Mad2 gene expression, albeit, with slower 
kinetics than those observed with the siRNA direct target 
Given the impact of LSF on mitosis, which was previously undescribed, when 
using siRNA to reduce LSF levels and determine its biological role, it was essential to 
take into account that some siRNAs can cause off target effects on Mad2 expression 
(Hubner et al., 2010).  To determine whether the potent LSF siRNA2 exhibited similar 
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same off target effects, Mad2 gene expression was measured in HCC cells treated with 
LSF siRNA 2 or control siRNA.  Mad2 RNA levels were indeed reduced after treatment 
with this LSF siRNA (Figure A1.7).  Mad2 gene expression was reduced to 
approximately 50 percent of the control levels at the time when maximal LSF protein 
reduction was predicted to have occurred, 72 hours post transfection (Figure A1.3c).  
 
Discussion 
Previous reports have shown that certain siRNA sequences can non-specifically 
reduce Mad2 transcript and protein levels through an unknown mechanism (Hubner et al., 
2010).  Transfection with the specific LSF siRNA 2, unlike transfection with the LSF 
siRNA used in Chapter 4, revealed an approximately 50% reduction in MAD2 RNA 
expression. A search using the National Center for Biotechnology Information (NCBI) 
revealed that the neither the sense nor antisense strand of LSF siRNA 2 duplex showed 
significant homology with the Mad2 mRNA, suggesting that the siRNA itself was 
unlikely to directly hybridize to the Mad2 RNA sequence.  As shown in asynchronous 
cells, Mad2 gene reduction occurs at a slower rate than that observed for the intended 
target of LSF siRNA 2, consistent with the notion that the non-specific event is not 
hybridization based but occurring upstream in the Mad2 pathway.  These data suggest 
that to confirm the impact of a particular siRNA on Mad2 regulation, the appropriate test 
is to measure gene expression levels in comparison to the controls as a semi-quantitative 
western blot may not reveal the subtle reduction in Mad2 expression.  Preferably, proper 
controls when examining cellular phenotypes would include an siRNA previously 
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confirmed not to result in this phenotype or an addition of an untreated cell population.  It 
is worth noting that the Mad2 reduction with this LSF siRNA was observed in both 
asynchronous and synchronous populations.  Finally, since the Mad2 off target effect 
occurred with slower kinetics compared to the LSF knockdown, confirmation of siRNA 
specificity requires evaluation of Mad2 expression at time points at least 72 hours 
following RNAi transfection. 
 The evaluation of LSF knockdown in hepatocellular carcinoma cells, using LSF 
targeting siRNAs with and without a non-specific Mad2 reduction, generated both 
overlapping and distinct phenotypes.  The identification of the Mad2 reduction for LSF 
siRNA2 induced a re-screen of candidate LSF siRNAs to identify sequences that did not 
impact Mad2 gene expression.  The data generated with the LSF siRNA utilized in 
experiments in Chapter 4 largely resulted in observations consistent with those from LSF 
siRNA2, with the exception of the length of time to progress through mitosis.  In 
addition, pure LSF knockdown resulted an observation of cellular senescence. The 
increased mitotic time is consistent with the results obtained with the LSF small inhibitor 
(Chapter 4), indicating that loss of LSF function is responsible for the lengthening of 
mitosis.  LSF knockdown in both contexts resulted in HCC cell death along with multi-
nucleation, and reduction in both Aurora B kinase and Cdc20 expression.  I hypothesize 
that the reduced mitotic time observed here was solely due to the incapacitation of the 
Spindle Assembly Checkpoint (SAC) due to nonspecific reduction of Mad2 levels.  
Importantly, the phenotypes described in Chapter 4, generated with the LSF siRNA that 
did not inadvertently reduce Mad2 levels, were consistent with the phenotypes generated 
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with small molecular inhibitors of LSF. Together, these data implicate LSF as a mitotic 
regulator and confirm the reduction of Aurora B Kinase and Cdc20 as an observation 
related to LSF mitotic regulation in HCC cells.    
     These findings support the requirement for screening siRNAs for nonspecific 
knockdown of Mad2 and doing so at multiple time points as the off target event could 
result in improper interpretation of data.  This is especially true when investigating 
mitotic proteins or when one needs to identify siRNAs that have no toxic consequence.   
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Figures 
Illustration A1.1 
 
 
Illustration A1.2 
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Figure A1.1 Phase contrast imaging of LSF siRNA 2-treated QGY-7703 cells 
suggests reduction in cell proliferation. 
QGY-7703 cells were transfected with either (a) 20 nM Control siRNA or (b) 20 nM LSF 
siRNA 2 prior to imaging according to illustration A1.1.  Cells were synchronized using a 
double thymidine block.  72 hours post release from the G1/S block phase contrast 
images were taken at a magnification of 20x.  Images are representative of greater than 
five experiments.  
  
 
 
216 
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Figure A1.2    Treatment of asynchronous HCC cells with LSF siRNA2 reveals an 
increase in cells with sub-G1 DNA content  
HCC cells were treated with LSF siRNA 2 or control siRNA at concentrations of 10 or 20 
nM. QGY-7703 cells, fixed and stained with propidium iodide, were analyzed at 24, 48, 
72 and 96 hours post release on a FACS Calibur to analyze DNA content. Cells 
transfected with control siRNA were analyzed at 0 hrs to determine instrument settings. 
Synchronized HCC cells transfected with control siRNA or LSF siRNA 2 were directly 
compared to evaluate cell cycle progression.  These results are representative of 3 
independent experiments.   
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Figure A1.3.  Aurora Kinase B and Cdc20 expression is significantly reduced upon 
LSF knockdown 
Synchronized, LSF siRNA-transfected HCC cells were lysed at various time points 
following G1/S release. (a) Immunoblots of the indicated proteins and protein 
modifications from cells at 0, 4, and 9 hours after release from the G1/S block.  Levels of 
Beta Actin were used for normalization.  Numbers depicted below each band represent 
percentage of protein relative to the level in the siRNA control sample.  Protein 
expression or phosphorylation was quantitated using the Odyssey Licor detection system 
where integrated intensity for the target protein or phosphorylation was normalized to the 
beta actin control.  Data are depicted as the area of pixels determined for (b) LSF (c) 
Aurora Kinase B (d) Cdc20 (e) Phosphorylated Histone Serine 3 and (f) Phosphorylated 
Histone Serine 28 normalized to the area of pixels detected for beta actin.  Results are 
representative of 3 independent experiments. mRNA expression is depicted for (g) Aurora 
kinase B and (h) Cdc20, with each target gene normalized to Beta Actin. Data are 
representative of two independent experiments.  
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Figure A1.4 Immunofluorescent analysis of synchronized QGY-7703 cells after LSF 
knockdown with LSF siRNA 2 reveals fewer cells in mitosis as well as observations 
of both multi-nucleated and apoptotic cells 
QGY-7703 cells were transfected with 20 nM of either LSF or control siRNA, and then 
synchronized at the G1/S border.  At 0, 5, 9 and 21 hours after release from G1/S, QGY-
7703 cells were fixed and stained with anti-alpha tubulin antibody and with DAPI.  
Images were analyzed on a Zeiss Axioimager at a 63x magnification. Approximately 100 
individual cells were analyzed within each group.  Representative images 9 hours after 
release from G1/S of the cells treated with control siRNA (left panels) or LSF siRNA 
(right panels).  Control cells show normal mitotic phenotypes, including examples of 
metaphase and cytokinesis.  LSF siRNA-treated cells show various defects, including 
cells with fragmented nuclei and multi-nucleation. 
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Figure A1.5 HCC cells expressing mEmerald-tagged histone H2B were analyzed by 
time lapse microscopy upon treatment with either LSF siRNA2 or control siRNA.   
Synchronized cells, using a double thymidine block, were imaged every 4 minutes at 63x 
magnification. Time from nuclear envelope breakdown to anaphase was determined for 
56-100 cells per sample treated with 20 nM of either LSF siRNA 2 or Control siRNA.  
The results here include multiple samples, 2 controls receiving the non-specific siRNA 
and 2 groups receiving LSF siRNA 2.  One experiment received 20 µM exogenous 
thymidine at the release from the G1/S block.  Because addition of thymidine did not 
affect the outcome, the error bars are standard deviations of the averages from the 
samples, plus or minus thymidine addition.   
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Figure A1.6 Synchronized HCC cells with LSF and Mad2 knockdown results in 
increasing numbers of cells with sub-G1 DNA content over time   
QGY-7703 cells were synchronized at the G1/S border post transfection with 20 nM 
control siRNA or 20 nM LSF siRNA (Illustration 5.1). At 0, 3.5, 9 and 21 and 27 hours 
after release from the G1/S block, cells were fixed and stained with propidium iodide for 
analysis of DNA content by flow cytometry.  Data are representative of greater than 4 
experiments.    
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Figure A1.7 Mad2 RNA levels are reduced in LSF siRNA 2 treated cells   
 LSF and Mad2 RNA levels from cells treated with either LSF siRNA 2 or Control 
siRNA. For asynchronous cells, samples were analyzed at 24, 48 or 72 hours post 
transfection. For examination in synchronous cells, the protocol in Illustration in A1.1 
was used.  RNA was isolated at 4 and 8 hours after the final release from G1/S.  Standard 
error represents averages from two independent experiments.  These data are consistent 
across 3 independent experiments, with the third experiment having slightly different 
time points. 
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Table AI.1.  Immunofluorescence of synchronized QGY 7703 cells after LSF 
knockdown reveals fewer cells in mitosis. 
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Table AI.2.  Immunofluorescence of synchronized QGY 7703 cells after LSF 
knockdown reveals multi-nucleated and apoptotic cells. 
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Butler, J. S., A. Chan, et al. (2016). "Preclinical evaluation of RNAi as a treatment for 
transthyretin-mediated amyloidosis." Amyloid 23(2): 109-118. 
 ATTR amyloidosis is a systemic, debilitating and fatal disease caused by 
transthyretin (TTR) amyloid accumulation. RNA interference (RNAi) is a clinically 
validated technology that may be a promising approach to the treatment of ATTR 
amyloidosis. The vast majority of TTR, the soluble precursor of TTR amyloid, is 
expressed and synthesized in the liver. RNAi technology enables robust hepatic gene 
silencing, the goal of which would be to reduce systemic levels of TTR and mitigate 
many of the clinical manifestations of ATTR that arise from hepatic TTR expression. To 
test this hypothesis, TTR-targeting siRNAs were evaluated in a murine model of 
hereditary ATTR amyloidosis. RNAi-mediated silencing of hepatic TTR expression 
inhibited TTR deposition and facilitated regression of existing TTR deposits in 
pathologically relevant tissues. Further, the extent of deposit regression correlated with 
the level of RNAi-mediated knockdown. In comparison to the TTR stabilizer, tafamidis, 
RNAi-mediated TTR knockdown led to greater regression of TTR deposits across a 
broader range of affected tissues. Together, the data presented herein support the 
therapeutic hypothesis behind TTR lowering and highlight the potential of RNAi in the 
treatment of patients afflicted with ATTR amyloidosis. 
 
Parmar, R., J. L. Willoughby, et al. (2016). "5'-(E)-Vinylphosphonate: A Stable 
Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates." 
Chembiochem. 
 Small interfering RNA (siRNA)-mediated silencing requires siRNA loading into 
the RNA-induced silencing complex (RISC). Presence of 5'-phosphate (5'-P) is reported 
to be critical for efficient RISC loading of the antisense strand (AS) by anchoring it to the 
mid-domain of the Argonaute2 (Ago2) protein. Phosphorylation of exogenous duplex 
siRNAs is thought to be accomplished by cytosolic Clp1 kinase. However, although 
extensive chemical modifications are essential for siRNA-GalNAc conjugate activity, 
they can significantly impair Clp1 kinase activity. Here, we further elucidated the effect 
of 5'-P on the activity of siRNA-GalNAc conjugates. Our results demonstrate that a 
subset of sequences benefit from the presence of exogenous 5'-P. For those that do, 
incorporation of 5'-(E)-vinylphosphonate (5'-VP), a metabolically stable phosphate 
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mimic, results in up to 20-fold improved in vitro potency and up to a threefold benefit in 
in vivo activity by promoting Ago2 loading and enhancing metabolic stability. 
 
Rajasekaran, D., A. Siddiq, et al. (2015). "Small molecule inhibitors of Late SV40 Factor 
(LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC 
model." Oncotarget 6(28): 26266-26277. 
 Hepatocellular carcinoma (HCC) is a lethal malignancy with high mortality and 
poor prognosis. Oncogenic transcription factor Late SV40 Factor (LSF) plays an 
important role in promoting HCC. A small molecule inhibitor of LSF, Factor 
Quinolinone Inhibitor 1 (FQI1), significantly inhibited human HCC xenografts in nude 
mice without harming normal cells. Here we evaluated the efficacy of FQI1 and another 
inhibitor, FQI2, in inhibiting endogenous hepatocarcinogenesis. HCC was induced in a 
transgenic mouse with hepatocyte-specific overexpression of c-myc (Alb/c-myc) by 
injecting N-nitrosodiethylamine (DEN) followed by FQI1 or FQI2 treatment after tumor 
development. LSF inhibitors markedly decreased tumor burden in Alb/c-myc mice with a 
corresponding decrease in proliferation and angiogenesis. Interestingly, in vitro treatment 
of human HCC cells with LSF inhibitors resulted in mitotic arrest with an accompanying 
increase in CyclinB1. Inhibition of CyclinB1 induction by Cycloheximide or CDK1 
activity by Roscovitine significantly prevented FQI-induced mitotic arrest. A significant 
induction of apoptosis was also observed upon treatment with FQI. These effects of LSF 
inhibition, mitotic arrest and induction of apoptosis by FQI1s provide multiple avenues 
by which these inhibitors eliminate HCC cells. LSF inhibitors might be highly potent and 
effective therapeutics for HCC either alone or in combination with currently existing 
therapies. 
 
Matsuda, S., K. Keiser, et al. (2015). "siRNA conjugates carrying sequentially assembled 
trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in 
vivo in hepatocytes." ACS Chemical Biology 10(5): 1181-1187. 
 Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-
acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to 
hepatocytes is a promising paradigm for RNAi therapeutics. Robust and durable gene 
silencing upon subcutaneous administration at therapeutically acceptable dose levels 
resulted in the advancement of GalNAc-conjugated oligonucleotide-based drugs into 
preclinical and clinical developments. To systematically evaluate the effect of display and 
positioning of the GalNAc moiety within the siRNA duplex on ASGPR binding and 
RNAi activity, nucleotides carrying monovalent GalNAc were designed. Evaluation of 
clustered and dispersed incorporation of GalNAc units to the sense (S) strand indicated 
that sugar proximity is critical for ASGPR recognition, and location of the clustered 
ligand impacts the intrinsic potency of the siRNA. An array of nucleosidic GalNAc 
monomers resembling a trivalent ligand at or near the 3' end of the S strand retained in 
vitro and in vivo siRNA activity, similar to the parent conjugate design. This work 
demonstrates the utility of simple, nucleotide-based, cost-effective siRNA-GalNAc 
conjugation strategies. 
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Rajeev, K. G., J. K. Nair, et al. (2015). "Hepatocyte-specific delivery of siRNAs 
conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene 
silencing in vivo." Chembiochem 16(6): 903-908. 
 We recently demonstrated that siRNAs conjugated to triantennary N-
acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, 
owing to uptake mediated by the asialoglycoprotein receptor (ASGPR). Novel 
monovalent GalNAc units, based on a non-nucleosidic linker, were developed to yield 
simplified trivalent GalNAc-conjugated oligonucleotides under solid-phase synthesis 
conditions. Synthesis of oligonucleotide conjugates using monovalent GalNAc building 
blocks required fewer synthetic steps compared to the previously optimized triantennary 
GalNAc construct. The redesigned trivalent GalNAc ligand maintained optimal valency, 
spatial orientation, and distance between the sugar moieties for proper recognition by 
ASGPR. siRNA conjugates were synthesized by sequential covalent attachment of the 
trivalent GalNAc to the 3'-end of the sense strand and resulted in a conjugate with in vitro 
and in vivo potency similar to that of the parent trivalent GalNAc conjugate design. 
 
Nair, J. K., J. L. Willoughby, et al. (2014). "Multivalent N-acetylgalactosamine-
conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene 
silencing." Journal of American Chemical Society 136(49): 16958-16961. 
 Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor 
ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the 
siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc are 
compatible with solid-phase oligonucleotide synthesis and deprotection conditions, with 
synthesis yields comparable to those of standard oligonucleotides. Subcutaneous (SC) 
administration of siRNA-GalNAc conjugates resulted in robust RNAi-mediated gene 
silencing in liver. Refinement of the siRNA chemistry achieved a 5-fold improvement in 
efficacy over the parent design in vivo with a median effective dose (ED50) of 1 mg/kg 
following a single dose. This enabled the SC administration of siRNA-GalNAc 
conjugates at therapeutically relevant doses and, importantly, at dose volumes of </=1 
mL. Chronic weekly dosing resulted in sustained dose-dependent gene silencing for over 
9 months with no adverse effects in rodents. The optimally chemically modified siRNA-
GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a 
wide range of diseases involving liver-expressed genes. 
 
Conforto, T. L., Y. Zhang, et al. (2012). "Impact of CUX2 on the female mouse liver 
transcriptome: activation of female-biased genes and repression of male-biased genes." 
Molecular Cell Biology 32(22): 4611-4627. 
 The growth hormone-regulated transcription factors STAT5 and BCL6 
coordinately regulate sex differences in mouse liver, primarily through effects in male 
liver, where male-biased genes are upregulated and many female-biased genes are 
actively repressed. Here we investigated whether CUX2, a highly female-specific liver 
transcription factor, contributes to an analogous regulatory network in female liver. 
Adenoviral overexpression of CUX2 in male liver induced 36% of female-biased genes 
and repressed 35% of male-biased genes. In female liver, CUX2 small interfering RNA 
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(siRNA) preferentially induced genes repressed by adenovirus expressing CUX2 (adeno-
CUX2) in male liver, and it preferentially repressed genes induced by adeno-CUX2 in 
male liver. CUX2 binding in female liver chromatin was enriched at sites of male-biased 
DNase hypersensitivity and at genomic regions showing male-enriched STAT5 binding. 
CUX2 binding was also enriched near genes repressed by adeno-CUX2 in male liver or 
induced by CUX2 siRNA in female liver but not at genes induced by adeno-CUX2, 
indicating that CUX2 binding is preferentially associated with gene repression. 
Nevertheless, direct CUX2 binding was seen at several highly female-specific genes that 
were positively regulated by CUX2, including A1bg, Cyp2b9, Cyp3a44, Tox, and 
Trim24. CUX2 expression and chromatin binding were high in immature male liver, 
where repression of adult male-biased genes and expression of adult female-biased genes 
are common, suggesting that the downregulation of CUX2 in male liver at puberty 
contributes to the developmental changes establishing adult patterns of sex-specific gene 
expression. 
 
Grant, T. J., J. A. Bishop, et al. (2012). "Antiproliferative small-molecule inhibitors of 
transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma." 
Proceedings of the National Academy of Science U S A 109(12): 4503-4508. 
 Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. 
Despite the prevalence of HCC, there is no effective, systemic treatment. The 
transcription factor LSF is a promising protein target for chemotherapy; it is highly 
expressed in HCC patient samples and cell lines, and promotes oncogenesis in rodent 
xenograft models of HCC. Here, we identify small molecules that effectively inhibit LSF 
cellular activity. The lead compound, factor quinolinone inhibitor 1 (FQI1), inhibits LSF 
DNA-binding activity both in vitro, as determined by electrophoretic mobility shift 
assays, and in cells, as determined by ChIP. Consistent with such inhibition, FQI1 
eliminates transcriptional stimulation of LSF-dependent reporter constructs. FQI1 also 
exhibits antiproliferative activity in multiple cell lines. In LSF-overexpressing cells, 
including HCC cells, cell death is rapidly induced; however, primary or immortalized 
hepatocytes are unaffected by treatment with FQI1. The highly concordant structure-
activity relationship of a panel of 23 quinolinones strongly suggests that the growth 
inhibitory activity is due to a single biological target or family. Coupled with the striking 
agreement between the concentrations required for antiproliferative activity (GI(50)s) and 
for inhibition of LSF transactivation (IC(50)s), we conclude that LSF is the specific 
biological target of FQIs. Based on these in vitro results, we tested the efficacy of FQI1 
in inhibiting HCC tumor growth in a mouse xenograft model. As a single agent, tumor 
growth was dramatically inhibited with no observable general tissue cytotoxicity. These 
findings support the further development of LSF inhibitors for cancer chemotherapy. 
 
Nakayama, T., J. S. Butler, et al. (2012). "Harnessing a physiologic mechanism for 
siRNA delivery with mimetic lipoprotein particles." Mol Ther 20(8): 1582-1589. 
 Therapeutics based on RNA interference (RNAi) have emerged as a potential new 
class of drugs for treating human disease by silencing the target messenger RNA 
(mRNA), thereby reducing levels of the corresponding pathogenic protein. The major 
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challenge for RNAi therapeutics is the development of safe delivery vehicles for small 
interfering RNAs (siRNAs). We previously showed that cholesterol-conjugated siRNAs 
(chol-siRNA) associate with plasma lipoprotein particles and distribute primarily to the 
liver after systemic administration to mice. We further demonstrated enhancement of 
silencing by administration of chol-siRNA pre-associated with isolated high-density 
lipoprotein (HDL) or low-density lipoprotein (LDL). In this study, we investigated 
mimetic lipoprotein particle prepared from recombinant apolipoprotein A1 (apoA) and 
apolipoprotein E3 (apoE) as a delivery vehicle for chol-siRNAs. We show that apoE-
containing particle (E-lip) is highly effective in functional delivery of chol-siRNA to 
mouse liver. E-lip delivery was found to be considerably more potent than apoA-
containing particle (A-lip). Furthermore, E-lip-mediated delivery was not significantly 
affected by high endogenous levels of plasma LDL. These results demonstrate that E-lip 
has substantial potential as delivery vehicles for lipophilic conjugates of siRNAs. 
 
Severgnini, M., J. Sherman, et al. (2012). "A rapid two-step method for isolation of 
functional primary mouse hepatocytes: cell characterization and asialoglycoprotein 
receptor based assay development." Cytotechnology 64(2): 187-195. 
 Primary mouse hepatocytes are an important tool in the biomedical research field 
for the assessment of hepatocyte function. Several methods for hepatocyte isolation have 
been published; however, many of these methods require extensive handling and can 
therefore compromise the viability and function of the isolated cells. Since one advantage 
of utilizing freshly isolated cells is to maintain an environment in which the cells are 
more comparable to their in vivo state, it is important to have robust methods that 
produce cells with high viability, good purity and that function in a similar manner to that 
in their in vivo state. Here we describe a modified two-step method for the rapid isolation 
and characterization of mouse primary hepatocytes that results in high yields of viable 
cells. The asialoglycoprotein receptor (ASGPR), which is one of the most abundant cell 
surface receptors on hepatocytes, was used to monitor the function of the isolated 
hepatocytes by demonstrating specific binding of its ligand using a newly developed flow 
cytometry based ligand-receptor binding assay. Also, an in vitro screening method for 
siRNA drug candidates was successfully developed utilizing freshly isolated hepatocytes 
with minimum culture time. 
 
 
Nguyen, D. N., S. C. Chen, et al. (2009). "Drug delivery-mediated control of RNA 
immunostimulation." Mol Ther 17(9): 1555-1562. 
 RNA interference (RNAi) has generated significant interest as a strategy to 
suppress viral infection, but in some cases antiviral activity of unmodified short-
interfering RNA (siRNA) has been attributed to activation of innate immune responses. 
We hypothesized that immunostimulation by unmodified siRNA could mediate both 
RNAi as well as innate immune stimulation depending on the mode of drug delivery. We 
investigated the potential of immunostimulatory RNAs (siRNAs) to suppress influenza A 
virus in vivo in the mouse lung. Lipidoid 98N12-5(1) formulated with unmodified siRNA 
targeting the influenza nucleoprotein gene exhibited antiviral activity. Formulations were 
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optimized to increase antiviral activity, but the antiviral activity of lipidoid-delivered 
siRNA did not depend on sequence homology to the influenza genome as siRNA directed 
against unrelated targets also suppressed influenza replication in vivo. This activity was 
primarily attributed to enhancement of innate immune stimulation by lipidoid-mediated 
delivery, which indicates increased toll-like receptor (TLR) activation by siRNA. Certain 
chemical modifications to the siRNA backbone, which block TLR7/8 activation but 
retain in vitro RNAi activity, prevented siRNA-mediated antiviral activity despite 
enhanced lipidoid-mediated delivery. Here, we demonstrate that innate immune 
activation caused by unmodified siRNA can have therapeutically relevant effects, and 
that these non-RNAi effects can be controlled through chemical modifications and drug 
delivery. 
 
